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MP THESISABSTRACT
Introduction: Carcinoembryonic antigen (CEA) is an oncofoetal antigen heterogeneously expressed
by colorectal cancer cells, which may provide a useful target for antibody guided tumour localisation
and therapy. The efficacy of tumour localisation would be improved by increased, more
homogeneous CEA expression. Colorectal cancer cell lines are known to show augmentation ofCEA
expression on exposure to various chemical agents or to changing physicochemical environments.
Aim: The aim of this work was to find chemical or environmental factors which successfully induced
increased CEA expression in 3 different colorectal cell lines, Lovo, Ht29 and Colo, which are
respectively high, low and non-expressors of CEA. Studies of differentiation were also undertaken,
by observing concomitant changes in cell proliferation and morphology.
Methods: The three cell lines were cultured in medium containing differentiating agents (Butyric
acid, gamma-Interferon and 5-Azacytidine and Theophylline), or a range of commonly used cytotoxic
drugs at a set dose, or in conditions of altered environmental factors (pH, temperature, oxygen supply,
radiation, and serum content of medium). According to the observed effects of these factors used
singly, combinations of chemical and physicochemical factors were also tested for additive or
synergistic reactions.
The growth, differentiation characteristics and CEA expression parameters were measured by a
combination ofElectron Microscopy, Immunocytochemistry and Fluorescein Activated Cell Sorting.
Membrane CEA expression and total CEA content were compared. In addition, the degree of release
of CEA by the growing cells into their medium was measured by Radioimmunoassay.
A limited investigation of the genetic events which accompanied observed differentiation and CEA
expression was conducted by immunostaining for oncogene products known to be associated with
proliferation, apoptosis or tumour progression, e.g.,p53, Bcl-2, K-ras, and c-myc.
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Results: The differentiating agents were found to induce different effects in the three cell lines, with
only the Ht29 cells showing increased CEA levels with each agent. It was noted that CEA expression
was seen to rise in the Colo cells with two agents, using the more sensitive FACS analysis (Wilcoxon
Rank Sum test).
5-Fluorouracil. hypoxia, serum-depletion and radiation induced increased CEA in some cells and not
in others; Chloroquine, Methotrexate and Taxol were universally successful CEAinducers. Of the
combinations, Butyric Acid plus Interferon was particularly effective, causing potentiated
augmentation ofCEA in Lovo and Ht29 cells.
Increases in CEA were frequently accompanied by significant growth inhibition (T-test, Correlation
co-efficients -0.4, -0.54 & -0.57 for Lovo, Ht29 and Colo respectively); but were not associated with
significant increases in CEA release into the supernatant, as measured by Radio-immunoassay.
Electron Microscopy studies showed mixed responses to the various agents, with signs both of cell
damage and of improved differentiation.
No striking changes in oncogene expression by Ht29 cells exposed to successful CEA-inducers were
observed; very slight changes in Bcl-2 or c-myc with 3 of the agents were noted.
Conclusions:
Apparent non-CEA expressing cells may be induced to express CEA using various agents.
Different colorectal cell lines respond to chemical and environmental changes to different extents, via
different mechanisms.
Potentially useful CEA-inducing agents include Butyric Acid, Interferon, Theophylline, 5-
Azacytidine, Chloroquine, 5-Fluorouracil, Methotrexate and Taxol.
The combination ofButyric Acid and Interferon is particularly powerful in CEA augmentation.
Increases in CEA expression are often accompanied by decreases in cell proliferation, but not by
increases in CEA release.
Augmentation of CEA expression may be accompanied by morphological features of cell damage or of
improved differentiation.
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CHAPTER ONE: GENERAL INTRODUCTION
COLORECTAL CARCINOMA
The impact of colorectal carcinoma can scarcely be underestimated: 20 000 people die from it every
year in the UK alone (260,124). The average age of the patients is 60 years and the incidence
increases with age. Men and women are equally susceptible. The geographical distribution of the
disease makes it predominantly a disease of the Western World. There is a high incidence in the UK,
Western Europe and North America, a low incidence in Asia and South America and only rare
occurrences in Africa and Japan. It has been found that migrants acquire the respective risks of the
areas to which they move. It has also been found however, that some genetic populations have veiy
different risk levels than others in the same environment, e.g. Maori's and nonMaori's in New
Zealand (5,78,133).
ONCOGENESIS OF COLORECTAL CARCINOMA
The Neoplastic Process
Neoplasia as defined by Willis (272) is a combination of disturbances in cell proliferation,
differentiation and the relationship between a cell and its surroundings. The mechanisms by which
abnormalities in these three areas can arise, instigatiing the growth of a tumour, are multiple and
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include inherited gene mutations, random mutations, and viral or physico-chemical induced
oncogenesis.
The genetic model of Colorectal Carcinoma proposed by Fearon and Vogelstein (91) provides a
clearly understandable theory of carcinogenesis as it occurs in the colon and rectum. In order to
construct the full model, the following concepts need to be accepted:
1. There is a progression from adenoma to carcinoma with most if not all carcinomas
starting as adenomas.
This concept was first explored in detail in 1975 by Muto et al (201). He studied 2231 benign polyps
and 275 malignant carcinoma specimens and the associated clinical histories, and noticed that:
a. There was a development from mild to severe epithelial atypia, with an increased
incidence ofmalignancy in specimens showing severe epithelial atypia.
b. There was an increasingly frequent incidence of benign tumour around the spreading edge
of invasive tumour.
c. Patients with the autosomal dominant condition Familial Adenomatous Polyposis (FAP)
showed a progression from having small benign polyps to invasive carcinomas over a period
of 12 years on average. (The genetics ofFAP will be more fully discussed later in this
introduction).
d. Performing a total colectomy, or removing rectal polyps by fulguration prevented the
development of rectal carcinoma.
e. The risk of having colorectal carcinoma varied directly with the number of polyps present.
He concluded that although not all polyps become invasive carcinomas, all carcinomas originate from
polyps. This conclusion was ratified by several authors including Kelvin et al (149), who quantified
the risks of invasion in adenomatous polyps as:
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> 10% if diameter > 2cm
5 - 10 % if diameter 1 - 2 cm
Negligible if diameter <5-6 mm
It should be noted that the risks of invasion in villous polyps were greater than in tubular polyps.
Pertinent to the science underlying these figures may be the findings of Vogelstein et al in 1988 (262),
that the number of ras oncogene mutations increases in proportion to the diameter of adenomas: and
those ofFearon et al in 1987 (93) that monoclonal patterns of chromosome inactivation may be
identified in both adenomas and carcinomas. This leads onto the second concept:
2. Colorectal Carcinoma arises due to the mutational activation of Oncogenes plus the
mutational inactivation of Tumour Suppressor Genes.
Oncogenes and Tumour Suppressor Genes
It is now recognised that a single malfunctioning gene may upset the systems of cell cycle control, cell
growth and differentiation (145,263): aberrant regulatory genes may initiate and maintain cell
transformation (oncogenes, first described in 1910 by Peyton Rous (140) or may fail to suppress the
transformation of the cell (the normal function of tumour supppressor genes, first described in 1971
by Knudson (155). This balance between positive and negative genetic stimuli was first forecast by
Boveri in 1914 (45).
Those cellular genes with the potential to transform the cell are known as proto-oncogenes, and the
aberrant genes they become on activation as oncogenes (37). They can be subdivided into nuclear or
cytoplasmic according to their mechanism of action, and may be activated by viral, chemical or
physical agents. Additionally, it is possible to have a hereditary predisposition for activation of
oncogenes (140).
Viral Activation: (I) DNA, eg papilloma viruses. These encode a protein which binds to a growth
regulatory peptide, disabling it.
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(ii) RNA. These may transduce cellular proto-oncogenes, cause insertional
mutagenesis or transactivation of a cellular gene.
(iii) Retro viruses, eg HTLV, HIV. These may initiate an autocrine stimulatory
system.
Chemical/ Physical Activation: Various chemical agents and other factors such as UV and X-Ray
radiation may damage cellular DNA, leading to mutated geno- and pheno- types. Alternatively, gene
amplification may occur, with intra- or extra-cellular influences inducing overexpression of an
encoded oncogene product.
Hereditorv predispositions: these include abnormalities of chromosome number or form.
One of the important oncogenes in colorectal carcinoma is ras. Mutated ras oncogenes were
reported to be capable of transforming primary cultured cells by Bos et al in 1987 (42). Hybridisation
work performed by the same team found ras mutations in 11/27 colorectal tumours studied. These
findings were repeated by Vogelstein et al in 1988 (262), who found that single base pair ras
mutations could cause cell transformation, and were seen in 40-50% of colorectal tumours.
Tumour Suppressor Genes:
The evidence for the existence of tumour suppressor genes was gathered from the study of cell hybrids
and of familial tumours:
Hybrids of tumorigenic and non-tumorigenic cells did not necessarily result in immortality in vitro or
tumour formation on transfection, suggesting an internal tumour regulation system, dominant over
genes inducing malignant transformation.
Familial tumours including Familial Adenomatous Polyposis, Retinoblastoma and Neurofibroma 1
were found to have in common a mutation on Chromosome 17. Loss of heterozygosity on 17p was
found to commonly occur in Breast, Lung and Colon carcinoma, suggesting the loss of a cell
regulatory gene important to suppress tumours in various types of cell (189).
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Tumour suppressor genes should induce 3 responses: Gl/S phase arrest, end-stage post-mitotic
differentiation and apoptosis (140), by activation of transcription or by blocking the interaction of
DNA polymerases with the rest of the DNA replication complex. Loss or inactivation of tumour
suppressor genes prevents the cell from following one of these pathways when appropriate.
In the colorectum, the most crucial tumour suppressor gene found to date is p53, which was first
identified by Baker et al in 1989 (75,16). She described a common allelic loss on 17p in > 70% of
colorectal carcinomas, with a very different p53 protein associated with these tumours than that found
in normal cells. The conclusion was that a mutant, ineffective form of p53 was present in the
tumours, with resulting non-suppression of transformed cells.
Another important regulatory gene in the colorectum is DCC ("Deleted in Colorectal Carcinoma")
which was cloned by Fearon et al in 1990 (92), is found on chromosome 18q and normally encodes a
cell adhesion molecule (CAM). This cell surface CAM regulates cell behaviour through interactions
with surrounding cells; deletions on 18q therefore remove this control on cell behaviour, leading to
the possibility of invasion. A high proportion (73%) of colorectal carcinomas has been found to have
allelic deletions in chromosome 18 (262).
A further significant site of allelic deletions in colorectal cancer is on Chromosome 5, which is
particularly prevalent in Familial Adenomatous Polyposis (262). Bodmer et al in 1987 used DNA
probes to identify the specific gene associated with FAP, on chromosome 5q21-22 (40). Some 20%
of colorectal cancers, without FAP, also show allelic deletions on chromosome 5.
3. Four - five genetic changes are required to form a tumour, occurring in any order.
Carcinogenesis in general has been found to be a multistep process (17). In the colon and rectum,
over 90% of carcinomas have previously been shown to have ^ 2 genetic alterations (262). The form
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of these genetic alterations may be at the nucleotide or chromosomal level, termed microsatellite and
chromosomal instability respectively (169). The two types of genetic instability may both be present
in one tumour.
Studies of genetic mutations by Sasaki et al in 1989 found evidence of loss of heterozygosity on 15
different chromosomes in patients with FAP, and on 8 different chromosomes in patients with non-
Polyposis associated Colorectal Carcinoma (234). It has already been noted above that the activation
or amplification of oncogenes such as ras may be necessary for the development of full-blown
carcinoma in Polyposis patients.
An interesting study by Delattre et al in 1989 found that distal colorectal carcinomas showed a far
greater preponderance of deletions or mitotic abnormalities, (e.g. hyperdiploidy), on chromosomes 5,
17 and /or 18, than was evident in proximal colorectal carcinomas, although ras mutations occurred
consistently throughout the colon and rectum (70).




























EPIDEMIOLOGY of COLORECTAL CANCER
There is much debate over the epidemiological factors which may or may not alter the risk of
developing colorectal carcinoma. Bowel flora variations in particular have been studied: high risk
populations have a greater proportion ofBacteroides to aerobic bacteria, but the increased degradation
ofbile salts this causes has not been shown to be carcinogenetic per se (5,201,138).
Several conditions are known to confer a higher risk of colorectal cancer, including Familial
Adenomatous Polyposis, multiple Adenomas. Gardner's Syndrome and Ulcerative Colitis (149). In
FAP. the risk of developing cancer borders on 100%. Adenomas in patients who do not have FAP
have a variable risk level for invasion (149,201). The risk varies most significantly with the size of
the adenoma, but also with histological type - villous adenomas, which are the least common, carry a
higher risk of invasion than tubular adenomas. Gardner's Syndrome is characterised by the presence
of polyps of multiclonal origin (144).
The risk of developing adenocarcinoma of the colorectum in patients with Ulcerative Colitis increases
with the time-span of the disease, becoming greater than 12% at 20 years, on average.
Other less common predisposing factors in the development of colorectal carcinoma include radiation
and ureterosigmoidostomy.
CLINICAL PICTURE:
Macroscopically, colorectal cancer may take the form of a protuberant mass, an ulcer or a solid
penetrating tumour. The typical presentation varies with the position of the cancer: right-sided
tumours tend to present as a mass, or with anaemia, left-sided tumours with obstruction and rectal
tumours with fresh bleeding or tenesmus (78).
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Microscopically, by far the most common type of cancer is the adenocarcinoma, which is the
histological tumour type studied throughout this work.
SPREAD:
As with most tumours, colorectal cancer may spread in several ways: directly, via the blood stream,
portal or systemic, via the lymphatic system or across the peritoneal cavity. Often there is an element
of all of these at presentation. The degree of spread through the bowel wall and into the lymphatic
system correlates with the prognosis, as first observ ed by Dukes (85). More precise recognition of
small hepatic and extrahepatic metastases has led to an improvement in the accuracy of this staging
system (268).
TREATMENT:
Surgery is the best treatment option for this disease. The first rectal excision for carcinoma was
performed by Von Volkermann in 1878. Unfortunately, in recent years there has been no change in
the overall survival for patients with colorectal cancer, being only 50% at 5 years (200). This is
partly because of the relatively small proportion of tumours picked up when still locally confined and
thus "curatively" excised - 30% of patients present initially with advanced metastatic disease (244).
An additional problem is that in the USA, one third of patients who have a so-called curative
resection suffer a recurrence of the disease (10). Non-surgical treatment, i.e. Radiotherapy and
Chemotherapy can slow the progression of the disease, but has not yet been shown to improve overall
survival.
A different approach to treatment may be called for, in order to specifically target the tumour cells -
thus pursuing the predictions for cancer treatment in this century made by Ehrlich, with his "Magic
Bullet Theory" (67). In order to consider cancer treatment at a cellular level, an indepth study of
individual neoplastic cells is required:
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Normal cell development involves differentiation from stem cells to mature cells. In neoplasia,
differentiation is suppressed genetically, so that the cells are "frozen" at an immature stage. This
may cause the expression of an altered phenotype. Differentiated cells express and secrete
cytostructural proteins. Neoplastic cells express particular cell-surface proteins or antigens. Some of
these antigens are promoters of adherence, which may be a necessary property of invading cells
(188). Carcino-embryonic Antigen is an example of a cell-surface antigen which is commonly
expressed by moderate to well-differentiated colorectal carcinoma cells and has a very important role
to play in cancer detection and therapy.
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CARCINO-EMBRYONIC ANTIGEN
Carcino-embryonic Antigen, (CEA), was first described by Gold and Freedman in 1965 (777).
Using the Ouchtertony technique of double diffusion, they demonstrated a high degree of antigen
cross-reactivity between normal rabbit sera with pooled human sera and rabbits immunised with
human tumour extract. They repeated the technique to look for the antigen in 322 different tissues -
normal, fetal and malignant(77<5). The antigen was positively identified in fetal tissues and cancers
originally derived from the areas of the gastrointestinal tract which are of stomatodeal origin. They
therefore coined the name Carcino-embryonic Antigen. Since that time, CEA has been extensively
studied and has also been identified in non-endodermally derived cancers and normal tissues,
including lung and breast and in non-cancerous tissues from the gastrointestinal tract (270,197,193).
Serial grafting of tumour cells in animal hosts lias proved that the CEA expressed in these tumour
cells arises from the tumour cells, and not the hosts (123).
Improved methods of detection ofCEA have been developed (104,279) and include:
Farr or ammonium sulphate technique
Z-gel technique
Radioimmunoassay - specific, non-specific or cross-reactive
CEA can be purified for close study by a combination of perchloric acid/ lithium diiodosalicylate
extraction, column or ion exchange chromatography and electrophoresis (104).
Structure:
Purified CEA has been subjected to a battery of investigations including acid hydrolysis, enzymatic
hydrolysis, periodic oxidation and neuraminadase oxidation (104). These methods have allowed a
detailed knowledge of the structure of CEA to be built up. CEA is a complex glycoprotein of 180
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OOOd molecular weight (256). It displays heterogeneity in terms of its protein:carbohydrate ratio,
and the concentrations of amino acid residues, sugar residues and sialic acid (17). Colonic
carcinoma CEA varies from other tumour CEA in these areas.
In general, the carbohydrate portion forms 50 - 65% of the total molecule. This further divides into:
N-acetylglucosamine (v40%)
Fucose, mannose, galactose, sialic acid (variable amounts)
N-acetylgalactosamine (minimal amount) (104,23,17)
These sugars are structured into linear or branched oligosaccharide chains of variable length. The
polypeptide part forms 35 -50% of the molecule. The amino acid residues are in chains with 7
extracellular domains, each having a sequence similar to immunoglobulin and intercellular adhesion
molecule domains. The sidechains of the amino acids have terminal COH and OH groups (23,112).
Colonic carcinoma CEA has a carbohydrate fraction of 49.5 - 63.7% and a fixed amino acid fraction.
Compared to gastric carcinoma CEA, there is only one fifth as much sialic acid and a higher
concentration ofN-acetylglucosamine (17).
The carbohydrate and polypeptide parts of CEA are linked by peptide bonds or O-glycosidic linkages.
In addition, there are intra-oligosaccharide chain disulfide bonds (23,277,112).
Location:
CEA is found free in serum, bile and intestinal contents and attached to various cells (256,139,175).
Its exact cellular position when it is expressed, has been determined by a number ofmethods:
Ultraviolet light studies of fluorescein-conjugated rabbit anti-CEA serum demonstrated that CEA
localised to the plasma membrane (114); studies with ferritin conjugated goat anti-CEA antiserum
confirmed the localisation of CEA to the plasma membrane and further specified its location to be on
the glycocalyx coating the cell surface membrane (182,113).
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There is a heterogeneity of CEA expression in seemingly identical cells. This has been illustrated by
studies of HT29 colorectal carcinoma cells where homogenous anti-CEA antibody penetration was
shown by ffeeze-drying, fixation and autoradiography, and yet the binding of these antibodies to the
cell-bound CEA was very heterogenous (55). Several foci of genes are thought to control the degree
of expression of CEA, with variation at transcriptional, post-transcriptional and DNA methylation
stages (44). The variation produced in the phenotype is mainly in the membrane-bound CEA
fraction, rather than in intracellular CEA (239). An important discovery in studying tumour cell
CEA expression, was that expression varies with tumour cell differentiation: there is a higher degree
of CEA expression in well-differentiated cancer cells compared to poorly differentiated cells
(41,72,125,41). The relation between CEA expression and differentiation is complex.
Circulating CEA was first demonstrated in 1969 by DMP Thomson et al (253), using a radioimmuno¬
assay technique. Normal levels of serum CEA in humans are usually taken to be 0 - 2.5ng/ml, and
do not vary with sex, race, age or diurnal rhythm (276,110). Levels are raised in many disease states
- both benign and malignant. As a general rule, a level of circulating CEA of 5.0ng/ml has been
taken to mark a cut-offpoint between benign and malignant disease, but this is not without
exceptions.
Disease States with Raised CEA:
Benign: Inflammatory Bowel Disease (92% patients with extensive Ulcerative Colitis)
(256,106,192,276)
Gastritis and Peptic ulcer disease (256)
Pancreatitis, especially alcoholic (256,173,276)
Alcoholic liver disease and other liver diseases (256,276)
Renal disease and Uraemia (197)
Benign Prostatic Hypertrophy (256)
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Bronchitis and Emphysema (255)
Benign Colorectal Polyps (5 - 10% only) (256,276)
Malignant: Carcinoma of the Gastrointestinal tract. Lung, Breast, Pancreas, Prostate, Thyroid and
female genitourinary tract (256,174,197,173,71,276).
In addition, serum CEA levels have been noted to be raised in cigarette smokers, without necessarily
having any of the pathological conditions listed above (256).
The raised levels of serum CEA in various liver diseases is thought to be due in some part to a
slowing of the metabolism of CEA, which is generally accepted to occur via the liver, with a normal
half-life of 1 - 8 days (256,175).
Antibodies to CEA have also been detected in the circulation - in approximately 70% ofpatients with
gastrointestinal cancer. Large volume tumours have been reported to have lower levels of circulating
anti-CEA antibodies, which may be due to saturation by the CEA released by the tumour tissue, but
other studies have reported no difference in circulating CEA antibodies with differing tumour size
(125,274).
Function of CEA
CEA is thought to have a role to play in intercellular recognition and adhesion. Cell lines studied for
fluorescein labelled CEA were found to display properties of aggregation in direct relation to their
degree of CEA expression, and to be prevented from aggregating by anti-CEA antibodies (34). CEA
is also thought to be important in the intercellular organisation of architecture (34), particularly in
malignant cells. Overproduction of CEA has been shown to be associated with disruption of the
normal lateral adhesion within cell layers and with disordered cell architecture (240).
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Clinical Relevance of CEA:
CEA is a tumour marker. It lias an important role to play in cancer detection and treatment as such,
although it can not be described as an ideal tumour marker (24). Features of the ideal tumour
marker include:
1. The tumour marker is produced or expressed by the diseased cells only, and is not found in health
or in benign diseases.
2. It is readily detectable in body fluids.
3. It is present at an early stage in the disease process.
4. It is present frequently enough for efficient screening pick-up of disease.
5. Levels of the tumour marker vary with the amount of tumour bulk
6. Levels of marker alter according to disease response to therapy.
Serum CEA levels have been extensively studied pre- and post- tumour excision, for long term follow-
up periods. It has been shown that the pre-operative serum CEA level varies proportionately with
tumour spread, and inversely with differentiation and 5 year survival (275,264,175). Throughout
therapy, whether it be surgical, by radiotherapy or chemotherapy, CEA levels have been found to
mirror almost all disease regressions and most disease progressions (137,264,248). The pattern of
CEA levels post-operatively has been found to be particularly informative: stable, elevated CEA
levels are highly predictive of incomplete excision, recurrent or metastatic disease; a transient rise is
not indicative of residual disease; and a fall to normal levels is strongly predictive of complete
excision of disease (246,182,141,249). CEA levels have been found to be more accurate in
diagnosing recurrent disease even than CT scanning (27). The National Health Symposium in 1981
declared that serial plasma CEA assays correlated to the stage of colorectal cancer, and were useful in
monitoring therapy (119).
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With long term follow-up, it has been found that an increase in CEA levels tends to precede clinical
evidence of recurrent disease by an average of 9 months. Rising CEA levels have been used as an
indication for second look laparotomy in several clinical trials. The results of the recent MRC study
are currently awaited.
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CLINICAL APPLICATIONS OF CEA - RAID AND RIGS
RADIOIMMUNODETECTION (RAID)
The expression of CEA on tumour cells can be used in the clinical context. Tagging the CEA
antigen with labelled antibody leads to the possible identification of tumour deposits which may not be
picked up by conventional investigations - X-ray, Ultrasound and Computed Tomography, and
therefore to the possibility of cell-specific therapy.
Historically, antibodies were first described as proteins in 1934 (188). Ground breaking work with
antibody-antigen localisation was performed by Pressman et al. in 1947, who succeeded in preparing
anti-tumour sera where Hericourt and Richet had failed in 1895 (219). They demonstrated that
innoculating rabbits with rat kidney extract and then injecting radiolabeled serum from these rabbits
back into rats caused localisation of radioactivity in the rat kidneys. Similar work with mouse
Wagner osteosarcoma extract was performed by the same team in 1953. The localisation of labelled
antibodies raised against the mouse tumours (in rabbits) to the tumour, which did not happen with
non-tumour rabbit anti-mouse antibodies led to the suspicion that tumours bear specific antigens
(68,218,202).
In 1975, Kohler et al further developed the technique of producing appropriate antibodies from live
animal sources to cell culture lines - thus improving the specificity of the purified antibodies to the
tumour antigens (218,158).
Radiolabelling of antibodies was initially performed using 131 Iodine. Subsequently,125 Iodine and111
Indium have replaced 131 Iodine. 125 Iodine has been found to give a better tumourtissue ratio than
131 Iodine, and 111 Indium has been found to be more efficacious in identification of hepatic metastases
(207,26,77).
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The technique of immunodiagnostic scanning was first developed in 1967, when131 Iodine labelled
anti-fibrin antibody was injected and external scans used to successfully locate 75% of a mixture of
tumours (210,245).
Goldenberg et al in 1978 and 1980 first successfully demonstrated radioimmunodetection of colorectal
cancer in two series of 18 and 37 patients. The patients were given 131 Iodine labelled goat anti-CEA
antibody, then scanned by external gamma scintillation photometry. Background radiation was
accounted for by digital subtraction. The results of the scans were then compared to the results of
conventional investigations and the operative findings. Radioimmunodetection was found to have a
sensitivity of 85% and a specificity of 98% in these series (120,122). A larger series of 170 patients
confirmed these findings, with 93% of tumours successfully located. Tumours which were negative
for CEA expression were not identified by RAID, but serum negativity for CEA did not affect tumour
localisation (121).
The favourable results ofGoldenberg were not initially matched by other groups (180,183). The
main problem was that background radiation was too high and false positives resulted from the
excretion of radiolabelled antibody in the reticuloendothelial system. Digital subtraction produced
improved scans, but toxicity problems were centred around the high uptake of radioactivity in the
reticulendothelial system.
Fragmented antibodies were developed in order to combat the toxicity problems. Removing the Fc
portion of the antibody enzymatically to leave F(ab')2 or Fab' fragments meant that there was less
non-specific binding of the antibody to Fc receptors and the lower weight of the fragments lead to
more rapid uptake by tumours, more rapid excretion by the kidney and thus shorter half-life in the
body.
Mach et al in 1981 successfully performed radiolocalisation of tumour using radiolabelled F(ab')
fragments (180). Subsequent xenograft and clinical trials confirmed the specific localisation of
tumours by whole and fragmented antibodies using autoradiography, and demonstrated that there is
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improved localisation, decreased toxicity and overall improved efficacy with fragments
(.51,52,147,163,166).
Comparisons between F(ab')2 and Fab' fragments did not reveal significant differences in toxicity or
accuracy (118). Fab' is cheaper and more readily available, however, and further studies have
revealed differences in pharmacokinetics: Fab' distributes more quickly into a larger distribution
volume, has a higher interstitiuin:plasma ratio and is cleared many times faster than whole antibody,
with F(ab'>2 fragments lying somewhere between the two (63).
Recent work has utilised 76Bromine in place of 12 Iodinc, with good results on PET scans (177).
Another new antibody imaging agent being researched is "CEA-Scan", which is an anti-CEA Fab
fragment labelled with technetium- 99m-pertechnate. External scintigrams taken using this agent
were found to give improved images of the pelvis and the extra-hepatic abdomen (229). Another
approach in immune-guided tumour detection has been to use fluoresceinated monoclonal antibodies
and laser immunophotoscanning. A preliminary study with primary colon carcinomas in 6 patients
showed successful tumour localisation in each patient with this method (100), demonstrating the
feasibility of immunophotodiagnosis for tumour detection clinically.
The uptake of radiolabelled whole or fragmented anti-CEA antibody by tumour cells has consistently
been found to be heterogenous (99,2). Factors affecting uptake were vascular permeability, vascular
volume and CEA accessibility. The size of tumours was also found to correlate with fragment uptake
(52,59), which may be due to these factors and to the rising interstitial pressure in larger tumours,
which leads to a pressure gradient from the centre of the tumour outwards, and compromises the
vasculature. Altering tumour blood flow with Tumour Necrosis Factor alpha was not found to
significantly alter radiolabelled antibody localisation (213), although the recent development of a
bispecific antibody for CEA and TNFa may improve the localisation and immuno-absorption of
TNFa, overcoming some of the problems with its short half-life and toxicity (228). Uptake of
radiolabelled antibody was also shown to be improved by the administration ofmannitol 15 minutes
pre-antibody injection in an animal model (2).
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Studies of human adenocarcinoma spheroids in culture with varying concentrations of131 I anti-CEA
antibody revealed a concave curve of increasing radiation with increasing concentration of131 Iodine.
A resistant population of cells was thought to account for this - possibly the innermost, potentially
hypoxic cells {164).
In comparison with conventional investigative measures, radioimmunolocalisation performs well, if
the tumours express the appropriate antigens. This may be more of a problem in poorly differentiated
tumours, but RAID has been found to pick up poorly diffentiated tumours masquerading as fibrosis on
Computed Tomography (269). Importantly, comparisons with CT scanning found that positive
retroperitoneal lymph nodes, less than 1cm in diameter, which were too small to be picked up by CT,
were identified using [1311] monoclonal antibody F(ab' )2 imaging (63,241).The pharmacokinetics,
dosimetry and accuracy ofRAID has been shown to be altered in patients with liver metastases or
raised liver enzymes, presumably due to altered hepatic clearance of injected antibody (32).
RADIOIMMUNOGUIDED SURGERY (RIGS!
The development of small, hand held gamma detector probes has also improved the efficacy of
radioimmunodetection of tumours, and has allowed the introduction of this technique into the
operating theatre (3,76,190). The probe has a role to play pre-, peri-and post-operatively: Radio-
immunoguided surgery means that a presumed "curative" resection of disease as estimated by the
human eye or hand may be extended if necessary if small, clinically occult lesions are picked up with
the probe. One series found that use of the probe altered the planned surgery in 8/31 patients and
another, in 3/16 patients (207,242). A trial by Arnold et al found that extra information, especially
in staging, was provided by the probe in 29/36 patients (7). A combination of pre-operative gamma
scan and intra-operative probe scanning has been found to be more accurate than ultrasound, CT and
clinical, including operative, findings (160).
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Post operative follow-up patients who are noted to have a sudden rise in serum CEA may be suitable
for second-look surgery, in which scenario, particularly when there is an absence of clinical symptoms
or signs, RIGS is helpful in identifying site of recurrence.
The relation between the expression of CEA by tumours, the uptake of radiolabelled antibody and
seropositivity for CEA has been studied. One trial showed no relation between the amount of
antibody uptake and the serum CEA (47), but a multicentre trial found that 80.3% ofCEA positive
patients compared to 63% of CEA negative patients had lesions identified by immunodetection (241).
THERAPY
Drug or radiation therapy can theoretically be specifically directed to cancer cells by attaching them to
appropriate antibodies.
In mouse models bearing human colon carcinoma tumours,90 Yttrium labelled anti-CEA antibodies
improved survival and increased cell kill (146, 54). Yttrium is a trace element which is a beta
emitter, and the tumour dose estimated to be delivered in these trials was 34 Gray. A clinical trial
where patients with B cell lymphoma were given131 I labelled antibodies against B cells, showed a
favourable response in 16/19 patients.
The development of bispecific antibodies has allowed improved efficiency of therapy delivery. The
antibodies bind to CEA and also to trace elements, eg Bismuth 211 (185), to cytotoxic drugs, eg
Melphalan, Etoposide and Methotrexate (235,214,254) or to immunologically active chemicals.
Animal trials have been promising (29); one clinical trial showed subjective improvements only
(53). In vitro trials of pre-immunising cells with biotinylated anti-CEA monoclonal antibody prior to
administration of cytotoxic bound anti-CEA Mab have dramatically reduced the required dose of
cytotoxic drugs; animal and clinical trials have yet to be performed, but there is a potential for
improving the efficacy of antibody targetted cytotoxic drug delivery (203 ).
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Conjugating antibodies to non-competing antigens which induce antibody dependant cell-mediated
cytoxicity has been investigated: a clinical trial of 189 patients showed 30% improved survival and
27% fewer recurrences (19,226,98). Delayed type hypersensitivity reactions have also been induced
using recombinant bacillovirus human CEA (33).
A monoclonal antibody with dual specificity for CEA and anionic boron cluster compounds has also
been developed. This antibody allows the selective accretion of a high concentration ofBoron-10 in
tumours for Boron neutron capture therapy (221).
Improving the uptake of anti-tumour antibodies is crucial to developing cell-specific therapy, and a




The goal ofDifferentiation Therapy has been succinctly defined by Ferrari et al ( 96) as: "To restore
the physiological balance between growth and differentiation signals, so that tumour cell lose their
self-renewal capacity and progress to terminal differentiation or death by apoptosis". Agents which
induce differentiation, whether they be natural, synthetic or recombinant compounds, act on the
signalling pathways which control the cell's commitment to cell proliferation or terminal
differentiation, (mutually exclusive events (.209)). Work by Leo Sachs on myeloid leukaemia cells
showed that it is possible to suppress malignancy using differentiating proteins, without necessarily
having to reverse genetic mutations (231). Using differentiation therapy as an alternative to
conventional cytotoxic strategies is not likely to be a viable option, since the response rate of tumour
cells will not be 100%, and remission would not therefore be achievable (28). The use of
differentiation therapy in combination with other treatment regimes such as tumour targetting and
cytotoxic therapy, however is a viable option.
DIFFERENTIATING AGENTS
Several workers have evaluated exposing various tumour cells to various of these differentiating
agents, (including polar solvents, Hexamthylene Bisacetamide (HMBA), Butyric acid, Retinoic acid,
Interferon and Transforming growth factor), to cytotoxic agents and to changing environmental
stresses. This work was initiated in 1971, when mouse erythroleukaemic (Friend) cells exposed to
Dimethyl sulfoxide (DMSO) were noted to undergo erythroid differentiation (103). The agents
which have subsequently been shown to induce MELC differentiation are as follows (187, 96):/
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POLAR COMPOUNDS: DMSO, HMBA





ANTIPROLIFERATIVE AGENTS Interferon. Cytotoxic Drugs
PHYSICAL AGENTS: Ultraviolet & X-ray radiation
The differentiation in the MELC cells was measured by terminal cell division; the presence of heme-
synthesising enzymes and membrane-associated eiythroid specific enzymes; increasing a and p -
globin mRNA; altered proportions of Hb™1 and Hbmin; and decreased expression of p53. The
translocation of the cells into nude mice caused death unless there was evidence of differentiation in
the cells by this criteria.
The National Cancer Institute now recommends a disease-orientated human tumour cell line panel for
testing ofmultiple potential differentiating agents, which may induce a variety of responses in the
different target cell types, and may interact with one another in multiple patterns (101).
Polar Solvents
Since 1971, the effects ofDimethyl Sulfoxide on leukaemia cells and ofDMSO and other polar
solvents on colorectal cancer cells have been further explored. Friend cells were induced to express
an erythrocyte membrane antigen by exposure to DMSO in 1973 (75). The Human Acute Myeloid
Leukaemia cell line HL60 grown with DMSO in 1978 was found to show increased functional activity
(phagocytosis activity was elevated from 10 to 90%); with changes in morphology to terminally
differentiated cells, and growth inhibition at concentrations of DMSO of >1.5% (61). HL60 cells
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grown in the presence ofDMSO have also been shown to undergo genetic changes, showing
decreased expression ofMPO and c-myc oncogenes, which are associated with differentiation and
proliferation respectively (4).
Human colon cancer cells were first grown in the presence ofN,N dimethyl formamide (DMF) by
Dexter et al in 1978 (75). Cell lines DLD-1 and HCT-15 were used. DMF was found to inhibit
clonagenicity, induce changed morphology and increase the membrane CEA expression, as measured
by fluorescent antibody assay. In addition, xenograft inoculation studies were performed and cells
pretreated with DMF found to show much less tumorogenicity than nontreated cells. Subsequent
studies agree with the growth inhibitory properties of these polar solvents, but variable effects on CEA
expression have been observed (102).
The human colorectal cancer cell line HRT-18 has also been grown in the presence ofDMSO,
(243,258). In both of those studies, DMSO was found to inhibit growth but also to result in
decreased CEA expression. Similar effects on cell growth were seen on exposing cell lines SW480
and SW620 to DMSO.
Hexamethvlene Bisacetamide
Friend cells were first tested with Hexamethylene Bisacetamide, by Reubens et al in 1976 (225), and
were found to undergo erythroid differentiation. Further experiments in 1977 studied the effect of
Hexamethylene Bisacetamide on the human malignant mesenchymal cell line CBT-glioblastoma.
The cells were seen to have increased procollagen synthesis, and an increased ratio of Type I: Type II
procollagen. On xenograft implantation, different types of tumour altogether were produced -
fibrosarcomata as opposed to glioblastomata.
28
Butyric Acid
Butyrate and its analogues have been found to be potent inducers of differentiation in both neoplastic
and non-neoplastic cells (205). Butyrate is a naturally occuring metabolite, produced in the colon
from bacterial fermentation. It is found in fruit and vegetables, and particularly in milk fat.
Butyric acid was found to induce similar changes to DMSO in Friend cells by Leder et al in 1975
(168). In addition, Butyric acid has been found to induce growth inhibition and morphological
changes in HeLa cells, neuroblastoma and Chinese hamster ovary cells. Another hamster tumour
line, the aggressive fibroblast BP6T line was found to show decreased clonagenicity, proliferation and
intracellular fibrinolysis, inhibited anchorage independent colony formation and a changed, more
uniform morphology and cell orientation on exposure to Butyric acid (167).
Human colorectal cancer cell line HRT-18 grown with Sodium butyrate has shown decreased growth
and increased CEA expression in repeated studies (243,258). The cell lines SW480 and SW620 also
show decreased growth on Sodium butyrate exposure. A comparison of normal colonic epithelial
cells and LIM 1215 colon cancer cells found that butyrate inhibited growth and induced increased
CEA expression in the neoplastic cells only (211).
DNA and RNA probes have been used to investigate the mechanism of CEA induction by Sodium
butyrate (255,234) and increased transcription and post-transcription rates have been found.
Retinoic Acid
Retinoic acid derivatives were first used in cancer therapy in the treatment ofBasal Cell Carcinoma in
the early 1960s (48). Since then, they have been used to treat Acute Myeloid Leukaemia, T-cell
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Lymphoma and bronchial tumours. The action ofVitamin A as a growth inhibitor, with concomitant
effects on epithelial differentiation has been well documented, but is not fully understood (176,1).
HRT-18 treated with retinoic acid has been shown to result in reduced growth and variable
suppression of CEA expression (243,258).
Interferon
Interferon was first noted to have anti-neoplastic effects in 1970, when it was shown to inhibit the
multiplication ofmouse neoplastic cells (8). Human colorectal carcinoma cell lines have since been
repeatedly shown to have dose-dependent growth inhibition and increased CEA expression on
exposure to Interferon (8,128,273). Comparisons of the various different interferons have identified
gamma-Interferon as the more potent growth inhibitor (159), and it has been confirmed as modulating
CEA mRNA levels in colorectal cancer cells (194). A comparison of 7 different human colorectal
carcinoma cell lines grown in the presence of gamma-Interferon found growth was inhibited in all 7
lines, suggesting a common receptor for Interferon. Interestingly, one of the cell lines which was
previously thought to be a non-expressor ofCEA was induced to express CEA by exposure to gamma-
Interferon.
Studies of polarised (suramin-treated) HT29.D4 human colorectal cancer cells demonstrated that the
administration of gamma-Interferon to the basolateral rather than the apical compartment resulted in
increased CEA expression, suggesting that the Interferon receptors lie in the basolateral membrane
(14).
A clinical trial of 6 colorectal cancer patients given alpha-Interferon preoperatively compared the
pretreatment biopsy tissue to the treated, resected specimens. CEA expression was found to be
increased in the patients who had some degree of CEA expression pre-treatment (186).
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Interferon has also been found to increase the expression of other membrane antigens by various
tumours: human lymphoblastoid cells and fibroblasts express increase HLA-A3, B2microglobulin
and HLA-B5 (94,22); melanoma cells express increased melanoma-associated antigen, B2m and
HLA-A,B,C and DR (108); and breast cancer cell line MCF7 expresses increased cell surface antigen
andHLA (127).
Xenografts of human breast tumour treated with gamma-Interferon for 4 days showed increased
radiolocalisation on administration of radiolabelled anti-HLA-DR antibody (232).
Growth Factors
The significance of growth factors in the neoplastic process has not been fully elucidated. Studies of
biopsied gastric malignancies show evidence of increased growth factor production compared to
normal tissue (35). However, Transforming Growth Factor (TGF) beta has been found to inhibit
lymphoid, myeloid and epithelial cell growth (201). In MOSER colorectal cancer cell lines, it has
been found to cause increased CEA production, and increased expression of acidic and basic epithelial
keratins - a sign of differentiation (57). TGF-beta is thought to target B23 protein, the synthesis of
which signifies a commitment to mitogenesis.
Studies of Insulin-like Growth Factor (IGF) effects on HT29.D4 cells by Remacle-Bonnet in 1992
concluded that the IGF-I receptor on these cells is an important control of differentiation (225).
Miscellaneous Differentiating Agents
Vaso-active Inhibitory Peptide and cyclic AMP have been shown to cause longer doubling times of
colorectal cancer cells in vitro and increased release of CEA into the cell supernatant (142).
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Xenograft studies with cAMP treated colorectal cancer cells demonstrated increased CEA expression
and increased localisation of radiolabelled anti-CEA antibodies (131).
CYTOTOXIC DRUGS & RADIATION
Human HL-60 leukaemia cells were exposed to a range of cytotoxic drugs by Collins et al in 1980
(60), including Actinomvcin-D. Adriamycin, Daunomycin, Cytosine arabinoside, Vincristine and
Hydroxyurea. All the agents had a growth inhibitory effect but only actinomycin-D slightly induced
cell differentiation. In another study, AML cell lines grown in the presence of Actinomycin,
Methotrexate, Cytosine, Vincristine and Daunomycin showed characteristics of improved
differentiation including lysosome secretion, enzyme activity, bacterial killing and increased
adherance (157).
Isolated studies exposing colorectal cell lines to 5-Fluorouracil, Doxorubicin and Docetaxol have
shown respectively increases in CEA expression, reduced proliferation rates or both (220,89,263).
Methotrexate has also been observed to induce significant differentiation in human colon cancer cells
(170).
Combining actinomycin-D or Cyclohexamide with gamma-Interferon has not been shown to increase
the augmented CEA expression seen with gamma-Interferon alone in studies ofHT29 colorectal
carcinoma cells (254).
5-Fluorouracil (5FU) given in combination with gamma-Interferon in vitro has been shown
consistently to cause synergistic growth inhibition, but studies disagree on whether the effects on CEA
expression are synergistic or independant of each other (179,69). One study on mice transfected with
human colon cancer cells confirmed that the combination of 5-Fluorouracil and Interferon produced a
better tumouricidal effect than the agents given alone (198).
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Radiotherapy
Radiotherapy alone has not been found to induce significant differentiation ofHL-60 leukaemia cells
(60); however, studies of gastric cancer MKN45 cell lines did find that radiotherapy induced dose-
related increased CEA expression (135). A study of the effects of pre-irradiation on
radiopharmacological localisation in human colon tumour xenografts using mono- and bi-specific
antibodies found significant increases in localisation of both antibodies after the radiation (129).
PHYSICO-CHEMICAL ENVIRONMENT
Temperature
Wong et al heated colorectal cancer cell LS174T cells in 1989. They found significant cell death
occurred at temperatures over 43 °C and a 40 - 50 % increase in CEA expression after one hour of
heating to 42'C (271). Xenografts bearing T380 colorectal cancer tumours were heated to 41.5°C for
45 minutes and a significant increase in radiolabeled antibody localisation was noted by Gridley et al
in 1991 (130).
Combining heat treatment (40°C for 30 minutes) with retinoic acid on gastric carcinoma MKN-45
cells produced more growth inhibition and CEA expression than with retinoic acid alone (156).
Early clinical trials of heat treatment for various cancers involved a high mortality and morbidity,
with the most responsive tumour type being melanoma (56). Heat treatment for colorectal cancer has
not been further clinically developed due to the adverse side effects and poor response.
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Starvation
Porro et al in 1986 grew several colorectal cancer lines including HT29 in serum free medium and
found growth inhibition and increased CEA production compared with growing in whole medium
(216). Substituting glucose with galactose had similar growth inhibitory and CEA augmentation
effects on HT29.D4 cells studied by Fantini et al in 1989 (90).
COMBINATIONS OF DIFFERENTIATING AGENTS
The interactions between differentiation agents may be additive, synergistic or antagonistic. If the
agents act on the cell through the same pathway, the results should be additive. Synergistic and
antagonistic interactions are more complex, with various converging and diverging mechanisms
(101).
The use of combinations of differentiating agents and cytotoxic drugs has been advocated to increase
the number of cells committed to programmed cell death. Work done on mouse erythroleukaemia
cells (MEL) using Trans-retinoic acid and Cytosine Arabinoside showed enhanced differentiation,
suggesting that the cytotoxic agent may generate a "differentiation- responsive state" (96).
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COLORECTAL CANCER CELLS IN VITRO
The first human colorectal cancer cells to be cultured in vitro were Ht29 cells, in 1964, by Fogh et al (
97). They were developed from a primary adenocarcinoma, removed from a 44 year old Caucasian
woman. Ht29 cells were described as showing an epithelial-like morphology, and were observed to
have abnormalities of chromosome number and structure. Specifically, Ht29 cells are aneuploid with
variable losses and gains of different chromosomes, e.g. 15% show a loss of chromosome 7, 34% a
loss of chromosome 15 and 12% a gain of chromosome 15 (169). They are known to express mutant
p53. Work written up by Zweibaum et al in 1991 (280) provided more information about the
characteristics ofHt29 cells: they were described as being poorly differentiated, with an absence of
tight junctions, domes, apical brush borders, mucus secretion and CEA expression. It was particularly
noted that the differentiation of the Ht29 cells could however be modulated, for example by growing
in glucose deprived medium or in the presence of Sodium Butyrate and that the cells could
successfully be transfected into nude mice.
Lovo cells were first reported to be established in culture by Drewinko et al, after four years of
working with them. The cells were originally taken from a metastatic nodule of Colorectal
adenocarcinoma (83). They were found to have an aneuploid karyotype (modal number 49), but with
variation in chromosomal content between cells in one clone (as also seen in Ht29 cells). They
showed chromosomal and microsatellite instability. Wild-type p53 expression was noted, precluding
mutated p53 as the cause for the genetic instability. Morphologically, they were seen to be cuboidal,
columnar or signet ring cells, which formed acinar structures. They characteristically had
desmosomes and terminal bars at the cell-cell junctions, and microvilli and a glycohalyx at the free
border. Internally, there were many microfibril bundles and ribosomes, but few lysosomes and no
Golgi apparatus. They had a large nucleus with a single nucleolus. It is relevant that CEA was
observed to be produced by the cells, a property which was retained in transfected cells (81).
Colo (Colo 320) cells are quite different to Ht29 and Lovo cells. They were established in 1979 by
Quinn et al (223), having been grown from a 55 year old woman's undifferentiated sigmoid
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carcinoma. Their modal chromosome number was 51, with multiple copies of chromosome 20
commonly appearing in metaphase, and chromosome 5 frequently deleted. Morphologically they
were spheroid cells, with much convoluted Golgi, many ribosomes and polysomes, large lipid
vacuoles and rarer clear or dense vacuoles. They did not have microvilli, and desmosomes were only
occasionally seen. Repeated radioimmunassay for CEA was negative, although the cells did produce
small amounts ofPTH, ACTH, Serotonin, Adrenalin and Noradrenalin. These properties make them
akin to the Amine Precursor Uptake and Decarboxylator (APUD) family, and a good model for the
more unusual types of Colorectal Cancer that exist.
The three cell lines Colo, Ht29 and Lovo represent a range of CEA secreting properties and
differentiation characteristics, and will be studied throughout this work.
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AIMS OF THIS WORK
The primary aim of this work is to find a chemical or environmental factor or combination of factors
which can successfully induce increased CEA expression in 3 different colorectal cell lines - Lovo,
Ht29 and Colo. Additive or synergistic augmenting effect by combinations of CEA-augmenting
agents will be sought.
The differentiating agents included in the study are Butyric Acid, gamma-Interferon and 5-
Azacytidine and Theophylline. The cell culture environment will be changed by altering pH, oxygen
supply and serum content of medium, and by exposing the cells to radiation. A range of commonly
used cytotoxic drugs at one fixed dose will also be studied. According to the observed effects of these
factors used singly, combinations of successful chemical and physicochemical factors will be tested.
CEA expression will be measured using Immunocytochemistry and Fluorescein Activated Cell
Sorting. Membrane CEA expression and total cell CEA content, reflecting cytosolic CEA, will be
compared.
Additional information on cell growth and differentiation characteristics will be gathered, by cell
counting and Electron Microscopy.
The amount of CEA released by the growing cells into their medium will be measured by
Radioimmunoassay of culture medium. Changes in CEA expression will be compared to changes
detected in CEA release.
In order to investigate genetically determined changes in the cell cycle which accompany perceived
changes in CEA expression and differentiation, a limited study of the changes in oncogene expression
in CEA-augmented will be conducted. Treated cells will be immunostained for oncogene products





The three cell lines, Lovo, Ht29 and Colo-320 were obtained courtesy of the European Collection of
animal Cell Cultures (ECACC). They were stored in Nunc Cryotubes (GIBCO) in liquid Nitrogen at
-160°C, preserved in a 10% solution of Dimethyl Sulfoxide (SIGMA), at a concentration of 5xl06
cells per millilitre.
When required, the Cryotubes were removed from the Nitrogen store and were rapidly defrosted in a
water bath at 37°C. The cell solutions were transferred by sterile pipetting under an incubator hood
into sterile universal containers, and diluted by the addition of 15 mis ofWhole Medium, i.e. 500ml
Dulbecco's Modified Eagle's Medium (NBL), 50mls Fetal Bovine Serum (GIBCO), 5 mis L-
Glutamine 200mM (SIGMA)and 5 mis Penicillin 10 000U & 10 mg Streptomycin per ml in 0.9%
Sodium Chloride Solution (SIGMA).
This solution was then ccntrifuged at 90rpm for 7 minutes, producing a cell pellet. The supernatant
fluid was discarded, the pellet flicked and resuspended in more Whole Medium, to a concentration of
106cells per ml. One ml of this suspension plus another 4mls ofWhole Medium was pipetted into
sterile 25cnr vented tissue culture flasks ( MARATHON), and placed in a humidified incubator set at
37°C, and 5% C02. The incubator was cleaned with Hycolin 2% Phenolic disinfectant (DEPUY
HEALTHCARE), an anti-fungal antiseptic, before and after each use and also exposed to Ultraviolet
light. Initially in the course of the work, the cells occasionally became infected with fungi, and were
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discarded, along with the Whole Medium currently in use. No mycoplasm infections were isolated at
any point.
According to the factor under investigation, the Whole Medium was altered by the addition of a
differentiating agent or cytotoxic drug at a specified concentration. The environmental factors were
investigated by altering the pH of the medium, adding Chloroquine. exposing the flasks to x-radiation
or growing the flasks in a sealed module (see Chapter 4 for specific methodology).
Feeding
The cells in the culture flasks were fed with more Whole Medium every 2-3 days. Initially, feeding
was required every three days only, but as the cells approached confluence (reached on average at 5
days), they needed more frequent feeding. All discarding of the old medium and pipetting of fresh
whole medium into the flasks was performed under sterile conditions in the incubator hood.
Harvesting
Under sterile conditions in the incubator hood, waste medium was discarded from the culture flasks
and 5mls sterile Phosphate Buffered Saline (PBS - SIGMA) pipetted into each flask to wash the cells
The PBS was then removed and 2mls Trypsin-EDTA (SIGMA), was added to each flask, to unstick
the adherant monolayer. The flasks were then incubated at 37°C for 7 -10 minutes (Lovo cells
requiring the longer incubation in Trypsin), agitated and the cells seen to have been lifted from the
flask base. Further Whole Medium was added (lOmls per flask) and a 1ml sample of this solution
was counted using the Hemocytometer (see below), with the remaining solution being centrifuged at
90rpm for 7 minutes. The supernatant was then discarded, the pellet flicked and resuspended in
fresh Whole Medium at the desired concentration, according to the cell count.
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Counting
Trypsinised cells in whole medium were counted pre-Centrifuging using a Neubauer Counting
Chamber. 800|j.l of the cell solution was removed, added to 100(j.l ofTrypan Blue (SIGMA) and well
mixed. A drop of the resulting solution was placed in the counting chamber and the cells present in a
marked 1mm2 area counted under light microscopy. The number of cells counted was then
extrapolated to the total number of cells by multiplication, according to the volume of cell solution.
The most efficacious mix of cell solution and Trypan Blue was determined using a Serial Dilution
experiment, described in Appendix 1.
Freezing Down
Harvested, counted cells in pellet form were resuspended at 5xl06 cells/ml inWhole Medium/ 10%
Dimethyl Sulfoxide. The supensions in cryotubes were gradually lowered (at a rate of 2 centimetres
per 15 minutes) into liquid Nitrogen in a freezing jar, before being transferred to stocks in the
Nitrogen banks.
Cytospins
Twin-frosted glass microscope slides (WESTERN LAB SERVICES) were pretreated with Poly-L-
Lysine (SIGMA). The slides were lined up with filter paper (SHANDON) and placed in a Shandon
Cytospin. Aliquots of lOOjal of cell solution, after the cells had been tiypsinised, counted, centrifuged
and resuspended in whole medium at a concentration of 106cells/ml, were placed in each cytospin
well, then spun at 800rpm for 5 minutes. The slides were dried at room temperature overnight.
They were then stored, uncovered, at -20°C.
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1MMUNOCYTOCHEMISTRY
The presence of CEA may be assumed by indirect two stage immunocytochemistry, first described by
Mason et al in 1969 (194). This involves staining CEA-expressing cells by tagging CEA with anti-
CEA antibody and further tagging that compound with a second peroxidase-labelled antibody. The
second antibody reacts with the immunostain, colouring the cells. The primary antibody used
throughout these experiment was A5B7, a CEA-specific mouse Immunoglobulin, first characterised
by Harwood et al in 1986 (136) and further validated as being suitable for in vitro and in vivo use by
Boxer et al (47). It was supplied by the Department of Clinical Oncology, Royal Free Hospital, Pond
Street, London.
Materials and Methods:
The flasks of growing colorectal cancer cells were harvested by washing, trypsinising and centrifuging
the cell suspension to produce pellets of cells. The cells were counted and re-suspended in Whole
Medium to a dilution of 106 cells per ml. Cytospins of each cell sample were made, as described
above, producing a circle of cells adherent to the glass slide. The cell circle was encircled with a
Paraffin pen (DAKO), and the slides left to dry overnight.
The slides were next fixed by immersion in Acetone (MERCK) at 4°C for 10 minutes. The acetone
was washed offwith PBS x 3.
A5B7 anti-CEA antibody in 0.1% Bovine Serum Albumin (BSA - SIGMA), at a 1:2000 dilution was
laid onto the slides, with 2 negative controls treated with PBS only. A further negative isotype-
specific control using mouse IgGi immunoglobulin at 10p.l/ml was prepared. (The BSA was required
to override background protein staining in the cells under investigation.) The slides were incubated
in a humidified chamber at room temperature for 45 minutes, before unbound antibody was washed
offwith PBS x 3.
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Peroxidase labelled Rabbit Anti-mouse peroxidase-conjugated secondary antibody (RAMP - DAKO),
at a concentration of 13pg/ml in 10% normal human serum (courtesy of self), was then applied to
every slide except one of the negative controls per set (which was treated with PBS to prevent drying
out) , and the slides again incubated in a humidified chamber at room temperature for 45 minutes,
before being washed in PBS x 3.
The slides were then immersed in 100ml TRIS/HCL buffer (SIGMA) containing 60mg 3,3'-
Diaminobenzidine Tetrahydrochloride (BDH), 1ml of 0.1M Imidazole (BDH) and 40pl 30%
Hydrogen Peroxide (SIGMA) for 5 minutes, to develop the immunostain. The stained slides were
washed in distilled water x 3, and counterstained with Mayer's Haemalum (HD SUPPLIES) for 5
minutes.
The above recipe was found to be the most efficacious, after trying variations of antibody
concentrations, antibody-exposure times, DAB-exposure times and deleting the Acetone fixation step.
The titration experiments are described in Appendix 1.
The slides were again washed in distilled water x 3, dried in Analar Methylated Spirits (BDH) x 3,
followed by Analar Xylene (BDH) x 3 and finally mounted with coverslips (MARATHON) using
DePeX fixative (GURR).
The slides were finally examined under light microscopy and graded according to the degree of brown
CEA-staining of the cells. An observer-based system of grades was used, with a range of arbitrary
units awarded from 0 for no staining to 10 for maximal 100% staining. This non-computerised
system was previously compared to a computer-analysed system, and a cell-bound ELISA, developed
in this department (13), and found to be as accurate and as reproducible. The observer-based
grading system was used in this work, after comparative validation studies grading the slides
produced in this work. Photographic examples of the grades awarded are shown on the next page.
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Grade 1 (Ht29 Control cells)
Grade 9 (Lovo control cells)
FLUORESCEIN ACTIVATED CELL SORTING
Introduction
Fluorescein Activated Cell Sorting (FACS) involves directing a laser beam of light through a
suspension of cells. The pattern of scattering of the light beam allows the number, size and
fluorescence of the cells to be accurately calculated and allows a sub-population within a mixed
population to be separated and characterised (237). Human colorectal cancer cells have a residual
low fluorescence. It is possible to highlight surface and cytoplasmic cell associated antigens, such as
CEA. by binding them to fluorescein-conjugated antibodies. The degree of expression of these cell
associated antigens can then be measured according to the degree of fluorescence seen with FACS.
The highlighting of the cell associated antigens is achieved by two stage immunostaining. A primary
anti-CEA antibody is first applied to the cells, followed by a fluorescein-conjugated secondaiy
antibody, which binds to the primary antibody.
Method
Three human colorectal cell lines, (HT29, Colo and Lovo) were grown in standard tissue culture for 5
days. The cells were then harvested by trypsinising, counted and re-suspended in whole medium at a
concentration of 3x 106 cells per ml. Aliquots of lOOpl of each cell suspension were pipetted into
separate FACS pyrex tubes (FALCON), one aliquot from each cell suspension for surface antigen
measurement and one for cytoplasm antigen measurement. A negative control tube for each cell line
was also prepared. When there were insufficient cells to make up aliquots of 3x 105cells each, the
cell suspensions were made up to 200pl, and fewer cells were read through the FACS Scanner (a
minimum of 1000 rather than 3000).
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The samples for cytoplasmic plus membrane antigen measurement were then permeabolised: 2 mis of
Ortho Permeafix (ORTHO DIAGNOSTIC SYSTEMS) at 0.5 concentration with distilled water was
added to the tubes which were incubated for 30 minutes at room temperature. The samples were then
centrifuged at 2000rpm for 5 minutes, the supernatants discarded and the pellets flicked. The cells
were then washed twice in PBS.A (PBS, Albumin 0.2%, Azide 0.2% - SIGMA) and re-spun at
2000rpm for 5 minutes after each wash. The albumin was used to prevent background cell protein
staining, and the azide as an anti-bacterial agent.
All the samples were then immunostained - the permeabolised and the non-permeabolised cells. The
primary mouse anti-CEA antibody. A5B7, at 10pi per ml in PBS.A was applied in lOOpl aliquots.
The negative control - mouse IgGi immunoglobulin at lOpl/ml was applied to negative control tubes.
The concentration of primary anti-CEA antibody was chosen after a titration experiment described in
Appendix 1. No positive controls were successfully identified, but high staining Lovo control cells
were included in every staining experiment as an internal positive control.
The samples were incubated for 30 minutes at room temperature, then washed twice in PBS.A, being
spun at 2000rpm for 5 minutes in between washes. The second, fluorescein conjugated antibody.
Goat anti-mouse Fluorescein Isothionate (FITC- SOUTHERN BIOTECHNOLOGY ASSOCIATES)
was then applied in 100pi aliquots at a concentration of 1:100 in PBS.A.
The samples were again incubated at room temperature for 30 minutes, then washed twice with
PBS.A and spun at 2000rpm for 5 minutes. They were then fixed in Paraformaldehyde (1%), and
stored at 4°C prior to being put through the FACS scanner. One to three thousand cells per sample
were exposed to the laser within the FACS scanner. Graphs showing the distribution of fluorescence
of the samples were obtained and analysed. The average value of the one to three thousand cells in





Cells in tissue culture have to be converted initially into cell suspensions, and eventually into a cell
pellet, which may be sectioned and then studied under the electron microscope.
Method
The adherent cells were separated from the culture flask using a cell scraper, and
Gluteraldehyde/Paraformaldehyde fixative was added to them. The fixed cell suspensions were
transferred to centrifuge tubes and centrifuged at lOg for 5 minutes. The cells were then washed
three times in PBS for 10 minutes, centrifuging in between each wash. After this, the cells were
fixed in Osmium Tetroxide (transferring solutions in fume cupboard) for one hour and 30 minutes.
They were then washed in water three times for 5 minutes each time.
A process of dehydration was then undertaken, through graded alcohols 30%, 50% for 5 minutes;
70% and 90% twice each for 5 minutes. The cells were then exposed to absolute alcohol three times,
for 10 minutes each time.
LEMIX resin was removed from the freezer, allowed to reach room temperature, and made up to a
50:50 mixture of resin/100% alcohol, which was infiltrated into the cells overnight.
A second batch of 100% resin ( at room temperature) was then allowed to infiltrate the cells for 5 - 6
hours.
The samples were then centrifuged in fresh 100% resin and polymerized at 70°C overnight to form a
cell pellet, from which sections could be cut.
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This processing and sectioning work was performed by the Electron Microscopy laboratory
technicians. The final stage of studying the sections under the Electron Microscope and taking
photographs of relevant cells was undertaken by myself.
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RADIOIMMUNOASSAY FOR CEA
An acceptably accurate method for measuring the amount of free CEA in a solution (such as plasma
in the clinical environment) is that of Radioimmunoassay (192). In this work, radioimmunoassay
was used to measure the amount of CEA being released into the supernatant medium by the cultured
colorectal cancer cells under investigation.
Procedure Principle
A solid phase two-site immunoradiometric assay kit called ELSA2-CEA was used (CIS BIO-
INTERNATIONAL). Monoclonal antibodies were prepared against sterically remote antigenic sites
on the CEA molecule: the first one is coated on the ELSA solid phase, the second one. radiolabeled
with Iodine 125, is used as a tracer.
The CEA molecules attached themselves to the solid ELSA-bound antibodies and in turn the
radiolabeled tracer antibody was bound to this compound, to form an antibody-antigen-antibody
sandwich. The unbound tracer was removed and the residual radioactivity measured taken as a
measure of the amount ofCEA present.
Method
All reagents were raised to room temperature, and a water bath was heated to 45°C.
300p.l of 125I labelled anti-CEA monoclonal antibody was dispensed into all groups ofELSA-tubes.
lOOp.1 of the standards, control serum or the experiment samples was added to appropriately labelled
ELSA-tubes.
Each ELSA-tube was gently mixed.
The tubes were incubated for 3 hours at 45°C.
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The tubes were then washed; the contents were aspirated, 3ml of Tween 20 washing solution added
and left for 2 minutes and then re-aspirated. This procedure was repeated twice.
The radioactivity bound to the ELSA was then measured with a gamma scintillation counter.
Results Analysis
A curve was drawn using the measured data from the standard concentration solutions supplied
(ng/ml CEA v cpm x 103). The concentrations of CEA in the experiment tubes were read from this
curve, according to their cpm values.
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CHAPTER THREE: RESULTS - DIFFERENTIATING AGENTS
Introduction
Colorectal cancer cells have been studied for signs of differentiation on exposure to various of the
differentiating agents (244,258,152,142„ 75). The expression of CEA by human colorectal cancer
cells has been observed as being augmented by certain of the differentiating agents, particularly
Butyric Acid, (244,258) and y- Interferon,(8,128,272,).
Preliminary studies were performed in the University Department of Surgery at the Royal Free
Hospital, comparing the effects ofButy ric Acid, gamma-Interferon, Theophylline. 5-Azacytidine,
Retinoic Acid and phorbol esters on the colorectal cancer cell lines Lovo and HT29. Growth rate and
CEA expression as measured by Immunocytochemistry was measured over a 7 day time scale. It was
found that only Butyric Acid and gamma-Interferon caused significant augmentation of CEA
expression Lovo and HT29 cells, with the maximum effects occurring by day 5 (72,13). The most
efficacious concentrations of each agent, from a serial dilution experiment (13), were: Butyric Acid
ImM; Theophylline lOmM; 5-Azacytidine lpM; Interferon lOng/ml. Colo cells were not studied,
and FACS analysis was not undertaken.
Aim
The aim of this experiment was to further explore the CEA augmentation effects previously seen with
Butyric Acid, Interferon. Theophylline and 5-Azacytidine using the more sensitive Fluorescein
Activated Cell Sorting analysis in addition to immunocytochemistry. Lovo, H29 and also Colo cells
were studied to give a fuller range ofCEA-expressing properties. Additional information of
intracellular effects of the differentiating agents was sought with Electron Microscopy and
Radioimmunoassay of supernatant CEA (see chapters 7 & 8).
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Methods
For each cell line, two control 25cm2 tissue culture flasks containing 106 cells were grown continually
in standard Whole Medium at pH 7.4 in an incubator at 37°C for 5 days. Five days of growing was
used in each experiment, as confluence was reached in the control samples at that point. Four
identical experiment flasks containing 106 cells were also grown in the incubator at 37°C, but in
Experimental medium containing the differentiating agent. The concentrations of differentiating
agents were identical to those found to be most successful in previous published work from the
department (13), that is: Butyric Acid ImM, Interferon lOng/ml, Theophylline lOmM, 5-Azacytidine
lpM.
On day 5, one of the experiment flasks was removed for Electron Microscopy. The remaining
experiment flasks and the control flasks were each harvested and counted.
The cells were then analysed by immunostaining with peroxidase or fluorescein-conjugated anti-CEA
antibody for Two-stage indirect Immunocytochemistry or Fluorescein Activated Cell Sorting.
The density of staining for CEA in the experimental samples was compared to the pooled control
samples.
Analysis of the immunocytochemistry and FACS results was undertaken using parametric and non-




The numerical values for the results illustrated in the graphs below may be found in Appendix 2.
The 4 differentiating agents. Butyric Acid, Interferon, Theophylline and 5-Azacytidine affected the 3
cell lines in differing ways as follows:
GROWTH
The changes in cell proliferation were measured by calculating the percentage of each experimental
cell count to the averaged control cell count, as illustrated below.
Proliferation in Cells exposed to Differentiating




Analysis of the results using the t-test was performed. Significant growth inhibition (at p<0.05) was
seen in the Colo cells exposed to Butyric Acid, Theophylline and 5-Azacytidine; in the Ht29 cells




The density of staining for CEA was measured in triplicate samples of cells exposed to each
differentiating agent, and compared to the average density of control samples from all of the
immunocytochemistry runs from all of the experiments.
Effect of Differentiating Agents on Density of Immunostaining for






































Analysis using the t-test showed significant augmentation in the Colo cells with 5-Azacytidine, the
Ht29 cells with Butyric Acid, Interferon and Theophylline, and the Lovo cells with Butyric Acid only.
FLUORESCEIN ACTIVATED CELL SORTING
Both membrane-bound and total cell CEA were measured and compared in triplicate in the
experiment samples. Changes in CEA expression were identified by comparing to a bank of all
control cell FACS results, from all of the experiments.
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FACS OF MEMBRANE-BOUND CEA:
Membrane CEA expression as measured by FACS












Analysis using the Mann Whitney-U test (at p<0.05) showed significant increases in membrane CEA
in Colo cells exposed to Theophylline and 5-Azacytidine, and in Ht29 and Lovo cells exposed to
Butyric Acid, Interferon and Theophylline.
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TOTAL CELL CEA CONTENT (Permeabolised Cells)
Total Permeabolised Cell Fluorescence as a Measure ofCEA































It is obvious from the above graph that the changes in the Lovo cells far outstrip those seen in the
Ht29 and Colo cells. Statistical analysis with the Mann Whitney-U test at p<0.05 confirmed
significant increases in fluorescence in Lovo cells exposed to Butyric Acid and to Interferon.
Significant increases, although of a lower magnitude, were also seen in Colo cells with Theophylline
and 5-Azacytidine, and in Ht29 cells with Butyric Acid, Interferon and Theophylline. These are
more clearly demonstrated in the following graph, which omits the Lovo cell results:
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Total Permeabolised Cell Fluorescence as a Measure ofCEA




Growth was significantly inhibited in the Lovo cells by all four differentiating agents; in Ht29 cells by
Theophylline, 5-Azacytidine and Interferon; and in Colo cells by Butyric Acid, Theophylline and 5-
Azacytidine (t-test; p^0.05).
Immunocytochemistry showed positive CEA augmentation (t-test; p^0.05) in Lovo cells exposed to
Butyric Acid only; and in Ht29 cells with Butyric Acid and Interferon. No change in CEA staining
was observed in the Colo cells with any of the 4 agents.
FACS measurement of membrane CEA staining showed positive CEA (Mann Whitney-U test;
p<0.05) in Lovo and Ht29 cells with Butyric Acid, Interferon and Theophylline; and in Colo cells
with Theophylline and 5-Azacytidine.
FACS testing for total cell CEA content showed significant CEA increases in Lovo cells with Butyric
Acid and Interferon; in Ht29 cells with Butyric Acid, Theophylline and Interferon; and in Colo cells
with Theophylline and 5-Azacytidine.
DISCUSSION
All four differentiating agents successfully augmented CEA expression in one or more of the cell
lines. It is noted that the cells responded in different ways to the various agents. It is interesting
that the agents which were less strongly inductive of CEA in Lovo and Ht29 cells, i.e. 5-Azacytidine
and Theophylline, were particularly successful with the Colo cells. These results concur with the
preliminaiy studies undertaken in this department (12,13), and with other sporadic studies
(244,258,272). Previous work on these differentiating agents in colorectal cancer cells has been
limited to single cell lines exposed to Interferon or Butyric acid; cell lines with variable natural CEA
expression have not been simultaneously exposed to the four differentiating agents tested in this work
for comparison of effects.
58
Augmentation in Colo cells has not been previously documented at all with the differentiating agents
studied in this work. This may be due to increased sensitivity of FACS analysis, compared to
immunocytochemistry.
The cell growth-inhibitory effects of the agents did not exactly mirror their CEA-augmentation
properties, but positive CEA augmentation was associated with growth inhibition in all cases except
Ht29 cells in Butyric Acid.
The varied patterns of response to the differentiating agents may be indicative of different pathways to
CEA expression within the colorectal cancer cells. Using a combination of these agents is a
potentially efficacious way of inducing increased CEA expression in a typical heterogeneous
colorectal cancer, different mechanisms of augmentation being one of the requirements for synergistic
reaction between agents. It is also possible that a combination of agents could induce additive or
synergistic augmentation within one type of cell, if CEA is being induced via different pathways.
Because each of the differentiating agents studied had positive effects on one or more of the colorectal
cancer cells, it was decided that dual combinations of each of them should be tested on the cells (see
Chapter5).
CONCLUSIONS
1. Colorectal cancer cells may be induced to express CEA by differentiating agents, even if they are do
not express CEA in their natural state.
2. The differentiating agents Butyric Acid, Theophylline, 5-Azacytidine and Interferon have variable
effects on different colorectal cancer cell lines, suggesting more than one mechanism for CEA
induction.
3. CEA augmentation in colorectal cancer cells by differentiating agents is usually, but not
invariably, accompanied by inhibition of cell replication.
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CHAPTER FOUR
RESULTS (ii): EFFECTS OF ALTERED ENVIRONMENT
Introduction
Sporadic experiments on isolated human colorectal cancer cell lines involving alterations in physical
environment have been performed over the past decade: Wong et al heated colorectal cancer cell
LS174T cells in 1989 and found significant cell death occurred at temperatures over 43°C with a 40 -
50% increase in CEA expression after one hour of heating to 42°C (269), although poor results from
subsequent clinical trials have resulted in a loss of interest in heat in colorectal cancer (56).
Porro et al in 1986 grew several colorectal cancer fines including HT29 in serum free medium and
found growth inhibition and increased CEA production compared with growing in whole medium
(216). Substituting glucose with galactose had similar growth inhibitory and CEA augmentation
effects on HT29.D4 cells studied by Fantini et al in 1989 (90).
Preliminary studies in this department on the effects of starvation, hypoxia and altered pH on growth
and CEA expression ofHT 29 human colorectal cancer cell fines suggested that changes in nutrition
and pH may cause decreased cell growth and increased CEA expression (12).
Aim
To further explore the effects of altering environment on cell growth and CEA expression on the
three colorectal cancer cell fines, Lovo, Ht29 and Colo, known to be high, low and non expressors of
CEA respectively, in their natural state. The alterations to cell environment studied were




Serum depletion effectively means markedly reducing the protein content of the culture medium,
which would be expected to affect the growth patterns of the cells. It should be emphasised that
serum depletion is a form of malnutrition, not complete starvation.
Four 106 cell samples of each cell line were grown in monolayer cell culture in protein-depleted
medium (Dulbecco's Modified Eagle's Medium with 0.5% Fetal Calf Serum, L-Glutamine, penicillin
and Streptomycin), alongside two samples of each cell line grown in whole medium (Dulbecco's
Modified Eagle's Medium, 10% Fetal Calf Serum, L-Glutamine, Penicillin and Streptomycin). After
5 days, one flask per cell line was removed for Electron Microscopy and the remaining cells were
harvested, counted and stained for immunohistochemistry and FACS scanning.
2. Altered pH
The culture medium used for all the cell culture work had a pH of 7.4. Initial studies on pH were
performed, altering the medium pH to 7.2 or to 7.6, by the addition of concentrated Hydrochloric acid
and Sodium Hydroxide respectively.
A further pH study was undertaken, using Chloroquine. Chloroquine is known to cross biological
membranes and to enter lysosomes. Once inside the lysosome it becomes protonated, is then no
longer free to traverse the membranes and so accumulates in the lysosome, mopping up Hydrogen
ions (74). The cytoplasmic pH being robbed of its hydrogen ions would thereby be expected to rise.
The three human colorectal cancer cell lines Lovo, HT29 and Colo were grown in standard monolayer
cell culture as described in Appendix 1, with triplicate samples of each grown in physiological, acidic
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medium, alkaline medium or medium containing 10 5 M Chloroquine. Simultaneously, two control
flasks were grown in unaltered whole medium. After 5 days, one of each of the experimental flasks
per cell line was removed for Electron Microscopy and the other experimental flasks and the control
flasks processed as described in Chapter 2: the cells were trypsinised, counted and stained for
Immunocytochemistry and FACS measurement of fluorescence.
3. Hypoxia
The initial study of the responses of colorectal cancer cells to hypoxic conditions involved almost total
oxygen deprivation. The positive results achieved in terms ofCEA expression led on to two further
experiments, with conditions of 5% and 12% Oxygen. These percentages would be more realistic
reflections of the situation in vivo and of the potential results of using capillary blocking microspheres
in vivo to cause hypoxia. It is not possible in vivo to achieve prolonged hypoxic conditions at oxygen
tensions of less than 5%; nevertheless, it is of interest to study the evolving pattern of changes in cell
behaviour caused by progressive decreases in oxygen tension.
For each of the three oxygen concentrations tested, four experimental flasks, fitted with air filters, per
cell line were grown in standard monolayer cell culture, but in a sealed module which was flushed
with one of the three gas mixtures (pure 100% Nitrogen gas, or a mixture of 5% Oxygen and 95%
Nitrogen, or a mixture of 12% Oxygen, 83% Nitrogen and 5% Carbon Dioxide), over 10 minutes to
expel residual oxygen from the module and from the flasks. After 5 days, one flask was removed for
Electron Microscopy and the remaining cells were harvested, counted and stained for




The effects of X-radiation on cancer cells in terms of growth retardation are well established. The
effects ofX-radiation on tumour associated antigen expression are less well investigated. This study
aimed to firstly find a dose of radiation which was inhibitory to the growth of human colorectal cancer
cells in vitro over a period of 5 days, and secondly to look for any associated change in CEA
expression at that dose. A preliminary titration experiment with Ht29 cells only was undertaken, and
identified 5Grays of radiation as an effective dose, with the maximum change in the cells observed 72
hours after irradiation (see Appendix 1).
Four samples each of the Lovo, HT29 and Colo cells were exposed to 5 Grays ofX-radiation, on Day
2 of a 5-day standard monolayer culture. Along with duplicate control flasks per cell line, the cells
were then harvested, counted and stained for immunocytochemistry and FACS scanning assay ofCEA
expression, (see Appendix 1). One flask per cell line was processed for Electron Microscopy.
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Results: Growth
The changes in cell numbers are depicted below, shown as percentages of the average numbers of
control cells.
Proliferation in Cells Exposed to Changes in their














As predicted, cell growth was inhibited by serum depletion. Altering the pH of the cell culture
medium had no appreciable effect on growth in any of the three cell lines, but altering the pH of the
internal cell environment by treatment with Chloroquine did inhibit cell growth, in all cells. Hypoxic
conditions of 1% Oxygen were very effective at decreasing cell growth, but there was no significant
effect at higher concentrations ofOxygen. 5Grays of X-radiation inhibited cell growth in the Ht29
cells only. (All results were analysed using the t-test, at p<0.05)
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CEA Expression: Immunocvtochemistry
Changes in the density of immunostaining for CEA are shown below:
Effect of Environmental Changes on Density of










Augmentation of CEA expression was seen in Ht29 and Colo cells with Chloroquine. in Colo cells
with <1% Oxygen only. Malnutrition, alterations in medium pH, X-radiation and Hypoxia at
concentration ofOxygen of >1% had no recordable effect on density of staining for CEA using
immunocytochemistry. All results were analysed using the t-test.
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FLUORESCEIN ACTIVATED CELL SORTING
The effects of changes in cell culture environment on FACS fluorescence, staining for membrane
CEA were as follows:
Membrane CEA Expression as Measured by FACS
Fluorescence in Colorectal Cancer Cells Exposed to





































Using the Mann Whitney-U test, (p<0.05), significant increases were observed in Colo cells exposed
to <1% or 5% Oxygen, to Ht29 cells exposed to <1% Oxygen, Chloroquine or 5Grays ofX-radiation,
and to Lovo cells only on exposure to Chloroquine.
Changes in the Ht29 and Colo cells are more clearly shown in the following graph:
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Membrane CEA Expression as Measured by FACS
Fluorescence in Ht29 and Colo Cells on Expsosure to






























FACS OF PERMEABOLISED CELL CEA
After permeabolising, FACS fluoresence values as a measure of total cell CEA showed significant
increases in Colo cells with <1% and 5% Oxygen, in Ht29 cells with Chloroquine and with <1%
Oxygen, and in Lovo cells with Chloroquine only (Mann Whitney-U test; p<0.05):
Total CEA expression as measured by FACS Fluorescence in































































Total Cell CEA as measured by FACS Fluorescence in Ht29
and Colo cells exposed to Environmental Changes
Discussion
1 Starvation:
Starvation caused inhibition of cell growth and proliferation, but had no effect on tumour associated
antigen expression. It is important that CEA augmentation was not found to be an inevitable
consequence of the cell growth inhibition and increased cell death seen in this experiment, and
conversely, that the increases in CEA expression seen in other experiments would appear not to be
due simply to a process of cell death.
2, Altered pH
The results show that Chloroquine has effects on a range of colorectal cancer cell lines, causing
growth inhibition and CEA augmentation, irrespective of the natural CEA-expressing status of the
cells. Chloroquine is known to have a major effect on the pH of the internal cellular environment
(74), and this change may be related to the change in cell behaviour in terms of CEA expression. It
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is possible, of course, that Chloroquine's actions on the cells are unrelated to its pH-changing
properties. An in-depth study of the intracellular action of Chloroquine which produced the recorded
changes in CEA is beyond the range of this work. Altering the external environment of the cells in
terms of pH had no such effect on CEA expression. Further information on the response of
colorectal cancer cells to Chloroquine may be gained by exposing the cells to combinations of
Chloroquine and differentiating or cytotoxic agents (Chapter 6).
3 Hypoxia
The results indicate that conditions of hypoxia, with less than 1% Oxygen are effective inhibitors of
cell growth and inducers of CEA expression in colorectal cancer cell lines which do not normally
express a high degree of tumour associated antigen. The increased CEA is not simply a by-product of
cell death, as the Trypan blue cell check/count established the presence of live cells. It was noted in
the previous experiment involving malnourishment of cells, that increased cell death was not
automatically accompanied by increased CEA expression. Lovo cells, which have a high background
level of CEA expression, were not induced to increase that level. The reason for the particular
response of Colo cells to hypoxia is not known; no direct comparisons of the responses of Colo and
Lovo cells to hypoxic environmental stresses or changes have been documented.
The relatively poor results with Oxygen concentrations of 5 and 12% does not bode well for trials of
hypoxia in vivo for CEA augmentation, as achieving levels ofOxygen below 5% would pose great
practical difficulties. Transient levels of Hypoxia of less than 5% may be achievable using techniques
of embolization with starch microspheres. The duration of hypoxia required to produce significant
CEA expression augmentation has not been investigated here.
4, X-Radiation
Irradiating the three colorectal cancer cell lines Lovo, Ht29 and Colo cells produced only slight
growth inhibition of the Ht29 cells, and a slight increase in CEA expression, again only in Ht29 cells.
It is possible that a higher dose of radiation might augment CEA, but the 5 Gray dose given here
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which was sufficient to cause significant growth inhibition in the Ht29 cells produced only slight,
although significant, increases in the membrane CEA expression in these cells.
Conclusions
1. Malnutrition is effective in curbing cell growth, but has no significant effect on CEA expression
in colorectal cancer cells in vitro.
2. pH changes per se produce little effect on CEA expression in colorectal cancer cells in vitro.
3. Chloroquine is an effective CEA-inducing agent in this in vitro study, which may be related to its
intracellular pH-changing properties; more in vitro studies and further work leading towards in
vivo applications are warranted.
4. Hypoxic conditions may inhibit colorectal cancer cell growth and increase CEA expression, but
only at extremes of hypoxia (<1%), and only in selected colorectal cancer cell lines.






Cytotoxic (literally - cell-killing) drugs may be classified in terms of their mechanism of action on
the growing cells within the cell cycle, and in terms of their chemical derivation. Some agents act on
a specific phase of the cell cycle only; others are non-cycle dependent. The cell-killing abilities of
each agent vary, and the proportion of normal cell deaths to neoplastic cell deaths also changes for
each agent. A further source of variation is present in tumour type - the rate of growth of tumours
alters their sensitivity to cell cycle interruptions by cytotoxic drugs. This means that seemingly more
aggressive, faster growing tumours may be more effectively treated by phase-specific agents. There





5. Random synthetic enzymes and hormones



















The agents used in this series of experiments are classified as follows:
1. Antimetabolites: Methotrexate, 5-Fluorouracil, Taxol, Azathioprine
These compounds may be incorporated into new nuclear material or may combine irreversibly with
cellular enzymes, thus preventing normal cell division from occurring. Methotrexate prevents DNA
synthesis by inhibiting the enzyme dihydrofolate reductase; 5-FU blocks thymidylate synthetase.
These actions are cell-cycle dependent, occurring only during the Gl/S or S phases.
2. Vinca Alkaloids: Vincristine, Etoposide, Carboplatin
These plant alkaloids are derived from the periwinkle and May apple plants respectively. Vincristine
acts by interfering with microtubule assembly which prevents mitosis, causing arrest of the cell cycle
at the metaphase stage. Etoposide also blocks mitosis, but via a mechanism unconnected to the
microtubule disruption.
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3. Alkylating Agents: Cyclophosphamide
The alkyl groups attached to these agents react with nucleic acids, disabling them and thus damaging
the cell DNA. In addition, the agents induce bond formation between DNA and RNA strands, which
impedes DNA replication and RNA translation.
4. Antibiotics: Doxorubicin, Mitomycin, Bleomycin
These antibiotics act by preventing DNA and RNA synthesis, by binding to DNA, uncoiling the DNA
helix, or fragmenting the strands ofDNA. Their actions on RNA are indirect, mediated by the
disabling ofDNA.
Relatively little work has been done on the effects of cytotoxic agents on CEA expression by colorectal
cancer cells in vitro. Studies of the effect of Fluorouracil on CEA expression have produced
conflicting results (182,183). Studies of other cytotoxic agents (Cyclohexamide, Actinomycin-D)
have demonstrated inhibition of growth ofHt29 colorectal cancer cells, but no differentiating effects
(181). The antimetabolites are the drugs used in current clinical practice; 5-Fluorouracil has been
shown to reduce recurrence of colorectal cancers, and post-operative intra-hepatic regimes have
shown a survival advantage of 5% at 5 years. Methotrexate is licensed as a second line drug, and
Taxol is awaiting approval, again as second line therapy.
Aim
To study the effects of the examples of commonly used cytotoxic drugs in each of the categories
outlined above, on colorectal cancer cells in vitro, particularly searching for changes in cell growth,
differentiation and CEA expression.
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Methods
In this study, the above-listed cytotoxic agents from each class of agent were separately added to
culture medium. Samples of 106 cells of each of the three colorectal cancer cell lines Lovo, Ht29 and
Colo, were grown in standard culture conditions in the altered culture medium, alongside duplicate
control samples for each cell line and each cytotoxic agent. Changes in cell growth, differentiating
features, CEA expression and CEA production analysed by Electron Microscopy,
Immunocytochemistry, FACS scanning and Radioimmunoassay, as outlined in Chapter 2. The
results for the Radioimmunoassay and Electron Microscopy studies may be found in Chapters 7 and 8
respectively.
The concentrations of cytotoxic agents were selected according to limited data available on
Vincristine. Etoposide and 5-Fluorouracil, advocating doses in the range of 1 - 20ng/ml (264,265). It
is difficult to extrapolate from an in vitro concentration to a realistic approximation of a clinical dose
range; the limited data available on Vincristine, Etoposide and 5-Fluorouracil suggested that these
concentrations were relevant to the clinical scenario, but it is recognised that other agents have
different cell-killing concentration properties, and undergo different metabolism clinically. Full
titrations of doses for each cytotoxic drug were felt to be beyond the range of this initial study;
therefore a fixed dose of lOng/ml of each agent was used.
Results
Ofall the agents listed above, only 5-Fluorouracil, Methotrexate and Taxol showed appreciable
growth inhibitory and CEA augmentation effects. There were also minor increases in CEA in the




The effects on average cell counts in the cells grown in 5-Fluorouracil, Methotrexate and Taxol
compared to control cells are shown below.
Proliferation in Cells exposed to Cytotoxic Agents,







































The effects of the various cytotoxic agents on the density of immunostaining for CEA are shown
below.














Statistical analysis using the t-test, and comparing against all of the control samples revealed
significant increases in immunostaining for CEA in Ht29 cells exposed to Methotrexate, Taxol and
Doxorubicin. None of the agents had any noticeable effect on staining for CEA in the Colo or Lovo
cells.
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FACS FLUORESCENCE: MEMBRANE CEA
The changes in membrane CEA expression on exposure to the various cytotoxic agents are chown
below:
Membrane CEA Expression as measured by FACS Fluorescence in














The results in the Colo and Ht29 cells are more clearly shown in the following graph, without the
Lovo cells:
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Membrane CEA Expression as measured by FACS















Analysis using the Mann-Whitney-U test revealed significant CEA augmentation in the Colo cells on
exposure to Methotrexate and Taxol; in the Ht29 cells with 5-Fluorouracil, Methotrexate and Taxol;
and in the Lovo cells with Methotrexate, Taxol, Doxorubicin, Vincristine and Etoposide.
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FACS FLUORESCENCE: TOTAL CEA CONTENT









































Total Cell CEA as measured by FACS Fluorescence in





The results in the Colo and Ht29 cells are more clearly shown in the following graph:/
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Total Cell CEA as Measured by FACS Fluorescence in













The Mann-Whitney-U test showed significant increase in total cell CEA content in the Colo cells with
Methotrexate only, in the Ht29 cells with 5-Fluorouracil, Methotrexateand Taxol; and the Lovo cells
with Taxol and Etoposide.
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Discussion
Of all the categories of cytotoxic agent studied, the anti-metabolites have consistently shown the
greatest effects with 5-FU, Methotrexate and Taxol all inhibiting growth and inducing CEA
expression in one or more of the colorectal cancer cell lines at the single tested dose of lOng/ml.
These three drugs are commonly used in the treatment of colorectal cancer in vivo, having
tumouricidal or at least tumouristatic effects. They are known to interfere with protein synthesis at a
nuclear level, so it may appear surprising that the colorectal cancer cells respond to them with
increased CEA glycoprotein synthesis. If there is an improvement in the differentiation of the cells,
however, selective inhibition and stimulation of various biochemical processes intracellularly would
be expected.
5-Fluorouracil
5FU had effects on each of the cell lines - it depressed growth in the Ht29 and Colo cells, increased
CEA staining according to immunocytochemistry in the Lovo cells, and increased FACS fluorescence
for CEA in the Ht29 cells.
There was an increase in CEA staining by immunocytochemistry in the Ht29 cells, but the effects
were not statistically significant. However, the effects on CEA in Ht29 cells according to FACS were
consistent with both parametric and non-parametric statistical analysis, and do point to a CEA-
augmentation effect of 5-FU in these cells. The total cell CEA was increased by 5-FU, but did not
significantly outstrip the increased level of membrane CEA. It is not expected that 5-FU should
induce increased intracellular synthesis of CEA. since its known mechanism of action is to prevent
DNA synthesis and thus prevent intracellular protein synthesis. The mechanism by which 5-FU
induces increased CEA expression is not clear.
The apparent increase in CEA staining in Lovo cells seen on immunocytochemistry was not
confirmed with the more accurate FACS analysis, and is therefore not taken as a sign of a definite
CEA increase.
82
It is noted that growth inhibition in the Colo cells was not accompanied by increased CEA, one
marker of differentiation. Growth inhibiting effects are not necessarily expected to be associated with
improved differentiation.
Methotrexate
Methotrexate showed inhibitory effects on cell growth in each cell line, and this was accompanied by
an apparent increase in membrane CEA expression, according to FACS analysis. The lack of
corresponding significant increases seen on immunocytochemistry may reflect the reduced sensitivity
of this method compared to FACS. Increases in total cell content ofCEA were seen in Ht29 and
Colo cells, but not in Lovo cells, which may imply an increased movement of intracellular CEA to
membrane sites, rather than an increase in CEA production by the cells; indeed, the action of
Methotrexate in blocking DNA synthesis, makes increased production of CEA most unlikely. How
Methotrexate does affect CEA expression is not clear; it may be an indirect effect of improved
differentiation induced by the agent; or may reflect a change in the population of cells, the more
quickly reproducing, poorly differentiated cells being wiped out by the Methotrexate to leave well
differentiated. CEA expressing cells. The latter possibility does not account for the changes in the
Colo cells, which have changed character from non-CEA expressing to CEA-expressing.
Taxol
Taxol was effective as an inhibitor of cell proliferation in all the cell lines studied, and induced
impressive augmentation of tumour-associated antigen expression in the Lovo and Ht29 cells. It was
also effective to a lesser extent in the Colo cells, which are naturally non-expressors of CEA. showing
some significant membrane CEA augmentation. Being a relatively new drug, Taxol has not featured
in the studies of CEA augmentation by cytotoxic agents reported to date. The above results can
therefore not be compared with historical data, but it is certainly exciting to find that Taxol has
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definite effects on colorectal cancer cell differentiation in vitro; it should be included in future in
vitro and in vivo studies.
Taxol is from the family of drugs which includes 5-Fluorouracil and Methotrexate. It might be
presumed that all three compounds have a similar mechanism of action; however, it is noted that they
show heterogeneity in their effects on the three different cell lines.
The only other drugs to have any effect on the colorectal cancer cells at this dose, were Etoposide,
Vincristine and also Doxorubicin, which induced a minor degree of CEA augmentation in Lovo cells.
Considering the degree of heterogeneity present even within one colorectal tumour in vivo, the narrow
range of activity of these three agents is likely to preclude them from attaining a useful role in
tumour-associated antigen targetting. Previous studies ofVincristine particularly have shown
differentiating actions on human AML cells (157). Further studies of the Vinca alkaloids at a range
of concentrations are needed before a role for them in CEA augmentation may be outlined.
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Conclusion
1. 5-FU is effective as a growth inhibitor in Ht29 cells and Colo cells, and as an inducer of CEA
expression in Ht29 cells. It does not appear to be a broad range CEA-inducer in different
colorectal cancer cell lines.
2. Methotrexate is effective in producing growth retardation and increased membrane CEA
expression in a range of colorectal cancer cells in vitro, whether they naturally express high
levels, low levels or no CEA.
3. Taxol shows both growth inhibitory and significant CEA-augmentation effects in colorectal
cancer cell lines, particularly those which naturally express CEA to a variable degree.




Results (iv): Combination Experiments
INTRODUCTION
The effects of the variations in environment, exposure to differentiating agents and to cytotoxic drugs
on the three colorectal cancer cell lines may be loosely summarised as follows:
Increased CEA (membrane) with:
LOVO: Butyric Acid, Interferon, Chloroquine, Methotrexate, Taxol, and 5-Fluorouracil and, (to a
lesser extent), Doxorubicin, Etoposide and Vincristine .
HT29: Butyric Acid, Theophylline, Interferon, Chloroquine, Hypoxia, Irradiation, 5-Fluorouracil,
Methotrexate, and Taxol.
COLO: Theophylline, 5-Azacytidine, Hypoxia, Chloroquine, Methotrexate and Taxol,
Decreased growth with:
LOVO: Starvation, Chloroquine, Hypoxia, Butyric Acid, Theophylline, 5-Azacytidine. Interferon, 5-
Fluorouracil. Methotrexate and Taxol.
HT29 : Theophylline. 5-Azacytidine, Interferon, 5-Fluorouracil, Methotrexate, Taxol, Chloroquine,
Hypoxia and Irradiation.
COLO: Butyric Acid, Theophylline, 5-Azacytidine, 5- Fluorouracil, Methotrexate, Mitomycin,
Taxol, Chloroquine, Starvation and Hypoxia
The discovery of augmented CEA expression in Colo cells is particularly interesting since they were
previously thought to be non-expressors of CEA - by immunocytochemistry analysis. The
immuncytochemistry results were generally found to follow the FACS results, but to be much less
sensitive (See Chapter 6).
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As a result of these preliminary findings, further experiments were set up to look for possible
synergistic effects between the various factors which had positive results on CEA expression in the
preceding experiments. As mentioned in Chapter one, combinations of differentiating or cytotoxic
agents may have additive, inhibitive or synergistic effects on tumour-associated antigen expression
and differentiation (101). Additive effects imply independent actions of two different agents,
synergistic and inhibitive effects, positive or negative interaction between agents.
Limited studies on combining differentiating and cytotoxic agents have been performed; mouse
erythroleukaemia cells (MEL) exposed to Trans-retinoic acid and Cytosine Arabinoside showed
enhanced differentiation (96). Little work on the effects of such combinations on colorectal cancer
cells has been published, and no trials of combining environmental changes with chemical
differentiating or cytotoxic agents have been reported.
AIM
To look for additive or synergistic differentiating effects on growth inhibition and augmented CEA
expression in the three colorectal cancer cell lines Lovo, Ht29 and Colo, on exposure to combinations
of the chemical agents and environmental changes found to successfully induce differentiation when
used singly. The range of combinations of effective agents was chosen based on successful agents,
and potential practical application, and was tested on all three cell lines.
The combinations studied were:
1. DIFFERENTIATING AGENT + DIFFERENTIATING AGENT
a. Butyric Acid + Theophylline
b. Butyric Acid + 5-Azacytidine
c. Butyric Acid + Interferon
d. Interferon + Theophylline
e. Interferon + 5-Azacytidine
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2. DIFFERENTIATING AGENT + CYTOTOXIC DRUG
a. Butyric Acid + 5Fluorouracil
b. Theophylline + 5Fluorouracil
c. 5-Azacytidine + 5Fluorouracil
d. Interferon + SFluorouracil
e. Interferon + Methotrexate
f. Butyric Acid + Methotrexate
g. Theophylline + Methotrexate
h. 5-Azacytidine + Methotrexate
3. DIFFERENTIATING AGENT + ENVIRONMENT CHANGE
a. Butyric Acid + Hypoxia
b. Butyric Acid + Chloroquine
c. Butyric Acid + Alkaline Medium
4. ENVIRONMENT CHANGE + CYTOTOXIC DRUG
a. Chloroquine + 5-Fluorouracil
b. Chloroquine + Methotrexate
METHODS
As in the previous chapters, and as described in Chapter 1, triplicate samples of each cell line were
grown for 5 days in medium altered by the addition of the 2 agents under investigation, in the same
concentrations as used in the single agent experiments. The cells were then counted, studied under




1. Differentiating Agent + Differentiating Agent
Proliferation of Cells exposed to Combinations of
Differentiating Agents, expressed as a Percentage of
Average Control Cell Counts
Combinations of Differentiating Agents
Significant growth inhibition (t-test; p<0.05) was seen in all cell lines with each combination of 2
differentiating agents, except the Colo cells with Interferon plus Butyric acid.
2. Differentiating Agent + Cytotoxic Agent
The effects of combining 5-Fluorouracil or Methotrexate with each of the differentiating agents are
shown in separate graphs below:
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Proliferation in Cells exposed to 5-Fluorouracil plus
Differentiating Agents, expressed as a Percentage of
Average Control Cell Counts
□ Colo
5Fu.BA 5FU.IFN 5FU.Theo 5FU.5Aza
5-Fluorouracil plus differentiating Agents
Significant growth reduction (t-test; p<0.05) was seen in the Lovo cells with all combinations, in the
Colo cells with all combinations except 5-Fluorouracil plus Interferon; and in the Ht29 cells with 5-
Fluorouraeil plus Interferon only.
Proliferation of Cells exposed to Methotrexate plus Differentiating
Agents, expressed as a Percentage ofAverage Control Cell
Counts
Mtx.BA Mtx.lFN Mtx.Theo Mtx.5Aza
Methotrexate plus Differentiating Agents
Methotrexate plus any of the differentiating agents induced significant growth inhibition in all of the
cell lines, except in Colo cells when combined with Interferon (t-test. p<0.05).
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3. Environmental FactoH- Differentiating or Cytotoxic Agent
Combinations of altered oxygenation, medium pH and intracellular pH (Chloroquine) were tested with
Butyric Acid. Chloroquine was also tested with 5-Fluorouracil and Methotrexate.
Proliferation in Cells exposed to Environmental Changes
plus Butyric Acid or a Cytotoxic Agent
□ Colo
BA.Hyp BA.Chloroq BA.Alk med Chloroq.5FU Chloroq.Mtx
Butyric Acid plus hypoxia induced growth inhibition in all the cells. With the exception of
Chloroquine plus Methotrexate in Lovo cells, all of the combinations involving Chloroquine caused





Statistical analysis was performed using the t-test. No evidence of synergistically positive reactions
was found in any of the experiments, which may reflect the lack of sensitivity of the naked eye
1 inmunocytochcmistry grading system.
1. Differentiating Agent + Differentiating Agent
Effect ofCombinations of Differentiating Agents on Density of























Analysis using the t-test (p<0.05) revealed no change in staining for CEA in the Lovo cells, although
used alone, Butyric acid had previously shown increased staining.
The Colo cells showed increased density of staining for CEA with Butyric Acid plus Theophylline or
5-Azacytidine and with Interferon plus 5-Azacytidine. Only 5-Azacytine was effective when the
agents were tried singly.
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Ht29 cells were found to have increased staining compared to controls with Butyric Acid plus
Theophylline. 5-Azacytidine or Interferon - little different to the situation with single agents, where
Butyric acid. Interferon and Theophylline were all effective inducers of increased CEA staining.










Effects ofCombinations of Differentiating Agents end Cytotoxic
Drugs on Density of Immunostaining for CEA in Colorectal Cancer
Cells
All four combinations involving 5-Fluorouracil induced increased staining for CEA in the Colo cells,
notable in that 5-Azacytidine only was effective as a single agent.
In the Ht29 cells, significant increases were seen with 5-Fluoruracil plus Interferon, Butyric acid or
Theophylline, the three differentiating agents seen to be effective singly.
The Lovo cells showed increased CEA staining with 5-Fluorouracil plus Butyric acid or Theophylline,
although used singly only Butyric acid was effective.
Methotrexate plus Interferon or Butyric acid was effective in inducing increased CEA staining in the
Colo cells, although none of these agents used singly had any significant effect. 5-Azacytidine which
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was effective used singly in the Colo cells, induced no CEA augmentation when combined with
Methotrexate.
Methotrexate with any of the differentiating agents induced increased staining for CEA in the Ht29
cells, which showed increased staining with all of the agents except 5-Azacytidine used singly.
Butyric acid alone and with Methotrexate induced CEA augmentation in the Lovo cells. Interferon
and Methotrexate were also effective as a combination, but not alone.
3.Environmental Factor* Differentiating or Cytotoxic Agent
Effects ofCombinations of Environmental Changes and
Differentiating Agents orCytotoxic Drugs on Density of







All of the combination involving Chloroquine resulted in increased staining for CEA in all of the cell
lines, and it is noted that Chloroquine used alone was similarly effective in all cell lines. Butyric acid
plus hypoxia induced increased CEA in the Colo cells only, and Butyric acid plus alkaline medium in
none of the cells. This compares to significant augmentation of CEA seen in Ht29 and Lovo cells
exposed to Butyric acid alone.
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FACS FLUORESCENCE: MEMBRANE CEA
All statistical analysis was performed using the Mann Whitney-U test, at a p value of <0.05.
1. Differentiating Agent + Differentiating Agent









In the Lovo cells, only the combinations involving Interferon were effective inducers of CEA,
although both Butyric acid and Theophylline when used singly, induced CEA.
The changes in the Colo and Ht29 cells are more clearly demonstrated in the following graph:
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Membrane CEA Expression as measured by FACS
Fluorescence, in Colo and Ht29 cells Exposed to










Significant augmentation of CEA was seen with all combinations in Colo cells, despite the fact that
only Theophylline and 5-Azacytidine were effective as single agents.
Ht29 cells showed increased staining for membrane CEA with Butyric acid plus Theophylline or
Interferon. All three of these agents were effective singly, but combinations other than the two
mentioned, or involving 5-Azacytidine did not induce increased CEA expression.
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2. Differentiating Agent + Cytotoxic Agent
MembraneCEAExpression as measured by FACS Fluorescence in












The changes in the Colo and Ht29 cells are more clearly shown in the following graph:
MembraneCEAExpression asmeasured by FACS Fluorescence in


















































In the Colo cells, 5-Fluorouracil plus Butyric acid. Theophylline or 5-Azacytidine, but not Interferon,
induced increased CEA. Used alone, neither 5-Fluorouracil nor Butyric acid were effective in Colo
cells. Methotrexate, which was successful used alone, produced increased CEA in combination with
Theophylline and 5-Azacytidine only.
In the Ht29 cells. Theophylline and 5-Fluorouracil lost their CEA-induction abilities when in
combination. 5-Fluorouracil was also ineffective when used with 5-Azacytidine. but otherwise, all
the combinations of successful single agents continued to produce increased CEA staining. No
evidence of a synergistic increase in CEA was seen.
Combinations of Interferon with 5-Fluorouracil or Methotrexate and ofButyric acid with
Methotrexate showed increased CEA augmentation in the Lovo cells. This compares to increased
augmentation seen with Methotrexate, Butyric acid. Interferon and Theophylline used as single
agents. Additive or synergistically increased levels ofCEA were not seen.
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3. Environmental FactoH- Differentiating or Cytotoxic Agent
Membrane CEAExpression asmeasured by FACS Fluorescence in
Colorectal Cancer Cells Exposed to Combinations of Environmental







Membrane CEA Expression as measured by FACS Fluorescence in
Colo and Ht29 Cells Exposed to Environmental Changes and









In the Colo cells, there was a small increase in CEA with Butyric acid and hypoxia, (smaller than
with hypoxia alone). There was a more substantial increase in CEA with Chloroquine plus Butyric
acid or Methotrexate, but not significantly different to the results produced by Chloroquine or
Methotrexate alone.
All of the combination except Butyric acid and alkaline medium produced increased CEA in the Ht29
cells, and all of the agents used alone except the alkaline medium had a similar effect.
In the Lovo cells, although Butyric acid, Chloroquine. 5-Fluorouracil and Methotrexate were all
effective as single agents, only the Chloroquine and Butyric acid in combination produced increased
CEA.
FACS FLUORESCENCE: TOTAL CELL CEA CONTENT
1. Differentiating Agent + Differentiating Agent
Total Cell CEA as Measured by FACS Fluorescence in







































Total CEAContent as measured by FACS Fluorescence in






















In the Colo cells, only combinations including Theophylline and 5-Azacytidine (the two successful
single agents) were effective inducers of CEA.
A quite different result was obtained in the Ht29 cells, where despite the effectiveness of all of the
agents except 5-Azacytidine when used alone, only the combination of Interferon and Butyric acid
induced augmentation of CEA.
In the Lovo cells, very impressive increases in CEA were seen in all of the Interferon combinations -
additive, if not synergistic increases, despite the ineffectiveness of Theophylline and 5-Azacytidine
used as single agents. The same effect was not seen with Butyric acid, where single success was lost
in combination with Theophylline or 5-Azacytidine.
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2. Differentiating Agent + Cytotoxic Agent








































Only Butyric acid and Interferon induced total CEA content increases in the Lovo cells when used
alone; combinations of these two agents with 5-Fluorouracil or Methotrexate were also effective CEA
inducers. Additionally, 5-Fluorouracil plus Theophylline produced significant augmentation of CEA,
despite the lack of results from these agents used singly.







Total CEAContent in Permeabolised Colo and Ht29 Cells exposed to










In the Colo cells, 5-Fluorouracil and Butyric acid, which were not effective as single agents, did
produce increased CEA in combination. Additionally, 5-Fluorouracil was effective in combination
with Theophylline and 5-Azacytidine, also successful single CEA-inducers. Methotrexate, however,
which was effective as a single agent, only produced increased CEA in combination with
Theophylline and 5-Azacytidine.
With the exception of 5-Fluorouracil plus 5-Azacytidine, all of the combinations of 5-Fluorouracil or
Methotrexate plus a differentiating agent produced augmentation of CEA in the Ht29 cells. No sign
of a synergistic response in CEA expression was seen. It is noted that 5-Azacytidine is the only agent
which did not induce increased CEA when used alone.
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3. Environmental Factor*- Differentiating or Cytotoxic Agent
Total CEAContent as measured by FACS Fluorescence in
Permeabolised Colorectal Cancer Cells Exposed to




















Only Chloroquine plus Methotrexate maintained the CEA-inducing effects of the agents used singly
in the Lovo cells. The positive effects ofButyric acid were lost in combination with Chloroquine.
hypoxia or alkaline medium, as were the effects ofChloroquine with 5-Fluorouracil.



























Total CEAContent as measured by FACS Fluorescence in
Permeabolised Colo and Ht29 Cells Exposed to Environmental

























Butyric acid plus hypoxia, and Chloroquine plus Butyric acid or Methotrexate produced increases in
total Colo cell CEA. Chloroquine was effective when used singly, but not in combination with 5-
Fluorouracil.
In the Ht29 cells, all of the combinations except Butyric acid plus alkaline medium produced
augmentation of CEA. Apart from that loss of action ofButyric acid, there was no significant
difference between the combination results and the results from the agents used singly.
105
Overall Summary of Combination Experiments
Most of the combinations of agents tested produced growth inhibition and CEA augmentation in the
three cell lines to a similar degree to that seen with the agents used separately. There were some
alterations, however, with some combinations being less effective at inducing CEA or inhibiting cell
growth , and some more effective. These changes were as follows:
Growth Inhibition
No increases in growth inhibition were measured. Impaired growth inhibition was seen in :
Colo cells: Ifn + 5FU
Ifn+ Methotrexate
Butyric Acid + Alkaline medium
Ht29 cells: 5FU + Butyric Acid
5FU + Theophylline
5FU + 5-Azacytidine
Butyric Acid + Alkaline medium




CEA Augmentation (membrane and total unless otherwise stated)
Cells Impaired CEA Augmentation Improved CEA Augmentation
Colo Interferon +Theophylline 5FU + Butyric Acid
Interferon + 5-Azacytidine 5FU + Theophylline
Interferon + 5FU 5FU + 5-Azacytidine
Interferon + Methotrexate






Butyric Acid + Alkaline medium (total)
Chloroquine + Methotrexate (memb)
Chloroquine + 5FU (total)
Butyric Acid + Interferon
Interferon + 5FU
Interferon + Methotrexate
Lovo 5FU + Butyric Acid Butyric Acid + Interferon
Butyric Acid + Alkaline medium
Butyric Acid + Hypoxia
Chloroquine + 5FU
Chloroquine + Methotrexate (memb)
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DISCUSSION
1. Differentiating Agent + Differentiating Agent
In the previous experiments described in Chapter two, exposing the colorectal cancer cells to Butyric
Acid, Theophylline or 5-Azacytidine resulted in quite different observed effects from one cell line to
another. It was postulated that more than one mechanism of action was involved in the induction of
CEA expression. The results of this first experiment combining differentiating agents again showed
a diversity of reaction from one cell line to another, and also showed some diversity of interaction
between the combined agents. Colo cells did not respond to Butyric Acid used alone, but did respond
to Theophylline or to 5-Azacytidine. In combination, the augmenting effects of Theophylline and 5-
Azactidine were not diminished by the addition ofButyric Acid. It may be that Butyric Acid cannot
penetrate Colo cells, or has no biochemical means of interfering with the mechanism of CEA
expression in Colo cells.
The Lovo cells did previously respond to Butyric Acid, but did not respond to Theophylline or 5-
Azacytidine. However, in combination, the positive effects ofButyric Acid were apparently negated
by Theophylline and by 5-Azacytidine. Similarly, the previously noted positive augmenting effects of
all three agents in Ht29 cells were significantly decreased or negated by the use of the agents in
combination..
If the reason behind these observations were simply a reaction between the differentiating agents
rendering them inactive, one would not have expected the positive response to the two combinations
seen in the Colo cells. Other possible explanations are: that the agents act separately on the cell, in
different positions along the CEA expression pathway, such that CEA expression may be potentiated
and/or inhibited with a possible summation of response amounting to zero change; or that the agents
compete with each other for sites of reaction within the cell, with some agents setting off reactions and
others merely blocking the site.
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The observed additive effects ofButyric Acid and Interferon on Lovo and Ht29 cells may be
understood if the two agents act on a CEA expression pathway in two entirely separate and
independent but similarly potentiating ways. The positive effect in the Colo cells (total CEA content
only) may be a result of a cumulated effect reaching a point of stimulation beyond the scope of one
agent alone.
The actions of Interferon plus Theophylline or 5-Azacytidine on Lovo and Colo cells might have
suggested that the use of these agents in combination do not affect their single actions on cells, were it
not for the inhibitory effects observed in the Ht29 cells. In the Ht29 cells, each of the agents used
separately did produce CEA augmentation but in combination no affect CEA was documented. As
noted in the discussion on p. 114. separate mechanisms of differentiation and CEA expression may
operate between different cell lines and within one cell type, all or none ofwhich may be stimulated or
inhibited by various chemical agents.
It is noteworthy that the "response order" of the cells, according to their degree of differentiation and
natural expression of CEA. (i.e. Lovo, followed by Ht29, followed by Colo) to differentiating agents,
has been lost in this experiment, with Colo cells showing mush greater CEA induction effects than
Ht29 cells.
Limited studies on CEA augmentation in the literature have so far not explored the mechanics of
reactions in this area of combining differentiating agents.
2. Differentiating Agent + Cytotoxic Agent
Mixed results were seen on FACS analysis in the different cell lines using combinations of 5FU,
Butyric acid, Theophylline and 5-Azacytidine: 5FU and Butyric Acid was the only combination to
produce CEA augmentation in the Ht29 cells, despite the fact that all of the agents used singly were
successful in inducing CEA expression in Ht29 cells. The Lovo cells were unaffected by 5FU and
Butyric Acid although again, both of these agents used separately had had positive, CEA-augmenting
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effects on Lovo cells. 5FU did continue to augment Lovo cell CEA in the presence of Theophylline
or 5-Azacytidine. however.
Perhaps the most noteworthy result was in the Colo cells, which showed a potentiation of the CEA
augmentation effects of Butyric Acid, Theophylline and 5-Azacytidine by use in combination with
5FU. The lack of response in terms of CEA expression in Colo cells exposed to Butyric Acid or 5-
Fluorouracil alone, makes their success in combination surprising. It may be postulated that either
the separate actions of the two agents on Colo cells act permissively on each other to allow the
observed CEA augmentation,
Interference ofButyric Acid and 5-Fluorouracil was also seen in the Lovo cells and of 5-Fluorouracil
plus Theophylline or 5-Azacytidine in Ht29 cells, but with a different endpoint, in that CEA
expression was increased by the agents used alone, but not in combination.
The effects of 5-Fluorouracil were altered in different ways in each cell line, by each differentiating
agent.
The effects of the various combinations on cell proliferation were different to their effects when used
separately, with the Ht29 cells in particular, where no growth inhibition was seen. The Colo and
Lovo cells continued to suffer growth inhibition with all three combinations of agents. These results
follow a trend of inverse correlation between cell growth and proliferation.
The CEA-augmenting effects, (according to FACS), ofMethotrexate, Butyric Acid, Theophylline and
5-Azacytidine on the three colorectal cancer cell lines were unchanged by using any of the
differentiating agents in combination with Methotrexate - no negation of the effects of the agents used
separately was seen; nor were there any additive or synergistic reactions.
The results from fmmunocytochemistry echoed those from the FACS, but were not sensitive enough to
identify the changes in the Colo cells or in all of the Ht29 cell samples.
Cell proliferation was inhibited in all the cell lines, to a similar degree as with the agents used alone.
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Interferon plus 5-Fluorouracil or Interferon plus Methotrexate were successM combinations in the
Lovo and Ht29 cells, showing potentiating or permissive effects of one agent on another. They show
promise for further exploration of CEA augmentation in vitro and in vivo, although the inhibition of
Methotrexate's previously noted positive effect on Colo cells may predict interference of the
differentiating (or CEA expressing) effect ofMethotrexate in some cells. The reasons why the effects
of Methotrexate may be potentiated in some cell lines, but inhibited in others when combined with a
differentiating agent are not clear from this work, and have not yet been investigated in general.
It is surprising that the results of differentiating agents in combination with 5- Fluorouracil differ so
widely from those ofMethotrexate, both being anti-metabolites from the same family. Methotrexate
and 5-Fluorouracil obviously differ to some extent in their chemical composition, and likewise are
affected in different ways (or not at all) by other compounds, such as the differentiating agents.
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3. Environmental Factor + Differentiating or Cytotoxic Agent
The CEA expression augmentation previously observed with Butyric Acid was not improved by
growing the cells in a hypoxic or alkaline environment; indeed the positive effects in Colo and Lovo
cells were negated by using combinations of the agents and environmental change.
Cell growth was inhibited by Butyric Acid plus hypoxia, but not by Butyric Acid plus alkaline
medium.
It might be expected that the differentiating actions of Butyric Acid would be neutralised to some
degree by an alkaline culture medium, if it is assumed that the differentiating properties of Butyric
Acid are related to its acidic nature.
Growing cells in a hypoxic environment should limit the proliferation rate, whatever other agents are
present. It is noteworthy that the small cohort of remaining cells growing in the hypoxic
environment were not more responsive to Butyric Acid than cells growing in a standard culture
environment, which may be attributed to changes in the activity of Butyric Acid or to a change in the
cell population. There is a valid question whether the remaining cohort of cells is made-up of
resistant, unresponsive (to differentiating agents) and poorly differentiated cells, or ofmore
differentiated, responsive, better-controlled cells. Since hypoxia alone produced increased amounts of
CEA production (generally taken as a mark of increased differentiation), the latter theory is favoured.
The drop in CEA expression with Butyric Acid and hypoxia may be due to decreased activity of
Butyric Acid itself or to interference with the pathway of CEA induction mediated by Butyric Acid in
the cells.
All three cell lines continued to show growth inhibition and augmentation when grown in the
presence of Chloroquine and Butyric Acid, although no additive or synergistic reactions were
documented. It is noted that the Colo cells showed a good response to the two agents, but did not
respond to Butyric Acid alone in previous experiments. Chloroquine is known to cause intracellular
alkalosis, but either this does not affect Butyric Acid or the CEA augmenting effects ofChloroquine
were too great to be overshadowed by the Butyric Acid.
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Chloroquine plus Methotrexate was effective at inducing CEA expression in all three cell lines, but
the positive effects ofChloroquine alone were seemingly counteracted in some way by the 5-
Fluorouracil, and vice-versa. No additive or synergistic results were seen when positive CEA
augmentation did occur. Methotrexate used alone was a stronger, more universal agent than 5-
Fluorouracil, and was perhaps strong enough to have some effect despite being in a potentially
inhibitory environment. The apparent inhibition of the previously noted effects of Chloroquine by 5-
Fluorouracil is more difficult to comprehend. The antimetabolite action of 5-Fluorouracil may simply
have limited the ability of the cells to respond to Chloroquine, but this should also have occurred in
the Methotrexate experiment. Methotrexate also having anti-metabolite actions. It is possible that
Chloroquine and 5-Fluorouracil work in completely opposite directions in terms of differentiation, so
that in combination an averaged, reduced effect is seen. The relation of CEA expression to
differentiation or de-differentiation has not been fully explored in the literature, and the accepted view
is that CEA expression is a marker of differentiation. The morphological changes accompanying
altered CEA expression may shed some light into the overall effects perpetrated on the cells, and
studies ofmorphological changes are documented in Chapter 8.
The mechanisms underlying these results are complex and potentially multiple. A full exploration
into the chemical events producing the above reported effects is beyond the scope of this work; logical
deductions apparent from the results only have been explored.
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Conclusions
• Interferon and Theophylline or Interferon and 5-Azacytidine do not produce better CEA-inducing
results on colorectal cancer cells than when used separately, and in fact may impede each others'
actions in selected cells.
• Butyric Acid and Interferon work together to produce an additive CEA-augmenting effect in
selected colorectal cancer cells.
• Combining Butyric Acid with Theophylline or 5-Azacytidine does not lead to improved CEA
augmentation in colorectal cancer cells in vitro; but may indeed interfere with the CEA-inducing
effects of the agents when used alone.
• Combining 5FU with one of the differentiating agents Butyric Acid. Theophylline or 5-
Azacytidine does not necessarily improve the CEA-augmenting effects of the agents used singly;
conversely possible synergistic reactions may occur in sporadic cell lines. It is not clear which
cells may be predicted to show a positive or a negative response in terms of CEA expression with
the various combinations of 5FU and differentiating agents.
• A combination of Interferon and 5-FU or Methotrexate has potential for improving CEA
expression in selected colorectal cancer cells. The action on CEA expression appears to be
accompanied by an inhibition of cell growth.
• Combinations ofMethotrexate and the differentiating agents Butyric Acid, Theophylline or 5-
Azacytidine did not add to the CEA-augmenting or growth inhibiting effects observed with any of
these agents used alone.
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• Using Butyric acid in conjunction with environmental changes of hypoxia or alkaline medium is
not a successful way of augmenting CEA expression or growth inhibition in colorectal cancer
cells in vitro.
• Using a combination of Butyric Acid and Chloroquine did not detract from or improve the CEA
augmenting effect of Chloroquine or ofButyric Acid when used alone.
• Combining Chloroquine with cytotoxic agents does not improve the CEA augmentation seen with
these agents used singly, and indeed may impede CEA induction in selected cell lines.
Many of the combinations of differentiating agents, cytotoxic drugs and environmental changes
produced similar or diluted effects on cell proliferation and CEA augmentation to those seen with the
agents used separately. Some evidence of additive or synergistic effects on CEA expression was seen,
however, most notably with the combination of Butyric acid and Interferon in both Lovo and Ht29
cells. The increases in CEA expression in the Lovo cells were quantitatively very high (reaching
seven times those seen in the Lovo control group), which is important in terms of potential bystander
effect.
The main combination of interest in producing augmentation of CEA expression was Interferon and
Butyric acid.
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CHAPTER SEVEN: CEA RELEASE
INTRODUCTION
One of the theoretical problems with using tumour-bound CEA in vivo as a target for radiolabeled or
cytotoxic agent-bearing antibodies is the mopping up of these antibodies by circulating CEA. In
1978 Goldenberg and his team showed that circulating CEA did not affect radiolocalisation of
radiolabeled anti-CEA antibody (122). They advocated computer subtraction techniques to remove
background bloodpool radioactivity prior to scintiscan interpretation. Since then the relationship
between serum CEA and tumour expression of CEA has been further studied: Siccardi et al in 1989
(241) found that sero-positive patients actually had a higher rate of lesion identification with anti-
CEA (Fab')2 fragments (80.3%) than sero-negative patients (63%). Boxer et al (47) in 1992 found
no relation between tumour radioacivity after injection of radiolabelled anti-CEA antibody, and serum
CEA levels. The mechanism of initiating CEA release from cells is not thought to be related to cell
death.
Despite these reassuring studies, it is important to assess the likelihood of rising serum CEA in
response to the CEA-expression inducing agents. The clinical relevance of potential increases in
CEA release by augmented cancer cells has been less well investigated. In vitro studies of the effects
of Suramin, a growth factor-binding competitor, on differentiation and CEA release by Ht29 cells
have been carried out by Fantini et al in 1990 (89) and Pommier et al in 1992 (215). Both studies
found that Suramin caused improved differentiation morphologically in the Ht29 cells, with increased
CEA expression but no change in CEA release.
AIM
The aim of this work was to measure the amount of CEA released into the supernatant by the three
colorectal cell lines. Colo, Ht29 and Lovo, after exposure to various agents known to increase their
CEA expression. This should provide a model for estimating the possible changes in release of CEA
by tumour cells in vivo into the circulation.
116
METHOD: RADIOIMMUNOASSAY FOR CEA
An acceptably accurate method for measuring the amount of free CEA in a solution (such as plasma
in the clinical environment) is that ofRadioimmunoassay. In this work, radioimmunoassay was used
to measure the amount of CEA being released into the supernatant medium by the cultured colorectal
cancer cells under investigation.
Procedure Principle
A solid phase two-site immunoradiometric assay called ELSA2-CEA was used. Monoclonal
antibodies were prepared against stearically remote antigenic sites on the CEA molecule: the first one
is coated on the ELSA solid phase, the second one, radiolabelled with Iodine 125, is used as a tracer.
The CEA molecules attached themselves to the solid ELSA-bound antibodies and in turn the
radiolabelled tracer antibody was bound to this compound, to form an antibody-antigen-antibody
sandwich. The unbound tracer was removed and the residual radioactivity measured taken as a
measure of the amount of CEA present.
Method
Supernatants from Colo, Ht29 and Lovo cells, which had been cultured in monolayer for 5 days, were
collected and frozen at -20° C for up to one month before being defrosted for radioimmunoassay.
(Work from the Royal Free Hospital Department of Clinical Oncology and at the ELISA
manufacturers CIS-Biotech has validated the unchanging nature ofCEA after freezing for one
month.) Supernatants were taken from three flasks of 106 cells per cell line grown in undoctored
whole Medium, and in medium containing Butyric Acid, Theophylline, 5-Azacytidine. Interferon, 5-
Fluorouracil, concentrated acid or concentrated alkali. In addition , supcrnatants were collected from
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three flasks of 106 cells per cell line grown in fetal calf serum-depleted whole medium, and from three
flasks of 106 cells per cell line grown in hypoxic conditions (Oxygen ^ 1%).
All reagents were raised to room temperature, and a water bath was heated to 45°C.
300pi of 125I anti-CEA monoclonal antibody was dispensed into all groups of ELSA-tubes.
100pi of the standards, control serum or the experiment samples were added to appropriately labelled
ELSA-tubes.
Each ELSA-tube was gently mixed.
The tubes were incubated for 3 hours at 45°C.
The tubes were then washed: the contents were aspirated, 3ml of washing solution added and left for
2 minutes and then re-aspirated. This procedure was repeated twice.
The radioactivity bound to the ELSA was then measured with a gamma scintillation counter.
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RESULTS ANALYSIS
A curve was drawn using the measured data from the standard concentration solutions supplied
(ng/ml CEA v cpm x 103). The concentrations ofCEA in the experiment tubes were read from this















0 203 150 196 191 185
4 1191 1067 1040 1118 1104.2
20 4271 4120 3753 3819 3990.6
80 15857 15326 14919 14880 15245.3
140 25667 25996 25509 25490 25665.6
200 34076 34276 32383 32638 33343.2
SLOPES: 171.45 173.37 165.77 166.43 169.25
The correlations between the four sets of controls were all between 0.97 and 1.04.
The graphs of the controls against the CEA standards were as follows:
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The equation for the average linear regression of the curves was: X = Y - 261.11 with r = 1.000.
187.30
Because all of the values ofmeasured radioactivity, i.e. the degree of CEA present in the supernatants,
lay at the lower end of the standard graphs, the linear regression curve was calculated for the curves
joining the points at 0, 4 and 20 ng/ml CEA standards: X = Y - 260.24 with r = 0.998.
187.43
The measured values of radioactivity for each of the Colo, Ht29 and Lovo supernatant samples were
substituted into the above equation to give X values, corresponding to the amount of CEA judged to be
present in each supernatant. The results were as follows:
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COLO CELLS:
CEA release in Colo cells (by Radioimmunoassay)
Con Stv Acd Alk Hyp BA Theo 5Aza Ifn 5FU
COLO Control Starv Acid Alkali Hypox B.A. Theo 5-Aza Ifn 5-FU
0.15 1.92 0.73 1.1 1.4 1.32 1.2 1.07 1.26 1.38
0.6 1.51 0.82 1.32 1.27 0.76 0.85 1.02 1.25 1.34




AVE 1.19 1.70 0.81 1.11 1.63 0.97 1.08 1.12 1.23 1.31
StDev 0.76 0.21 0.08 0.21 0.51 0.30 0.20 0.13 0.04 0.09
Ttest 0.64 0.43 0.86 0.41 0.65 0.82 0.88 0.93 0.80
The results show no significant change in CEA release by Colo cells exposed to various differentiating
agents, 5Fu or environmental changes compared to normally grown control Colo cells, on analysis
with the T-test and the Wilcoxon Rank Sum. It is particularly noted that even in conditions
previously shown to significantly increase CEA expression in the Colo cells, i.e. exposure to
Theophylline, 5-Azacytidine and Hypoxia, there was no reciprocal increase in CEA release.
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HT29 CELLS:
CEA release in Ht29 cells (by Radioimmunoassay)
CEA ng/ml
HT29 Control Starv Acid Alkali Hypox BA. Theo 5-Aza Ifn 5-FU i
0.71 1.80 1.27 0.96 1.30 1.32 1.17 1.63 1.62 1.88
0.50 1.94 1.18 1.07 1.13 1.40 0.88 1.09 1.40 1.56




AVE 0.94 3.03 1.27 1.11 1.13 1.32 1.12 1.35 1.49 1.71
StDev 0.40 2.00 0.20 0.17 0.17 0.08 0.22 0.27 0.12 0.16
Ttest 0.03 0.21 0.26 0.47 0.16 0.49 0.16 0.06 0.02
The results show significant increases in CEA release by Ht29 cells exposed to 5-Fluorouracil or
grown in nutritionally deficient medium, compared to normally grown control Colo cells using the T-
test and the non-parametric Wilcoxon Rank Stun. It is of note, however, that exposure to Butyric
Acid. Interferon.Theophylline, 5-Azacytidine and Hypoxia did not result in a similar increase in CEA
release. A definite relationship between increasing CEA release with increased CEA expression has
therefore not been shown.











LOVO Control Starv Acid Alkali Hypox B.A. Theo 5-Aza Ifn 5-FU
12.49 5.89 7.93 7.38 5.69 25.59 3.49 2.96 11.82 10.09
44.26 5.31 6.55 6.52 3.03 15.27 3.50 3.62 9.99 16.43




AVE 26.52 4.36 7.22 7.29 3.31 18.36 3.40 3.24 11.97 21.70
StDev 10.47 2.17 0.69 0.73 0.40 6.29 0.16 0.34 2.06 14.95
Ttest 0.01 0.02 0.02 0.01 0.26 0.01 0.01 0.05 0.59
The third hypoxic Lovo cell supernatant was found to have become infected; it was therefore
discounted from the results.
CEA release in LOVO cells (by Radioimmunoassay)
T I i i i i i i i
Con Stv Acd Alk Hyp BA Theo 5Aza Ifn 5FU
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Summary and Discussion
The results are pertinent to the living population of cells in whichever conditions were being tested.
CEA measured does not refer to CEA from dead cells, the initial processing step involved discarding
medium containing dead cells. Significant decreases were shown in CEA release by Lovo cells
exposed to the differentiating agents and environmental changes which did not augment their CEA
expression, significant with the T-test and the Wilcoxon Rank Sum. In contrast, the factors
previously shown to induce increased CEA expression in Lovo cells, ie Butyric Acid, Interferon and
5-Fluorouracil had no effect, either positive or negative, on CEA release. The relevance of the
inverse relationship between CEA expression and release in Lovo cells is not clear. In all three cell
lines, the induced increases in membrane CEA were accompanied by no increases in CEA release into
the supernatant.
The overall results confirm the absence of a direct relationship between the expression of CEA it's
subsequent release. It seems feasible that a change in the characteristics of the cell, i.e. improved
differentiation, may be occurring, rather than simply the stimulation of producing a cell glycoprotein.
There has been much discussion and work done on the relevance of circulating CEA to tumour-
associated CEA in the last 20 years. The general conclusions have been that CEA in serum does not
impede the localisation of anti-CEA antibodies to tumour CEA. Limited work has been carried out
on the reciprocal changes in CEA expression and release induced by exposure to the differentiating
agent Suramin only (89, 215). This work produces similar results to those achieved with Suramin,
over the range of differentiating agents, cytotoxic drugs and environmental changes tested.
Conclusions
The augmentation of CEA expression in colorectal cancer cells in vitro does not cause a reciprocal
increase in CEA released into the culture supernatant. Using this experiment as a model for the
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clinical situation, it is reassuring that background circulating CEA is unlikely to be directly increased
by the augmentation of CEA expression in tumour cells, according to these results.
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CHAPTER EIGHT
MORPHOLOGICAL CHANGES ON ELECTRON MICROSCOPY
Introduction:
The morphological characteristics apparent on Electron Microscopy of the three human Colorectal
cancer cell lines, Lovo, Ht29 and Colo were described when the cell lines were first established.
Lovo:
The cells are cuboidal or columnar and often take a glandular form. They have uniform microvilli
and often a fuzzy glycocalyx at their free border, and desmosomes or junctional complexes at their
cell;cell interface. The nucleus is large with a single nucleolus. There are many ribosomes and
microfibril bundles, few lysosomes, intracytoplasmic vacuoles and the occasional section ofGolgi
(83).
Ht29:
These cells are less well differentiated than the Lovos. They grow in an unpolarised fashion, do not
exhibit tight junctions between cells and have only sparse disorganised microvilli. There is a high
nucleus to cytoplasm ratio, with relatively few organelles (280).
Colo:
Colo cells represent the more unusual types ofColorectal carcinoma, being related to the Amine
Precursor Uptake & Decarboxylation (APUD) family. They are also undifferentiated cells, tend to be
spheroid and have few desmosomes at the cellxell junctions. They do not tend to have microvilli, but
do have much Golgi apparatus, large lipid vacuoles, ribosomes and polysomes (226).
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Aim:
To study the effects of a range of differentiating agents, environment changes and cytotoxic drugs,
and combinations of these, on the morphology of the three cell lines Lovo, Ht29 and Colo.
Method:
Triplicate flasks containing 106 cells of each cell line were grown in each type of experimental
condition (i.e. in medium containing Butyric Acid/ Interferon etc) alongside the flasks grown up for
immunocytochemistry and FACS analysis. After the five day growth period, the cells for Electron
Microscopy were fixed with Gluteraldehyde/Paraformaldehyde, scraped off the flasks and converted
from monolayer culture into cell suspensions. They underwent dehyration in graded alcohols and
were infiltrated with LEMIX resin to form cell pellets. The pellets were then sectioned. Three
sections from each flask pellet were studied under the Electron Microscope, and photographed. (See




The changes in the Lovo cell morphology, with the addition of differentiating agents ranged from
evidence of cell destruction (cell swelling, blebbing, vacuolation, necrosis and the presence of cell
debris) to that of improved differentiation (increased organelles, Golgi and rough Endplasmic
reticulum; improved celhcell junctions with desmosomes; increased acinar formation). The most
effective agents in terms of CEA augmentation caused both cell death and/or improved differentiation
- there was no monopoly on either type of effect by the successful CEA-inducers. The most striking
changes are listed below, and demonstrated in the photographs overleaf:
Summary of Results: Lovo cells (compared to control samples):
1. Butyric Acid (photo 2): Generally an increase in the number of organelles was seen, with more
Mitochondria, lysosomes and rough Endoplasmic Reticulum.
2. Interferon: A mixed picture of cell damage (signs ofblebbing) and of increased intracellular
lysosomes was seen. Additionally, several inclusion bodies, presumed to contain Interferon were
noted.
3. Theophylline: Increased numbers of organelles, particularly mitochondria, were observed.
4. 5-Azacytidine: Increased numbers ofmitochondria were again seen, and also inclusion bodies.
5. Hypoxia 1% 02 (photo 3): Some evidence of necrotic cell damage was seen with disruption of
the cell membrane and cytoplasmic debris. An increase in the numbers of organelles was also
noted however.
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6. Chloroquine: Signs of cell damage were the prominent features, particularly with vacuolation.
7. Methotrexate: The main change seen with Methotrexate was enlargement of the cells. The
significance of this is not apparent.
8. Butyric Acid + 5-Azacytidine (photo 4): Increased numbers of organelles, particularly
mitochondria and Golgi were seen. Additionally, there were some appearances suggestive of acini
formation.
9. Interferon + Theophylline: An increased amount of rough Endoplasmic Reticulum and ofGolgi
was seen.
10. Interferon + 5-Azacytidine: Similar increases in rough Endoplasmic Reticulum and Golgi to
those noted above were seen.
11. Butyric Acid + Methotrexate: Enlarged cells with increased numbers of organelles were seen.
12. Chloroquine + 5-Fluorouracil: Increased numbers of lysosomes, desmosomes and Golgi
apparatus was noted.
13. Chloroquine + Butyric Acid: Predominantly signs of cell damage were seen, with vacuolation
and necrosis.
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PHOTOGRAPH ONE: LOVO CONTROL CELLS
PHOTOGRAPH TWO: LOVO CELLS IN BUTYRIC ACID
PHOTOGRAPH THREE: HYPOXIC LOVO CELLS (1% 02 )
HT29 CELLS
As with the Lovo cells, a range ofmorphological changes was seen, from signs of cell damage and
death to signs of increased differentiation and cell activity.
Summarvof Results: Ht29 cells (compared to control samples):
1. Theophylline: An increased amount of rough Endoplasmic Reticulum was noted.
2. 5-Azacytidine: Signs of cell damage were noted, with some vacuolation, but increased numbers of
ribosomes were also seen - suggesting differentiating changes in the cells.
3. Radiation 5Gy: Possible signs of differentiation were noted, with enlarged mitochondria and
increased Golgi apparatus.
4. Hypoxia (1% 02 ): The cells were seen to be damaged, with necrosis and cytoplasmic debris in
lysosomes.
5. Chloroquine ± But Acid/ 5FU/ Mtx: All of the cells exposed to Chloroquine showed florid signs
of cell damage, with necrosis and vacuolation (Photo 2)
6. Methotrexate: Increased numbers of organelles were seen, including microvilli, ribosomes and
rough Endoplasmic Reticulum.
7. Taxoi: An increased number of lipid-containing vacuoles was seen, the significance ofwhich is
unclear.
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8. Interferon + Theophylline: Signs of improved differentiation were noted, including an increase
in mitochondria and rough Endoplasmic Reticulum and the presence of tight junctions (Photo 3).
9. 5FU + IFN/ Theophylline/ 5-Azacytidine: Cell damage with vacuolation was observed.
10. Methotrexate + But Acid/ 5-Azacytidine: Features seen included more mitochondria and
acinus formation, consistent with improved differentiation.
(Photo 4)
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PHOTOGRAPH ONE: HT29 CONTROL CELL
PHOTOGRAPH TWO: HT29 CELL IN CHLOROQUINE
PHOTOGRAPH THREE: HT29 CELL IN INTERFERON + THEOPHYLLINE
COLO CELLS
Many of the effects seen in the Lovo and Ht29 cells were repeated in the Colo cells, e.g the signs of
cell death associated with Chloroquine and Hypoxia in particular. The most pertinent changes to the
Colo cells' morphology were as follows:
Summary of Results: Colo cells (compared to control samples):
1. Interferon: As noted with the Lovo cells, the presence of inclusion granules of ?Interferon was
seen, along with increased Golgi apparatus.
2. Theophylline: Increases in rough Endoplasmic reticulum, and in numbers of lipid vacuoles were
seen.
3. 5-Azacytidine: The predominant change was that of cell damage, manifested by blebbing.
4. Chloroquine ± ButAcid/ Methotrexate: Features of cell damage again predominated, including
necrosis; vacuolation, and an increased number of lipid vacuoles. (Photo 2)
5. Hypoxia (1% 02: Cell damage with lipid vacuolation and necrosis was noted.
6. Radiation (5Gray): An increased amount of rough Endoplasmic Reticulum was seen.
7. 5-Fluorouracil: Signs of cell damage were seen, including vacuolation and increased cytoplasmic
debris.
8. Methotrexate: The cells were enlarged, with increased amounts ofmitochondria and Golgi.
9. Interferon + Theophylline: An increase in rough Endoplasmic Reticulum was seen.
136
10. 5-FU + Butyric Acid/ Theophylline (Photo 3): An increase in lipid vacuoles or lysosomes was
seen.
11. Methotrexate + 5-Azacytidine (Photo 4): As with Methotrexate alone, the cells were enlarged,
with increased Golgi, ribosomes and rough Endoplasmic Reticulum.
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PHOTOGRAPH ONE: COLO CONTROL CELLS


























PHOTOGRAPH THREE: COLO CELLS IN 5-FLUOROURACIL PLUS BUTYRIC ACID
Summary
The various agents and environmental factors produced reactions in the three cell lines which tended
towards either cell damage or improved cell differentiation. It can be seen from the summary




Hypoxia 1% Hypoxia 1% Hypoxia 1%
Chloroquine Chloroquine Chloroquine
5-Fluorouracil Chloroquine+ But Acid Chloroquine+ But Acid
Interferon + Theophylline Chloroquine+ Methotrexate
Chloroquine+ But Acid Chloroquine+ 5-Fluorouracil










5-Fluorouracil + Theophylline Methotrexate + But Acid Methotrexate
5-Fluorouracil + But Acid Methotrexate + 5-Azacytidine But Acid+ 5-Azacytidine
Methotrexate + 5-Azacytidine Interferon + Theophylline Interferon+ Theophylline
Interferon+5-Azacytidine
Methotrexate + But Acid
Chloroquine +5 FU
Discussion:
According to these results, it appears that the Lovo cells, which express the most CEA by far of the
three cell lines, show the greatest improvements in differentiation, with the greatest number of agents.
However, when the factors, or combinations of factors, which produced the largest increases in CEA
expression are studied, signs of cell damage are commonly seen , (particularly with Chloroquine or
Chloroquine + Butyric Acid), or indeed of little morphological change (with Butyric Acid + Interferon
- the most universally successful combination).
It is noted that Methotrexate caused signs of improved differentiation in all three cell lines, alone and
in combination with the differentiation agents. When in combination with Chloroquine, however,
the cells continued to succumb to necrosis and vacuolation. The effects of 5-Fluorouracil were
dissimilar to those ofMethotrexate, despite them being from the same family of anti-metabolite
cytotoxic agents.
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It appears therefore, that a mixed picture of improved differentiation and cell damage accompanies
augmentation of CEA expression. There may be several reasons for this:
1. Cell damage involving destruction of the cell membrane may cause the release of intracellular
CEA, with apparent increases in membrane CEA representing simply the glycoprotein in transit out
of the leaking cell. It would be expected that increases in CEA in the supernatants of damaged cells
would be seen; the results in Chapter 6 confound this theory.
2. CEA expression may be a feature ofmore than one intracellular event - increasing during cell
differentiation and also during periods of cell damage.
3. Improved differentiation, highlighted by increases in CEA expression, lead to improvements in the
cell's ability to recognise its neoplastic qualities, and switch on suicidal pathways.
Much greater understanding of the intracellular meaning of, and events related to. differentiation is
required before the above observations may be properly explained.
Conclusions:
The Electron Microscopy studies of the morphology of the cell lines on exposure to the various
differentiating agents, environmental changes, cytotoxic drugs and combinations of these suggest that
there are changes in the structure of the cells, indicative both of cell damage and imminent death, and
of improved differentiation associated with augmentation of CEA expression. This dual effect of cell
death and differentiation may be paradoxical but useful, since the desired results are that the cells
should be propelled into either differentiating or self-destructing, rather than continuing to proliferate
in an undifferentiated state. The results from cell counting, immunocytochemistiy and FACS
confirm that the effective CEA-inducers often have significant growth inhibitory effects.
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CHAPTER NINE
CHANGES IN ONCOGENE EXPRESSION IN AUGMENTED CELLS
AIM:
The purpose of this experiment was to investigate whether the induction of CEA expression is
accompanied by changes in the expression of tumour associated genes and their product. The
improved differentiation observed in CEA-augmented cells might be expected to be related to various
genetically engineered changes within the cell cycle. A preliminary experiment was designed,
looking for evidence of expression of 4 oncogenes - Bcl-2, p53, K-ras and c-myc in augmented and
non-augmented Ht29 colorectal cancer cells.
Background:
The deregulation of physiological cell death and apoptosis is an integral part of carcinogenesis,
affected by a number of oncogenes, mutated tumour suppressor genes and associated factors.).
Failure of normal apoptosis mechanisms is a factor in the inappropriate survival and propagation of
cancer cells. Apoptosis may be induced by many extra-and intra-cellular physiological and
pathological stimuli, or by the withdrawal of inhibitory factors. The actions and interactions of the
various genetic stimuli involved in apoptosis and the cell cycle are complex. A brief outline is given
below.
As described in the introduction to the thesis, oncogenes are transforming genes, which may be
activated by chemical or physical carcinogens to effect a phenotypic malignant transformation on
their cell. The normally functioning cellular counterparts to the oncogenes are termed proto-
oncogenes, and are usually important regulators of biological processes such as cell division. The
products of tumour suppressor genes are negative growth regulators (140). The following diagram is
a representation of the interaction of proto-oncogenes. tumour suppressor genes and growth factors on
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the regulation of the cell cycle (140). The tumour suppressor genes, eg p53, are thought to act at the
level of transcription of c-myc and c-fos. Several tumour suppressor genes may act in differing ways
at one point, or separately at several points in the cell cycle.
► ►
Competence Progression
In order to enter the G1 phase of the cycle, the quiescent cells need to be stimulated by Platelet-
derived Growth Factor (PDGF), or Fibroblast-derived Growth Factor (FGF). This stimulation is
followed by a transient rise in c-myc or fos, after which Epidermal-derived Growth Factor (EDGF) or
Insulin-like Growth Factors (IGF) is needed to continue with DNA synthesis.
There are several checkpoints during the cell cycle, where regulatory genes may be activated or
suppressed to proceed or delay meiosis and mitosis (267):
1. G1 phase
During Gl, ie pre-DNA replication, p53 is crucial in delivering a veto to the cell cycle. This occurs
if there are breaks in the DNA, which cause the activation of p53. In turn, p53 activates WAF1
which inhibits Gl cyclin-dependant kinases, arresting the cells in Gl (20). If p53 itself is mutated, a
fairly common point mutation, malignant transformation may be induced rather than suppressed.
C-myc is another oncogene which acts in Gl causing arrest and apoptosis (753The actions of both
p53 and c-myc may be overridden by the product of activated Bcl-2, which inhibits apoptosis
(20,755). Bcl-2 is found in the lower half of the colonic crypts, and has been found to be expressed
by a high proportion of Colorectal adenomas, carcinomas and their metastases (211; CC4).
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Overexpression ofBcl-2 prevents the apoptosis usually induced by steroids, y-irradiation, growth
factor depletion and other cell injuries (206).
2. G2 phase - pre mitosis.
The cell cycle may be interrupted in G2 if there are DNA breakages or mutation, which activate
regulatory genes such as MEC1 and RAD9. A number of otherMEC and RAD genes have been
identified which respond to DNA replication errors in G2, and DNA repair errors in S phase.
Mutations in MEC and RAD genes cause defective checking at G2. There is a complex interaction
between the G2 checkpoint and protein kinase p34, a positive regulator of cell division, via regulatory
genes such as WEE1 and CDC25. Transition from G2 to metaphase normally occurs when the
relevant cyclin protein is synthesised or stabilised, when p34 combines with the cyclin, and when that
combination is phosphorylated. Mutations in the regulator}' genes, or interference from radiation or
drugs such as hydroxyurea, may result in premature activation of p34 and inappropriate entry into
mitosis.
3. Metaphase arrest.
This occurs if the microtubule assembly or function has been defective.
The degree of expression of c-myc and mutant p53 has been found to increase in a progression from
normal colonic epithelium, through adenomas to carcinomas. Conversely the degree of expression of
Bcl-2 has been found to fall through this same progression of normal epithelium to colonic carcinoma.
This study looked at the expression of c-myc, mutant p53 and Bcl-2 in the human colorectal cancer
cell line Ht29, grown in monolayer culture with or without the addition of CEA-augmenting agents.
Ht29 cells were selected for use in this experiment as they showed the greatest propensity for change
on exposure to the various differentiating agents and other factors. In addition, the oncogene K-ras,
which is particularly associated with colorectal carcinoma was checked. The ras family of genes are
forms of proto-oncogenes with specific point mutations which induce malignant tranformation (238).
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One previous study by La Rocca et al (161) has looked at the relationship between CEA expression
and oncogene expression, (c-myc & K-ras among others) in 1 ldifferent colorectal cell lines ( not
including Ht29). They found that the expression of CEA was associated with a more differentiated
cell phenotye, but they did not find a specific relationship between expression of CEA and expression
of the oncogenes.
Brach et al in 1993 looked at oncogene expression in myeloid leukaemia cells on exposure to
cytotoxic drugs plus hamatopoetic growth factors; they found that there was a down regulation of c-
myc, with features of improved differentiation in response to Leukaemia Inhibitory Factor plus
Arabinofuranosylcytosine (49). A study of human Hepatoma cell lines by Saito et al in 1991
demonstrated a decrease in the expression of c-myc by cells exposed to Sodium Butyrate (234).
146
METHOD:
Replicate flasks containing 106 Ht29 cells were grown in standard monolayer tissue culture in a
humidified incubator at 37°C for 5 days. Six control flasks were set up, along with 21 experiment
flasks - three for each variable. The control flasks were grown in Whole Medium - Dulbecco's
Modified Eagle's Medium containing 10% Fetal Calf Serum. Glutamine, Penicillin and Streptomycin.
The experiment flasks were grown with the same medium but with the addition of Butyric Acid
(ImM), Theophylline (lOmM), 5-Azacytidine (lpM), Interferon (lOng/ml), 5-Fluorouracil (lOng/ml)
or Methotrexate (lOng/ml). The last set of experiment flasks was incubated in Whole Medium, in a
sealed module with a gas mixture of > 99% Nitrogen, <1% Oxygen. All of these changes to the
growing conditions of the cells have been previously shown to have induced increased CEA
expression.
After five days, the cells were harvested by trypsinisation, spun down, counted and resuspended at
106cells per ml in whole medium. Four cytospins were then made from each flask. These were fixed
in Acetone at 4°C for 10 minutes, before being immunostained for Bcl-2, p53, K-ras and c-myc as
follows.
The acetone was washed offwith PBS x 3.
The primary antibodies were laid onto the slides, with 2 negative controls treated with PBS only. A
further negative isotype-specific control using mouse IgGl at lOpl/ml was prepared. The primary
antibodies were:
1. Monoclonal Mouse Anti-Human Bcl-r Oncoprotein at 4mg/L (DAKO).
2. Monoclonal Mouse Anti-Human p53 protein at 8mg/L (DAKO).
3. Clone 234-4.2 Mouse Monoclonal antibody to K-ras protein at 10p.g/ml (ONCOGENE
RESEARCH PRODUCTS)
4. Mouse Monoclonal Antibody to c-myc Oncoprotein at lOmg/L (NOVOCASTRA).
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The slides were incubated in a humidified chamber at room temperature for 45 minutes, before
unbound antibody was washed offwith PBS x 3.
Peroxidase labelled RAMP (Rabbit AntiMouse antibody) at a concentration of 13pg/ml in 10%
normal human serum was then applied to every slide except one of the negative controls per set
(which was treated with PBS to prevent drying out). and the slides again incubated in a humidified
chamber at room temperature for 45 minutes, then washed in PBS x 3.
The slides were then immersed in 100ml tris/HCL buffer containing 60mg 3,3'-diaminobenzidine
tetrahydrochloride, 1ml of 0.1M imidazole and 40pl lOOvol H202 for 5 minutes, to develop the
immunostain. The slides were then washed in distilled water x 3, and counterstained with Mayer's
Haemalum for 5 minutes.
The slides were again washed in distilled water x 3, dried in methylated spirits x 3, immersed in
xylene x 3 and finally mounted with DPX.
After 24 hours of drying, the cytospins were studied under light microscopy, and the scored according
to the degree of staining, using the same duplicated, blind single observer-based marking system as




Degree of BCL-2 Expression; Ht29 cells
Control BA Th 5Az Ifn 5Fu Mtx Hyp
BCL-2 Control B.A. Theoph 5-Aza IFN 5FU Mtx Hypox
Flask 1 0 2 0 1 1 1 1 0
Flask 2 1 1 0 1 0 1 1 0




Average 0.33 1.33 0 2 0.67 0.67 1.33 0
St. Dev 0.52 0.58 0 1.73 0.58 0.58 0.58 0
T-test 0.03 (W) 0.32 0.05 0.41 0.42 0.03 (W) 0.32
* Denotes the three extra control flasks
W denotes significance using the Wilcoxon Rank Sum test.
The results show a slight but significant increase in Bcl-2 expression in the Ht29 cells treated with
Butyric Acid and Methotrexate, on analysis with the parametric t-test and the non-parametric
Wilcoxon Rank Sum test.
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d53
Degree of p53 Expression; Ht29 cells
p53 Control B.A. Theoph 5-Aza IFN 5FU Mtx Hypox
Flask 1 4 10 7 9 6 10 9 8
Flask 2 9 9 3 10 10 5 8 8




Average 7.0 9.33 4.67 9.67 8.0 8.0 8.67 8.0
St. Dev 2.76 0.58 2.08 0.58 2.0 2.65 0.58 0
T-test 0.20 0.24 0.15 0.60 0.62 0.35 0.56
* Denotes the three extra control flasks
The results show no significant differences in p53 expression in the CEA-augmented cells compared
to the control cells, on analysis with the parametric t-test and the non-parametric Wilcoxon Rank Sum
test. All of the cells stained strongly for p53.
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K-ras












Control BA Th 5Az Ifn 5Fu Mtx Hyp
K-ras Control B.A. Theoph 5-Aza IFN 5FU Mtx Hypox
Flask 1 0 0 0 0 0 0 0 0
Flask 2 0 0 0 0 0 0 0 0




Average 0 0 0 0 0 0 0 0
St. Dev 0 0 0 0 0 0 0 0
T-test NA NA NA NA NA NA NA
* Denotes the three extra control flasks











Ifn 5Fu Mtx HypControl BA Th
C-myc Control B.A. Theoph 5-Aza IFN 5FU Mtx Hypox
Flask 1 0 0 0 1 4 0 0 0
Flask 2 0 0 0 2 0 0 1 0




Average 0.17 0 0 1.67 1.67 0 0.33 0
St. Dev 0.41 0 0 0.58 2.08 0 0.58 0
T-test 0.52 0.52 0.003 (W) 0.11 0.52 0.63 0.52
* Denotes the three extra control flasks
W denotes significance using the Wilcoxon Rank Sum test.
The results show a slight but significant increase in c-myc expression in the Ht29 cells treated with 5-
Azacytidine. on analysis with the parametric t-test and the non-parametric Wilcoxon Rank Sum test.
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Discussion
There was no universal change in the expression of Bcl-2, p53, K-ras or c-myc accompanying
changes in CEA expression in cultured Ht29 cells. Very slight increases in Bcl-2 and c-myc
expression were observed with sporadic CEA-inducing agents:
Bcl-2: Increases with Butyric Acid, 5-Azacytidine & Methotrexate
C-myc: Increase with 5-Azacytidine.
Overall there were few differences between the control and the augmented Ht29 cells, despite the
highly significant changes in proliferation rates and degree of CEA expression previously noted in
these cells on exposure to the various factors studied above. Bcl-2 was the only oncogene product
whose expression was increased slightly by selected CEA-augmenting factors. It is interesting that
Bcl-2 expression has been shown to be protective against apoptosis by previous studies (206)-
increased expression of Bcl-2 may therefore reflect better differentiated cells protecting themselves
against injury or may be a feature of ongoing cell injury, induced by the so-called differentiating
factors. The previous chapter's work on the morphological features ofHt29 cells exposed to Butyric
Acid, 5-Azacytidine and Methotrexate found that the latter two agents induced more a differentiated
intracellular appearance, but that cells in Butyric Acid predominantly showed signs of injury and
damage. It would appear that CEA-inducing agents may affect a colorectal cancer cell line in quite
different ways, to produce the same end result of growth inhibition and CEA augmentation.
Conclusions:
1. There are variations in the response of a single cell line to different CEA-inducing agents and
factors, which may be translated into altered Bcl-2 expression.
2. Improved differentiation of colorectal cancer cells exposed to CEA-inducing agents may involve
processes other than the cell cycle regulators investigated here.
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CHAPTER TEN: CONCLUSIONS andDISCUSSION
1. SINGLE CEA-INDUCERS:
Differentiating Agents: Butyric Acid (Lovo & Ht29 augmentation)
Interferon (Lovo & Ht29 augmentation)
Theophylline (Ht29 & Colo augmentation)
5Azacytidine (Ht29 & Colo augmentation)
The differentiating agents studied all produced significant augmentation of CEA, associated with
growth inhibition in the Ht29 cells. Butyric Acid and Interferon had the same effects of CEA
augmentation and growth inhibition in the Lovo cells; and Theophylline and 5-Azacytidine in the
Colo cells. The fact that the effects of the agents altered from one cell line to another suggests that
CEA expression may be regulated by more than one mechanism, and that these agents act via
different mechanisms. This has potential clinical relevance for two reasons:
1. It may be possible to achieve additive or synergistic augmentation effects by using more than one
agent simultaneously.
2. The likelihood ofColorectal cancer cells in vivo being unaffected by any of the differentiating
agents is reduced if there is more than one possible mechanism to be exploited. It should be noted
that in this work, it was not expected that Colo cells would express CEA, since they have been
previously documented in an unaltered state as being non-expressors (223).
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Altered Environment: Chloroquine (Lovo, Ht29, Colo)
Hypoxia 1% (Ht29,Colo)
(Hypoxia5% - Colo, less effective)
In altering the environment of the cultured cells, the most impressive changes in CEA expression and
cell proliferation were seen with Chloroquine, which was active in all three cell lines, causing
changes in CEA expression of a high magnitude. These results are interesting, since Chloroquine is
a well-established drug in clinical use. Obviously, more work has to be done in vitro, with multi-cell
spheroids, and in transfected animals before it is known whether the administration of Chloroquine to
patients could improve the efficacy of tumour targetting. The Electron Microscope picture of cells
exposed to Chloroquine in general showed dying cells only, rather than differentiated cells, although
it is certain that some cells did survive, and that they expressed increased CEA. The serial dilution
doses studied indicated a cut off point at S:10"5 Molar concentration. A more graduated decline in
efficacy would be expected, and further titration studies with smaller gradations in concentration may
show this. Extrapolating to human dose regimens from in vitro studies is not accurate; however, dose
titration figures from animal studies may be more informative.
The effects of extreme hypoxia with <1% Oxygen in the Colo and Ht29 cells were impressive,
although the magnitude of Colo cell effects decreased and the Ht29 cell effects were lost as the
concentration ofOxygen climbed to over 5%. The Lovo cells showed no appreciable change under
hypoxic conditions. Clinically it is possible to temporarily block a tumour's arterial blood supply
using injected dissolvable starch microspheres. Whether the window of time before the microspheres
dissolve is long enough to induce CEA expression in the cells, and whether the degree of hypoxia
attainable using this embolisation method is sufficient, is unclear. It is interesting, however that
either the cells which are clearly damaged, as seen in the Electron Microscope pictures or those which
are particularly resistant to a hostile external environment are seen to express significantly greater
amounts of tumour-associated antigen, CEA.
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Cytotoxics: 5-Fluorouracil (Ht29)
Methotrexate (Lovo, Ht29, Colo)
Taxol (Lovo, Ht29, Colo)
(Etoposide - Lovo)
The anti-metabolite cytotoxic drugs were the only agents to cause CEA augmentation at the single
dose tested of lOng/ml. Methotrexate and Taxol induced CEA increases in all the cell lines and 5-
Fluorouracil in the Ht29 cells only. Etoposide caused increased total CEA in the Lovo cells, but had
no apparent effect on membrane expression. The best agent overall was Methotrexate, which
interestingly was superior to 5-Fluorouracil. the most commonly used cytotoxic agent in colorectal
cancer, in terms of growth inhibition and CEA augmentation.
Clinically it might be possible to give a patient a dose of Methotrexate, leave time for the
disseminated tumour cells to express more CEA; then administer a bispecific antibody to CEA and to
Methotrexate. This would potentially improve the penetration ofMethotrexate and increase its
cytotoxic effect. A bispecific antibody for CEA and Methotrexate has already been developed (105).
More studies on Methotrexate in cell spheroids and transfected animals is needed before the true
possibilities of this type of regime are known; CEA response times and dose responses to
Methotrexate would have to be elucidated.
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2. COMBINATIONS OF AGENTS/ ALTERED ENVIRONMENT AS CEA
INDUCERS;
There are two important considerations in judging which of the combinations studied were potentially
useful:
a. Those which had positive effects on all three cell lines.
This is relevant in consideration of the variability in the behaviour of colorectal cancers from one
patient to the next; and as a model of any one colorectal cancer, which may be heterogeneous in terms
of its CEA expression.
b. Those which resulted in the greatest degree ofCEA expression in any of the cell lines.
This applies particularly to the Lovo cells, which express far more CEA than the other cell lines. It is
relevant in the context ofBystander Effect, where anti-CEA antibody-conjugated agents, such as
Methotrexate (214) or a-emitting Bismuth-211 (183), sent to CEA targets on the Lovo-type high
CEA-expressor cells would be expected to have effects on the surrounding non CEA-expressing
cancer cells.
a. Combinations which augment CEA in all three cell lines:
(i). Chloroquine + Butyric Acid (Best)
(ii). Interferon + Butyric Acid (Colo less marked - total CEA only)
(iii). Methotrexate + Theophylline
(iv). Methotrexate + 5-Azacytidine
There was a potentiation of the effects of Interferon by Butyric Acid, or vice versa, with a greater
degree of CEA expression seen in the Lovo and Ht29 cells than with either of the agents used singly.
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A similar effect was seen in the Colo cells, which were unaffected by Butyric Acid or Interferon used
alone.
Methotrexate plus Theophylline or plus 5-Azacytidine did cause augmentation of all the cell lines, but
the magnitude of CEA increases was not significantly greater than with Methotrexate alone.
The effects ofChloroquine alone were similarly little altered by the addition of Butyric Acid, except in
Colo cells where the degree of CEA augmentation was greater than with Chloroquine alone, despite
the fact that Butyric Acid alone did not induce increased CEA expression in the Colo cells.
b. Combination which produced the highest level CEA in Lovo cells:
Interferon + Butyric Acid
The combination of Interferon and Butyric Acid produced very high levels of CEA expression in Lovo
cells, both in the cytoplasm and on the membrane. The figures were just over double those achieved
with the single agents, and between 5 and 7 times the figures in non-augmented Lovo cells. This
could reflect an additive or a synergistic effect of the two agents.
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3. COMPARISON OF CHANGES IN GROWTH AND CEA (BY FACS)
The relationship between growth inhibition and CEA augmentation was analysed by calculating the





A perfect inverse correlation would give a value of -1; the correlation values for each of the three cell
lines begin to approach this, suggesting an inverse relationship between cell proliferation and CEA
expression, which is to be expected if CEA expression is taken as a marker of differentiation. It is
noteworthy that the relationship is not strong, particularly in the Lovo cells, suggesting that changes
in CEA expression are not merely a function of inhibited cell growth.
4. COMPARISON OF FACS AND IMMUNOCYTOCHEMISTRY RESULTS
The sensitivity of Immunocytochemistry was found to be inferior to that of FACS from the beginning
of the experiments: the Lovo cells which appeared almost maximally stained in the non-induced state
with Immunocytochemistiy, were clearly shown using FACS to stain much more densely when
exposed to certain of the differentiating agents.
The accuracy of this initial impression was checked by plotting the Immunocytochemistry results
against the FACS membrane results; this also provided a useful validation of the results obtained.
The correlation coefficients of the graphs between the Immunocytochemistry and FACS membrane






The correlation coefficients indicate a direct relationship between the Immunocytochemistry results
and the FACS membrane results, strongest in the Ht29 and Colo cells, and weakly positive in the
Lovo cells.
5. CHANGES IN MORPHOLOGY PERTAINING TO DIFFERENTIATION
Changes in the CEA-augmented cells were seen under Electron Microscopy. In general, the
differentiating agents caused signs of improved morphological differentiation in all the cell lines; the
environmental changes, signs of cell damage; and the cytotoxic drugs and combination therapies a
mixture of both cell damage and improved differentiation. The most effective CEA-inducers did
show associated growth-inhibiting properties, so one should expect to see signs of cell death and of
improved differentiation in the CEA-expressing survivors.
6. CORRELATION BETWEEN CEA EXPRESSION & RELEASE
There was no correlation between the augmentations of CEA expression and CEA release into the cell
supernatants in the Ht29 and Colo cells (Correlation coefficients -0.02 and -0.002 respectively). In
the Lovo cells, there was a veiy weakly positive relationship, with a correlation coefficient of 0.48. It
is noted, however, that the agents which caused increases in Lovo CEA expression did not cause
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reciprocal rises in CEA release; but the agents which apparently decreased the Lovo CEA expression,
were associated with decreases in CEA release.
These results are reassuring if the culture/supernatant set-up is taken as a model of the human
tumour/ circulation relationship. If the background CEA were to dramatically rise due to the
inducing agents, one might worry about a possible sink effect by circulating CEA, reducing the
efficacy of targetting by administered anti-CEA antibodies. The potential for interference between
circulating and cell-bound CEA in tumour targetting is a controversial point (47,242).
7. CHANGES IN ONCOGENE PRODUCT EXPRESSION
CEA-induced, i.e. differentiated. Ht29 cells were not shown to express greater or lesser degrees of p53
or K-ras than non-induced Ht29 cells. A slight increase in Bcl-2 expression was observed in Ht29
cells induced with Butyric Acid or with Methotrexate; and a slight increase in c-myc expression was
seen in Ht29 cells induced with 5-Azacytidine. Overall, there were no striking changes observed in
oncogene or tumour suppressor gene associated with augmentation of CEA. Judging by the relatively
convincing inverse relationship between cell proliferation and CEA expression augmentation, some
changes in the regulation of the cell cycle must be occurring. Further studies of the various controls
in the cell cycle are needed before these changes are elicited, and before their relationship to the
mechanisms of CEA expression may be understood.
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CONTRIBUTION TO SURGICAL KNOWLEDGE
a. Behaviour ofColorectal Cancer cells
Different cell lines were seen to respond in specific and distinctive ways to differentiating agents,
cytotoxic drugs, environmental changes and combinations of these factors, suggesting that more than
one mechanism of cell differentiation may operate in the cells, and that these mechanisms may be
vulnerable to stimulation or inhibition in a variety ofways.
"Non" CEA expressors (i.e. Colo cells, in this work) may be induced to express and be seen to
express CEA with sensitive FACS imaging.
Increased CEA expression correlated with decreased cell proliferation in all the cell lines. Both
tumour-associated antigen expression and growth inhibition are indicative of differentiation in cancer
cells; it may be deduced that the agents and environment changes which produced increases in CEA
expression and inhibition of growth may have a differentiating effect on the colorectal cancer cell
populations.
Cell Morphology
Electron Microscopy studies of morphological features accompanying increased tumour-associated
antigen expression showed mixed evidence for increased tumour differentiation and for tumour cell
damage. Methotrexate almost universally lead to features of improved differentiation in all the cell
lines; and Chloroquine conversely lead to cell damage and death.
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The fact that signs of improved differentiation or of cell damage were seen to accompany increases in
CEA expression suggests that the relationship between cell growth, differentiation and CEA
expression is not a straightforward linear progression from an uncontrolled undifferentiated cell
towards a controlled, differentiated CEA-expressing cell
c. Survey Of Potentially Useful Agents/ Combinations OfAgents To Improve
Tumour Targetting Efficacy
Four groups of agents or factors were studied: differentiating agents, cytotoxic drugs, changes in
enviromnental conditions and combinations of successful members of each of the preceding three
groups.
Of the differentiating agents, all four tested (Butyric Acid, Interferon, Theophylline and 5-
Azacytidine) were found to be effective in up to two of the three cell lines. The cell line which
responded to all of the four agents was the Ht29 line.
The cytotoxic drugs were all tested at a single dose level only; at that dose (lOng/ml) the anti¬
metabolites 5-Fluorouracil, Methotrexate and Taxol were successful in inducing increased CEA
expression, the latter two agents in all three cell lines.
Many of the combinations of differentiating agents, cytotoxic drugs and enviromnental factors
interacted negatively to reduce the overall CEA augmenting effects seen, and other combinations
produced no difference in effect from either one of the factors used singly. Methotrexate plus
Theophylline or 5-Azacytidine produced consistent increases in membrane CEA expression and total
CEA content, but these did not differ significantly from the results obtained from Methotrexate alone..
The combination of Interferon and Butyric Acid did result in an additive increase in CEA expression,
most notable in the Lovo cells.
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d. Relationship between CEA Expression & Release
No correlation was found between the changes in CEA expression induced by the various
differentiating, cytotoxic or environmental factors and the degree ofCEA released into the cell culture
supernatants - further evidence that augmenting CEA expression does not automatically lead to a
reciprocal rise in CEA release.
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FURTHER WORK
The continuation of the work in this project may be sub-categorised into in vitro and in vivo work.
In Vitro:
Further studies of colorectal cancer cells in vitro which would follow on from this work include
studies of cells in monolayer and in spheroids or organelles.
In both of these set-ups, the best positive results achieved in this work should be verified as being
repeatable. Additionally, the successful CEA-augmenting factors or combinations of factors should
be tested on cultured normal, non-cancerous colon cells.
Successful CEA-inducing agents such as Chloroquine in particular, warrant closer study, checking a
smaller range of serial dilutions.
One further study to be considered is to test whether the factors which produced significant increases
in CEA also induce increases in other membrane or tumour- associated antigens.
In Vivo:
Before any clinical application of CEA induction can be considered, the positive CEA augmentation
results should be shown to be achievable in tumour transfected animals, with the desired endpoint of
increased localisation of labelled anti-CEA antibodies to the tumour cells. Dose: response curves for
effective agents or combinations would be required.
As mentioned in the in Vitro section, the surrounding non-diseased colon in the transfected animals
could also be studied for reciprocal changes in CEA expression.
The behaviour of resistant populations of cells, which did not respond to the differentiating agents, or
which were left after treatment would also be of interest.
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APPENDIX ONE: TITRATION EXPERIMENTS
TRYPAN BLUE TITRATION EXPERIMENT
Introduction
In order to count cells, a measured quantity of trypsinised cell suspension pre-Centrifuging is mixed
with a measured quantity ofTrypan Blue Stain (0.4%) and injected into a hemocytometer. Non¬
viable cells take up the Trypan Blue stain and show up dark. If cells are exposed to too much Trypan
Blue for too long a time, viable cells as well as non-viable cells may begin to take up the dye.
Aim
To expose cells suspended in whole medium to serial dilutions of Trypan Blue, comparing the ratios
of viable to nonviable cells with the various dilutions.
Method
A Colorectal cancer cell line, Lovo, was grown up in standard tissue culture: one million cells
initially injected into a 25cm2 culture flask in 5mls of whole medium ( Dulbecco's Modified Eagle's
Medium, 10% Fetal Bovine Serum, Penicillin 50 OOOu, Streptomycin 50mg and Glutamine 5mls) and
incubated in a humidified chamber at 37°C. On day 5, the cells were washed in PBS, incubated in
2mls Tiypsin-EDTA for 10 minutes and re-suspended in whole medium. Aliquots of lOOql of the
cell suspension were added to Ependorf tubes containing varying amounts of Trypan Blue, and were
thoroughly mixed. Five minutes after mixing, a drop of each solution was injected into a
Hemocytometer and the viable and non-viable cells counted.
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Results
The cell counts were as follows:
Trypan (pi) 200 100 100 100 100
Lovo susp (pi) 100 100 200 400 800
Cone Try:Lov 2:1 1:1 1:2 1:4 1:8
Viable cells 39.94 xlO6 32.25 xlO6 25.69 xlO6 26.02 xlO6 24.96 xlO6
Non-viable cells 7.13 xlO6 7.13 xlO6 6.66 xlO6 2.73 xlO6 2.88 xlO6
% Non-viable 17.8% 22.1% 25.9% 10.5% 11.5%
Average % non-viable cells: 17.56%
Standard Deviation: 5.25
There was a significant reduction in non-viable cell percentage (p^O. 1) above dilutions of the Trypan
Blue in cell suspension of 1:4.
Conclusion
Improved accuracy in cell counting with regard to cell viability may be achieved by diluting the





1. To demonstrate the presence of CEA in HT29 Colorectal Cancer Cell lines by two stage indirect
immunocytochemical staining.
2. To establish the most efficacious concentration of anti-CEA antibody by serial dilutions.
3. To compare the quality of cytospins of cells in Fetal Calf Serum with cells in Whole Medium.
Introduction:
CEA, (Carcinoembryonic Antigen), is a glycoprotein membrane adhesion molecule which is
expressed to a variable degree by human colorectal cancer cells. HT29 cells are human colorectal
cancer cells which may be grown in vitro and which have been demonstrated in previous research to
be low expressors of CEA.
The presence of CEA may be assumed by indirect two stage immunocytochemistry. This involves
staining CEA-expressing cells by tagging CEA with anti-CEA antibody and further tagging that
compound with a second peroxidase-labelled antibody. The second antibody reacts with the
immunostain, colouring the cells.
Materials and Methods:
A flask of growing HT29 cells was harvested by washing, trypsinising and centrifuging the cell
suspension to produce a pellet of cells. The cells were counted and resuspended in either fetal calf
Serum or whole medium to a dilution of 106 cells per ml.
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Replicated 100pi aliquots of each solution were pipetted into separate Shandon Elliot Cytospin
Chambers.
Glass microscope slides were prepared by spreading with Poly-L-Lysine. They were then dried, fitted
with filter papers into the Shandon Elliot Cytospin and spun for 5 minutes at 800 rpm. A circle of
cells adherent to the glass slide was produced. The cell circle was further encircled with a paraffin
pen, and the slides left to dry overnight.
The slides were next fixed by immersion in acetone at 4°C for 10 minutes. The acetone was washed
off with PBS x 3.
Serial dilutions of A5B7 anti-CEA antibody in 0.1% BSA, at 1:50, 1:150, 1:450, 1:1350 and 1:4050
were laid onto separate slides, with 2 negative controls per set (cells in medium and cells in FCS).
The slides were incubated in a humidified chamber at room temperature for 45 minutes, before
unbound antibody was washed offwith PBS x 3.
Peroxidase labelled RAMP (Rabbit AntiMouse antibody) at a concentration of 13pg/ml in 10%
normal human serum was then applied to every slide except one of the negative controls per set, and
the slides again incubated in a humidified chamber at room temperature for 45 minutes, before being
washed in PBS x 3.
The slides were then immersed in 100ml tris/HCL buffer containing 60mg 3,3'-diaminobenzidine
tetrahydrochloride, 1ml of 0.1M imidazole and 40pl lOOvol H2C>2 for 5 minutes, to develop the
immunostain. The slides were then washed in distilled water, and counterstained with Mayer's
Haemalum for 5 minutes.
The slides were again washed in distilled water, dried in methylated spirits, immersed in xylene and




Slide Fixn A5B7 Diln RAMP DAB CEA grade (arbitrary units)
1 + + 1 50 + + 1
2 + + 1 150 + + 1
3 + + 1 450 + + 1.5
4 + + 1 1350 + + 0.5
5 + + 1 4050 + + 0.25
6 + - - + + 0
7 + ~ ~ " + 0
Cells in FCS:
Slide Fixn A5B7 Diln RAMP DAB CEA
1 + + 1 50 + + 2
2 + + 1 150 + + 2
3 + + 1 450 + + 0.5
4 + + 1 1350 + + 1
5 + + 1 4050 + + 1
6 + - - + + 0
7 + - - - + 0
1. CEA was demonstrated in both sets ofHT29 cells, although the cells spun in medium were
slightly fainter, with poorer morphology compared to those spun in FCS.
2. All dilutions of anti-CEA antibody positively stained the cells. The colour was beginning to fade
by dilution to 1:4050 in the cells spun in medium.
Discussion:
These results confirm that HT29 colorectal cancer cell lines produce CEA, indirectly visualised by
immunocytochemistiy. It is suggested that diluting anti-CEA antibody up to 1:2000 should provide
acceptable results with immunostains. It is also suggested that spinning cells in fetal calf serum is
superior to spinning them in whole medium, although acceptable results may be achieved using whole
medium. Whole medium is cheaper, readily available and more convenient to use in the quantities




1. To explore the accepted recipe for indirect two stage immunocytochemistry in visualising CEA,
checking the effects of altering time of exposure to anti-CEA antibody, time of exposure to DAB or of
omitting fixation in Acetone.
2. To demonstrate the presence of CEA on Lovo cells by indirect two stage immunocytochemistry
using fluorescein-conjugated or Rhodamine-conjugated Rabbit anti-Mouse Immunoglobulin.
Introduction:
CEA (Carcinoembryonic Antigen) is a glycoprotein membrane adhesion molecule, which is expressed
to a variable degree by human colorectal cancer cells. Lovo cells are human colorectal cancer cells
which may be grown in vitro and which have been demonstrated in previous research to be high
expressors of CEA.
The presence of CEA may be assumed by indirect two stage immunocytochemistry. This involves
staining CEA-expressing cells by tagging CEA with anti-CEA antibody and further tagging that
compound with a second peroxidase-labelled antibody. The second antibody reacts with the
immunostain, colouring the cells. A standard recipe involves fixing cytospins in Acetone, incubating
with A5B7 anti-CEA antibody for 45 minutes, further incubating with peroxidase-labelled Rabbit
anti-Mouse immunoglobulin and then developing the immunostain in DAB (3,3-diaminobenzidine
tetrahydrochloride) buffer for 5 minutes. The need for stringent adherence to these timed steps was
explored by altering various components of the recipe and recording the resultant degrees of CEA
demonstrated.
In addition. 2 slides were treated with fluorescein labelled second antibody instead ofRAMP, as a
comparison with the technique of light microscopic immunocytochemistry.
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Materials and Methods:
A flask of growing Lovo cells was harvested by washing, trypsinising and centrifuging the cell
suspension to produce a pellet of cells. The cells were counted and resuspended in whole medium to
a dilution of 106 cells per ml.
Replicated lOOpl aliquots of solution were pipetted into separate Shandon Elliot Cytospin chambers.
Glass microscope slides were prepared by spreading with Poly-L-Lysine. They were then dried, fitted
with filter papers into the Shandon Elliot Cytospin and spun for 5 minutes at 800 rpm. A circle of
cells adherent to the glass slide was produced. The cell circle was further encircled with a paraffin
pen, and the slides left to dry overnight.
The slides were next fixed by immersion in acetone at 4°C for 10 minutes, with the exception of one
negative control slide. The acetone was wshed off with PBS x 3.
A dilution of A5B7 anti-CEA antibody in 0.1% BSA at 1:2000 was applied to the separate slides,
with 2 negative controls. The slides were incubated in a humidified chamber at room temperature for
15, 45 or 75 minutes, before unbound antibody was washed offwith PBS x 3.
Peroxidase labelled RAMP (Rabbit AntiMouse antibody) at a concentration of 13pg/ml in 10%
normal human serum was then applied to 7 slides, leaving one of the negative controls and 2 others.
These latter 2 slides were overlaid with 1:20 dilutions ofRhodamine-conjugated Rabbit anti-Mouse
immunoglobulin and Fluorescein-conjugated Rabbit anti-Mouse immunoglobulin respectively. The
slides were again incubated in a humidified chamber at room temperature for 45 minutes, then
washed in PBS x 3.
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All slides except the TRITC and FITC treated cytospins were then immersed in 100ml tris/HCL buffer
containing 60mg 3,3'-diaminobenzidine tetrahydrochloride, 1ml of 0.1M imidazole and 40pl lOOvol
H202 for one, 5 or 20 minutes, to develop the immunostain. The slides were then washed in distilled
water, and counterstained with Mayer's Haemalum for 5 minutes.
The TRITC and FITC slides were overlaid with 50:50 Glycerol/PBS and coverslips.
The remaining slides were again washed in distilled water, dried in methylated spirits, immersed in
xylene and finally mounted with DPX and coverslips.
Results:
Slide Acetone A5B7 Time 2nd Ab DAB Time CEA Morphol.
1 + + 45 mins RAMP + 5 mins +/- Poor
2 0 + 45 mins RAMP + 5 mins + Poor
3 + 0 RAMP + 5 mins Good
4 + 0 RAMP + 5 mins Good
5 + + 15 mins RAMP + 5 mins ++/+++ Good
6 + + 75 mins RAMP + 5 mins +++ Good
7 + + 45 mins RAMP + 1 mins +/- Poor
8 + + 45 mins RAMP + 20 mins + Poor
9 + + 45 mins TRITC 0 ++ Good
10 + + 45 mins FITC 0 ++ Good
The above results indicate that omitting the fixation step in Acetone in the traditional recipe for
immunocytochemistry, and altering the time of immersion in DAB both adversely affect the degree of
CEA staining and the quality of the morphology of the cells in the finished slide. Altering the time
of exposure to A5B7 in the humidifier did not adversely affect CEA staining or morphology.
CEA was successfully visualised on the Lovo cells by two-stage indirect immunocytochemistry using
fluorescein and rhodamine conjugated rabbit anti-mouse immunoglobulin.
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FLUORESCEIN ACTIVATED CELL SORTING EXPERIMENT 1
ANTIBODY TITRATION
Introduction
Fluorescein Activated Cell Sorting (FACS) involves directing a laser beam of light through a
suspension of cells. The pattern of scattering of the light beam allows the number, size and
fluorescence of the cells to be accurately calculated. Human colorectal cancer cells have a residual
low fluoresence. It is possible to highlight surface or cytoplasmic cell associated antigens, such as
CEA, by binding them to fluorescein-conjugated antibodies. The degree of expression of these cell
associated antigens can then be measured according to the degree of fluoresence seen with FACS.
The highlighting of the cell associated antigens is acheived by two stage immunostaining. A primary
anti-CEA antibody is first applied to the cells, followed by a fluorescein-conjugated secondary
antibody which binds to the primary antibody. Commercially available antibodies come in very
concentrated form; it is necessary to establish the most efficacious dilution of antibody by performing
serial dilutions.
Aim
To find the optimum concentration ofprimary anti-CEA antibody (A5B7 Mouse IgG type antibody)
and of the negative control (Mouse IgGi) for immunostaining and FACS.
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Method
Three human colorectal cell lines, (HT29, Colo and Lovo) which are low, high and non-expressors of
CEA respectively, were grown in standard tissue culture for 7 days. The cells were then harvested by
trypsinising, counted and resuspended in whole medium at a concentration of 106 cells per ml.
Fourteen Aliquots of lOOpl of each cell suspension were pipetted into separate pyrex tubes, 7 for
surface antigen measurement and 7 for cytoplasm antigen measurement.
The samples for cytoplasmic antigen measurement were then permeabolised: 2 mis ofOrtho
Permeafix at 0.5 concentration with distilled water was added to the tubes which were incubated for
30 minutes at room temperature. The samples were then centrifuged at 2000rpm for 5 minutes, the
supernatants discarded and the pellets flicked. The cells were then washed twice in PBS.A (PBS,
Albumin 0.2%, Azide 0.2%) and respun at 2000rpin for 5 minutes after each wash.
All the samples were then immunstained - the permeabolised and the non-penneabolised cells.
Varying amounts ofA5B7 (1,2,5 and 10 pi) in 100pi aliquots in PBS.A were applied. Two
concentrations of the negative control mouse IgG] (10 and 20pi of lOOpg/ml) were applied to negative
control tubes. The positive control used was W6/32 MHC Class 1 antibody, which was used at
standard FACS-recommended concentration.
The samples were incubated for 30 minutes at room temperature, then washed twice in PBS.A, being
spun at 2000rpm for 5 minutes in between washes. The second, fluorescein conjugated antibody
(Rabbit anti-mouse Fluorescein Isothionate) was then applied in 5pl aliquots at a concentration of
1:100.
The samples were again incubated at room temperature for 30 minutes, then washed twice with
PBS.A and spun at 2000rpm for 5 minutes. They were then fixed in Paraformaldehyde (1%). and
stored at 4°C prior to being processed throught the FACS scanner.
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Results
5000 cells from each sample were put through the FACS cytometer, and the mean fluorescence
measured was as follows:


















HT29 10.88 12.35 69.42 14.83 14.76 14.74 14.29
Lovo 16.75 25.93 21.59 111.02 84.97 40.21 32.90
Colo 15.01 15.96 39.37 14.68 18.54 13.43 19.68



















HT29 17.65 17.05 150.61 24.41 25.02 17.70 13.36
Lovo 29.20 64.11 30.90 112.10 83.49 56.84 25.91












-veConIO -veCon20 +veCon A5B710 A5B720 A5B750 A5B7100
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The results suggest that the concentrations of A5B7 used are too high - the best results were achieved
with A5B7 concentration of lOpg/ml. There was no significant difference in the results with
negative control antibody at 10 or 20pl/ml.
Conclusions
1. Negative control antibody may be used efficaciously at a concentration of lOpl/ml.
2. Further dilutions of A5B7 up to a maximum of lOpg/ml are recommended, in order to establish
the minimum acceptable concentration of primary antibody for FACS measurement of Fluorescein-
conjugated CEA
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FLUORESCEIN ACTIVATED CELL SORTING EXPERIMENT 2
ANTIBODY TITRATION
Aims
1. To find the optimum concentration of primary anti-CEA antibody (A5B7 Mouse IgG type antibody)
and of the negative control (Mouse IgGO for immunostaining and FACS, using a range of dilutions
antibody extending beyond those used in Fluorescein Activated Cell Sorting Antibody Titration
Experiment 1.
2. To test the suitability ofRFDR.2 MHC Class 11 antibody as a positive control against anti-CEA
antibody.
Method
The human colorectal cell lines, Lovo, which is a high expressor ofCEA was grown in standard tissue
culture for 7 days. The cells were then harvested by trypsinising, counted and resuspended in whole
medium at a concentration of 106 cells per ml. Thirty-eight Aliquots of lOOpl of each cell suspension
were pipetted into separate pyrex tubes, 19 for surface antigen measurement and 19 for cytoplasm
antigen measurement. In each category, 9 serial dilutions of anti-CEA antibody. 9 serial dilutions of
negative control mouse IgGl and a standard positive control, RFDR.2, were tested.
The samples for cytoplasmic antigen measurement were then penneabolised: 2 mis of Ortho
Permeafix at 0.5 concentration with distilled water was added to the tubes which were incubated for
30 minutes at room temperature. The samples were then centrifuged at 2000rpm for 5 minutes, the
supernatants discarded and the pellets flicked. The cells were then washed twice in PBS.A (PBS,
Albumin 0.2%, Azide 0.2%) and respun at 2000rpm for 5 minutes after each wash.
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All the samples were then immunstained - the permeabolised and the non-permeabolised cells.
Varying amounts of A5B7 (100, 33, 10, 3.3, 1, 0.33, 0.1, 0.03 and 0.01pg/ml) in 100pi aliquots in
PBS.A were applied. An identical range of concentrations of the negative control mouse IgGi was
applied to negative control tubes. The positive control used was RFDR.2 MHC Class 11 antibody,
which was used at standard FACS-recommended concentration.
The samples were incubated for 30 minutes at room temperature, then washed twice in PBS.A, being
spun at 2000rpm for 5 minutes in between washes. The second, fluorescein conjugated antibody
(Rabbit anti-mouse Fluorescein Isothionate) was then applied in 5pi aliquots at a concentration of
1:100.
The samples were again incubated at room temperature for 30 minutes, then washed twice with
PBS.A and spun at 2000rpm for 5 minutes. They were then fixed in Paraformaldehyde (1%), and
stored at 4°C prior to being run through the FACS scanner. The average fluorescence of 3000 cells
in from each sample was demonstrated.
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Results
The fluorescence of permeabolised cells is a measure of the total cytoplasmic and membrane-bound
CEA; that of non-permeabolised cells reflects membrane-bound CEA only.
Mean Fluorescence of Lovo cells
Concentration Perm A5B7 Perm IgGl Nonperm A5B7 Non-perm IgGl
100 pg/ml 36.53 21.48 44.77 11.37
33 pg/ml 56.14 21.32 20.55 28.45
10 (ig/ml 73.04 23.12 53.87 33.07
3.3 pg/ml 59.91 13.25 52.68 22.94
1 pg/ml 44.08 11.21 26.77 20.96
0.3pg/ml 39.71 12.09 21.05 13.98
0.1 pg/ml 39.11 13.46 18.16 42.24
0.03 pg/ml 18.65 12.52 39.26 15.17
0.01 pg/ml 23.53 13.29 44.49 47.54





1. Concentrations above 33 and below 0.33 pg/ml do not show significant differences between the
anti-CEA antibody and the negative control, fgGl. The optimum range of concentration falls
between 10 and 3.3pg/ml.
2. The proposed positive control RFDR.2 is expressed by Lovo cells to a lesser degree than CEA, and




To identify a concentration of Chloroquine able to inhibit cell growth and induce CEA expression by
serial dilutions
Method:
16 flasks each containing one million HT29 cells were grown in standard monolayer culure for 5
days. Duplicate control flasks were grown in normal culture medium - Dulbecco's Modified Eagle's
Medium with 10% Fetal Calf Serum. Glutamine and Penicillin-Streptomycin. Chloroquine was
added to this culture medium for the remaining 14 flasks, with two flasks for each serial xlO dilution
from 10"3 M to 10 9 M Chloroquine.
After 5 days' growth, the cells were tiypsinised, counted and stained with A5B7 anti-CEA mouse
monoclonal antibody and Fluorescein-conjugated goat anti-mouse antibody. The average




Control Chlor Chlor Chlor Chlor Chlor Chlor Chlor
10"9M £001O 10_7M 10"6M 21o © 2 ur3 M
Sample 1 12.7 22.9 17.9 13.6 10.6 <0.1 <0.1 <0.1
Sample 2 16.7 18.1 12.8 14.2 15.4 <0.1 <0.1 <0.1
Ave 14.7 20.5 15.4 13.9 13.0 <0.1 <0.1 <0.1
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Sample 1 31.3 15.9 24.2 18.5 19.7 121.2 50.7 45.2
Sample 2 38.3 13.5 17.2 23.1 20.9 67.6 108.7 67.4







Control Chi 10-9 Chi 10-8 Chi 10-7 Chi 10-6 Chl10-5 Chi 10-4 Chi 10-3
A marked cut offwas seen between 10 5 and 10 6 M Chloroquine: concentrations more dilute the
10 5 Molar Chloroquine did not inhibit cell growth or augment CEA expression, whereas
concentrations of 10~5 M, 10~4 M and 10 3 M severely impeded cell growth and induced augmented
membrane CEA expression.
Conclusion





The purpose of this experiment was to identify a) a dose of radiation causing growth inhibition of
HT29 cells in vitro; and b) the time after radiation that the cells exhibited growth inhibition and any
changes in CEA expression
Methods
Triplicate samples ofHT29 cells (one million cells approximately per sample) were irradiated with
2Grays or 5Grays of X-radiation. The cells were harvested at 3, 24, 48 and 96 hours after the
radiation for the 2 Gray samples, and at 3, 48 and 72 hours after the radiation for the 5 Gray samples.
All the cell samples were counted and stained for membrane CEA using two-stage fluorescein






Cell Counts x 106 cells
IRRADIATED
Cell Counts x 10® cells
















The cell counts showed a growth inhibition measurable 24 hours after irradiation (t-test, p=0.008).
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CEA EXPRESSION
The corresponding measurements ofCEA expression (in arbitrary units) by fluorescein-stained FACS
scanning were as follows :
PLUS 3 HOURS PLUS 24 HOURS PLUS 48 HOURS PLUS 96 HOURS
Control 1 15.36 13.80 18.62 27.34
Control 2 16.67 14.52 18.39 23.35
Control 3 25.39 15.24 21.27 23.48
X-rayed 1 14.14 13.62 21.58 24.74
X-rayed 2 34.06 14.13 21.37 26.32
X-rayed 3 19.61 13.06 22.63 25.38
Negative 20.85 15.23 20.58 22.33





Cell Counts x 106 cells
IRRADIATED
Cell Counts x 106 cells












The cell counts showed significant growth inhibition measurable 4 . 48 and 72 hours after irradiation
(t-test, p^0.05. The corresponding measurements of CEA expression by fluorescein-stained FACS
scanning were as follows:
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CEA EXPRESSION (arbitrary units)
PLUS 3 HOURS PLUS 48 HOURS PLUS 72 HOURS
Control 1 65.38 42.92 24.30
Control 2 67.93 47.90 30.08
Control 3 63.23 44.85 33.09
X-rayed 1 64.32 43.33 43.44
X-rayed 2 66.06 54.22 49.50
X-rayed 3 67.39 53.80 45.23
Negative 67.00 25.55 21.77
Analysis of these results by the student's t-test showed a significant rise in CEA expression
measurable 72 hours after irradiation (p=0.006).
Discussion
The above results show growth inhibitory effects of fairly high dose radiation (5Gray) observable 48
hours after irradiation, and a small but significant increase in CEA expression measurable 72 hours
after irradiation. The smaller 2 Gray dose of radiation had no effect on cell growth or CEA
expression.
Conclusion
Treating colorectal cancer cells with a single 5 Gray dose of irradiation may result in transient growth
inhibition, and a rise in CEA expression observable after 72 hours.
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APPENDIX 2
The data for the positive growth inhibitory and CEA augmentation (Immunocytochemistry and
FACS) results from Chapters 2 to 5 are presented below.
Contents: Page
a. Growth Results 192
b. Immunocytochemistry Results 205





COLO COLO COLO HT29 HT29 HT29 LOVO LOVO LOVO
control BA BA control BA BA control BA BA
106cells 106cells %con 106cells 106cells %con 106cells 106cells %con
5.5 1.9 30.9 5.6 2.9 40.8 2.9 1.3 39.4
6.8 1.2 19.5 8.6 5.0 70.4 3.7 0.5 15.2
1.1 17.9 3.9 54.9 0.7 21.2
Ave 22.8 55.5 25.3
St Dev 7.1 15.0 12.6
t-test 0.004 0.10 0.01
Theophylline (Theo):
COLO COLO COLO HT29 HT29 HT29 LOVO LOVO LOVO
control Theo Theo control Theo Theo control Theo Theo
106cells 106cells %con 106cells 106cells %con 106cells 106cells %con
5.5 0.2 3.3 5.6 1.5 21.1 2.9 0.5 15.2
6.8 0.2 3.3 8.6 1.3 18.3 3.7 0.1 3.0
0.5 8.1 1.3 18.3 0.1 2.0
Ave 4.9 19.2 7.1
St Dev 2.8 1.6 7.0
t-test 0.001 0.01 0.002
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5-Azacvtidine:
COLO COLO COLO HT29 HT29 HT29 LOVO LOVO LOVO
control 5-Aza 5-Aza control 5-Aza 5-Aza control 5-Aza 5-Aza
106cells 106cells %con 106cells 106cells %con 106cells 106cells %con
5.5 0.1 1.6 5.6 0.4 5.6 2.9 0.1 3.0
6.8 0.1 1.6 8.6 0.2 2.8 3.7 0.1 3.0
0.1 1.6 0.2 5.6 0.1 3.0
Ave 1.6 4.7 3.0
St Dev 0 1.6 0
t-test 0.001 0.009 0.002
Interferon:
COLO COLO COLO HT29 HT29 HT29 LOVO LOVO LOVO
control IFN IFN control IFN IFN control IFN IFN
106cells 106cells %con 106cells 106cells %con 106cells 106cells %con
14.3 11.2 92.2 12.7 2.9 25.4 9.6 3.0 36.1
10.0 6.6 54.3 10.1 2.6 22.8 7.0 0.5 6.0
8.3 68.3 2.8 24.6 0.7 8.4
Ave 71.6 24.3 16.8
St Dev 19.2 1.3 16.7




COLO COLO COLO HT29 HT29 HT29 LOVO LOVO LOVO
control Chlor Chlor control Chlor Chlor control Chlor Chlor
106cells 106cells %con 106cells 106cells %con 106cells 106cells %con
10.1 0.1 0.9 12.0 0.1 0.8 12.6 0.2 1.9
12.0 0.1 0.9 14.0 0.1 0.8 8.3 0.5 4.8
0.2 1.8 0.1 0..8 0.1 1.0
Ave 1.2 0.8 2.6
St Dev 0.5 0 2.0
t-test 0.0006 0.0004 0.008
Starvation:
COLO COLO COLO HT29 HT29 HT29 LOVO LOVO LOVO
control Starv Starv control Starv Starv control Starv Starv
106cells 106cells %con 106cells 106cells %con 106cells 106cells %con
7.0 1.3 17.1 14.4 3.6 34.3 10.2 1.6 19.4
8.2 2.3 30.3 6.6 3.5 33.3 6.3 0.6 7.3
2.4 31.6 4.2 40.0 3.4 41.2
Ave 26.3 35.7 22.6
St Dev 8.0 3.6 17.2





























4.4 0.1 2.5 3.6 0.1 2.7 5.4 0.1 2.1
3.6 0.1 2.5 3.9 0.1 2.7 4.0 0.1 2.1
0.1 2.5 0.1 2.7 0.1 2.1
Ave 2.5 2.7 2.1
St Dev 0 0 0






























1.6 0.6 42.8 10.9 9.2 80.7 1.2 3.3 103.1
1.2 1.3 92.9 11.9 8.2 71.9 5.2 4.3 134.4
0.4 28.6 6.0 52.6 4.7 146.8
Ave 54.8 68.4 128.1
St Dev 33.8 14.4 22.5





























1.6 0.7 50.0 10.9 7.6 66.7 1.2 5.3 165.6
1.2 1.0 71.4 11.9 11.2 98.2 5.2 4.2 131.2
0.8 57.1 6.1 53.5 5.4 168.8
Ave 59.5 72.8 155.2
St Dev 10.9 23.0 20.8
t-test 0.06 0.22 0.34
Radiation:
COLO COLO COLO HT29 HT29 HT29 LOVO LOVO LOVO
control DXT DXT control DXT DXT control DXT DXT
106cells 106cells %con 106cells 106cells %con 106cells 106cells %con
4.6 5.8 130.3 8.9 5.6 61.9 7.2 4.1 56.2
4.9 4.7 105.6 9.2 4.3 47.5 7.4 4.3 58.9
5.1 146 6.5 71.8 6.6 90.4
Ave 127.3 60.4 68.5
St Dev 20.4 12.2 19.01




COLO COLO COLO HT29 HT29 HT29 LOVO LOVO LOVO
control 5FU 5FU control 5FU 5FU control 5FU 5FU
106cells 106cells %con 106cells 106cells %con 106cells 106cells %con
11.1 6.2 60.0 5.0 0.7 8.4 2.2 1.0 54.1
9.6 5.9 57.0 11.6 0.5 6.0 1.5 1.5 81.1
6.0 58.0 0.3 3.6 1.4 75.7
Ave 58.3 6.0 70.3
St Dev 1.5 2.4 14.3
t-test 0.005 0.05 0.19
Methotrexate:
COLO COLO COLO HT29 HT29 HT29 LOVO LOVO LOVO
control Mtx Mtx control Mtx Mtx control Mtx Mtx
106cells 106cells %con 106cells 106cells %con 106cells 106cells %con
13.2 1.4 10.1 22.8 0.9 5.5 8.9 1.4 13.3
14.6 0.8 5.8 9.8 0.7 4.3 12.1 2.2 21.0
0.8 5.8 2.2 13.5 2.3 21.9
Ave 7.2 7.8 18.7
St Dev 2.5 5.0 4.7
t-test 0.0002 0.05 0.006
Taxol:
COLO COLO COLO HT29 HT29 HT29 LOVO LOVO LOVO
control Tax Tax control Tax Tax control Tax Tax
106cells 106cells %con 106cells 106cells %con 106cells 106cells %con
8.5 2.9 38.4 6.4 0.1 1.9 7.5 0.6 6.8
6.6 1.4 18.5 4.1 0.2 3.8 11.0 0.6 6.8
2.3 30.5 0.1 1.9 7.5 1.1 12.5
9.2
Ave 29.1 2.5 13.0
St Dev 10 1.1






























14.3 10.5 86.4 12.7 6.9 60.5 9.6 6.0 72.3
10.0 8.5 70.0 10.1 11.0 96.5 7.0 2.8 33.7
10.1 83.1 14.3 125.4 5.1 61.4
Ave 79.8 94.1 55.8
St Dev 8.7 32.5 19.9
t-test 0.26 0.83 0.10
Vincristine:
COLO COLO COLO HT29 HT29 HT29 LOVO LOVO LOVO
control Vine Vine control Vine Vine control Vine Vine
106cells 106cells %con 106cells 106cells %con 106cells 106cells %con
16.0 10.5 86.4 29.5 20.1 88.2 13.7 11.0 101.4
21.5 22.4 119.5 16.1 9.8 43.0 8.0 9.7 89.4
16.7 89.1 16.9 74.1 4.9 45.2
Ave 88.2 68.4 78.7
St Dev 31.8 23.1 29.6
t-test 0.68 0.34 0.52
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Combinations
BUTYRIC ACID & THEOPHYLLINE:
COLO COLO COLO HT29 HT29 HT29 LOVO LOVO LOVO
control Ba+Th Ba+Th control Ba+Th Ba+Th control Ba+Th Ba+Th
106cells 106cells %con 106cells 106cells %con 106cells 106cells %con
5.6 0.1 1.7 12.6 1.4 12.1 4.2 0.1 1.8
6.1 0.1 1.7 10.5 0.8 6.9 5.0 0.1 1.8
0.1 1.7 2.9 25 6.5 0.1 1.8
6.7
Ave 1.7 14.7 1.8
St Dev 0 9.3 0
t-test 7x10-5 0.003 0.0006
BUTYRIC ACID & 5 AZACYTIDINE:
COLO COLO COLO HT29 HT29 HT29 LOVO LOVO LOVO
control Ba5az Ba5az control Ba5az Ba5az control BaSaz Ba5az
106cells 106cells %con 106cells 106cells %con 106cells 106cells %con
5.6 0.1 1.7 12.6 3.5 30.2 4.2 0.2 3.6
6.1 0.1 1.7 10.5 5.3 45.7 5.0 0.1 1.8
0.2 3.4 5.2 44.8 6.5 0.1 1.8
6.7
Ave 2.3 40.2 2.4
St Dev 1 8.7 1
t-test 8x10-5 0.008 0.0006




























7.4 7.2 81.8 6.5 2.8 34.6 7.5 0.1 1.1
10.3 8.7 98.9 9.7 1.6 19.8 11.0 0.1 1.1
11.0 125.0 2.8 34.6 7.5 0.1 1.1
9.2
Ave 101.9 2.5 1.1
St Dev 21.8 1.1 0






























5.6 0.1 1.9 3.3 0.6 17.6 7.5 0.1 1.1
4.8 0.1 1.9 3.4 0.8 23.5 7.5 0.1 1.1
0.1 1.9 0.6 17.6 11.0 0.1 1.1
9.2
Ave 1.9 19.6 1.1
St Dev 0 3.4 0
t-test 0.0001 9x10-5 0.0003




























5.6 0.1 1.9 3.3 1.2 35.3 7.5 0.1 1.1
4.8 0.1 1.9 3.4 1.9 55.9 7.5 0.1 1.1
0.1 1.9 1.6 47.1 11.0 0.1 1.1
9.2
Ave 1.9 46.1 1.1
St Dev 0 10.3 0
t-test 0.0001 0.007 0.0003
199
5-FLUOROURACIL & BUTYRIC ACID:
COLO COLO COLO HT29 HT29 HT29 LOVO LOVO LOVO
control 5FU.B 5FU.B control 5FU.B 5FU.B control 5FU.B 5FU.B
106cells a a 106cells a a 106cells a a
106cells %con 106cells %con 106cells %con
1.6 0.4 28.6 15.2 5.3 43.8 10.4 5.2 46.4
1.2 0.2 14.3 9.0 6.5 53.7 12.4 3.1 27.6
0.3 21.4 8.6 71.1 5.8 51.8
Ave 21.4 56.2 41.9
St Dev 7.2 13.8 12.7
t-test 0.007 0.14 0.01
5-FLUOROURAC1L & THEOPHYLLINE:
COLO COLO COLO HT29 HT29 HT29 LOVO LOVO LOVO
control 5FU. Th 5FU. Th control 5FU. Th 5FU. Th control 5FU. Th 5FU. Th
106cells 106cells %con 106cells 106cells %con 106cells 106cells %con
1.6 0.4 7.1 15.2 10.6 87.6 10.4 0.5 4.5
1.2 0.2 7.1 9.0 10.2 84.3 12.4 0.6 5.4
0.3 7.1 16.1 133.1 2.7 24.1
Ave 7.1 101.7 11.3
St Dev 0 27.3 11.1
t-test 0.003 0.96 0.003
5-FLUOROURACIL & 5-AZACYTIDINE:
COLO COLO COLO HT29 HT29 HT29 LOVO LOVO LOVO
control 5FU.5a 5FU.5a control 5FU.5a 5FU.5a control 5FU.5a 5FU.5a
106cells 106cells %con 106cells 106cells %con 106cells 106cells %con
1.6 0.1 7.1 15.2 7.2 59.5 10.4 0.1 0.9
1.2 0.1 7.1 9.0 6.3 52.1 12.4 0.1 0.9
0.1 7.1 6.2 51.2 0.1 0.9
Ave 7.1 54.3 0.9
St Dev 0 4.6 0
t-test 0.003 0.10 0.003
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METHOTREXATE & BUTYRIC ACID:
COLO COLO COLO HT29 HT29 HT29 LOVO LOVO LOVO
control Mtx.Ba Mtx.Ba control Mtx.Ba Mtx.Ba control Mtx.Ba Mtx.Ba
106cells 106cells %con 106cells 106cells %con 106cells 106cells %con
6.2 3.5 51.5 4.7 1.2 24.0 4.2 0.9 16.1
7.3 3.8 55.7 5.3 1.3 26.0 5.0 0.7 12.5
5.3 77.9 1.3 26.0 6.5 0.7 12.5
6.7
Ave 61.8 25.3 13.7
St Dev 14.1 1.2 2.1
t-test 0.05 0.0005 0.001
METHOTREXATE & THEOPHYLLINE:
COLO COLO COLO HT29 HT29 HT29 LOVO LOVO LOVO
control Mtx.Th Mtx.Th control Mtx.Th Mtx.Th control Mtx.Th Mtx.Th
106cells 106cells %con 106cells 106cells %con 106cells 106cells %con
6.2 0.2 2.9 4.7 0.7 14.0 4.2 0.3 5.4
7.3 0.2 2.9 5.3 0.5 10.0 5.0 0.5 8.9
0.2 2.9 0.5 10.0 6.5 0.5 8.9
6.7
Ave 2.9 11.3 7.7
St Dev 0 2.3 2.0
t-test 0.0005 0.0003 0.0008
METHOTREXATE & 5-AZACYTIDINE:
COLO COLO COLO HT29 HT29 HT29 LOVO LOVO LOVO
control Mtx.5A Mtx.5a control Mtx.5a Mtx.5a control Mtx.5a Mtx.5a
106cells 106cells %con 106cells 106cells %con 106cells 106cells %con
6.2 0.4 5.9 4.7 0.6 12.0 4.2 0.1 1.8
7.3 0.5 7.4 5.3 0.7 14.0 5.0 0.1 1.8
0.5 7.4 1.0 20.0 6.5 0.1 1.8
6.7
Ave 6.9 15.3 1.8
St Dev 0.9 4.2 0
t-test 0.0006 0.0006 0.0006
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INTERFERON & 5-FLUOROURAC1L:
COLO COLO COLO HT29 HT29 HT29 LOVO LOVO LOVO
control Ifn.SF Ifn.5F control Ifn.SF Ifn.SF control IJh.SF Ifn.5F
106cells U U 106cells U U 106cells U U
106cells %con 106cells %con 106cells %con
7.4 8.8 100.0 6.5 1.1 13.6 7.5 0.1 1.1
10.3 7.1 80.7 9.7 1.1 13.6 7.5 0.1 1.1
5.1 58.0 0.8 9.9 11.0 0.1 1.1
9.2
Ave 79.6 12. 1.1
St Dev 21.0 2.1 0
t-test 0.37 0.01 0.0003
INTERFERON & METHOTREXATE:
COLO COLO COLO HT29 HT29 HT29 LOVO LOVO LOVO
control lfn.Mtx Ifn.Mtx control Ifn.Mtx lfh.Mtx control lfn.Mtx Ifn.Mtx
106cells 106cells %con 106cells 106cells %con 106cells 106cells %con
7.4 5.6 63.6 6.5 1.0 12.3 7.5 0.1 1.1
10.3 7.1 80.7 9.7 0.8 9.9 7.5 0.1 1.1
8.7 98.9 1.6 19.8 11.0 0.4 4.5
9.2
Ave 81.1 14.0 1.1
St Dev 17.6 5.2
t-test 0.36 0.01 0.0003
BUTYRIC ACID & HYPOXIA (1%QXYGEN):
COLO COLO COLO HT29 HT29 HT29 LOVO LOVO LOVO
control Ba.Hyp Ba.Hyp control Ba.Hyp Ba.Hyp control Ba.Hyp Ba.Hyp
106cells 106cells %con 106cells 106cells %con 106cells 106cells %con
15 1 6.1 17.5 0.1 0.5 11.1 0.9 10.5
17.7 0.7 4.3 22.9 0.1 0.5 7 0.8 9.3
0.5 3.0 0.1 0.5 0.5 5.8
Ave 4.5 0.5 8.5
St Dev 1.6 0 2.4
t-test 0.0006 0.002 0.01
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BUTYRIC ACID & ALKALINE MEDIUM;
COLO COLO COLO HT29 HT29 HT29 LOVO LOVO LOVO
control Ba.Alk Ba.Alk control Ba.Alk Ba.Alk control Ba.Alk Ba.Alk
106cells 106cells %con 106cells 106cells %con 106cells 106cells %con
15 21.4 130.5 17.5 26.0 128.7 11.1 19.1 222.1
17.7 15.0 91.5 22.9 29.0 143.6 7 8.5 98.8
14.2 86.6 26.0 128.7 6.3 73.3
Ave 108.9 133.7 131.4
St Dev 24.1 8.6 79.6
t-test 0.88 0.06 0.70
BUTYRIC ACID & CHLOROOUINE:
COLO COLO COLO HT29 HT29 HT29 LOVO LOVO LOVO
control Ba.Chl Ba.Chl control Ba.Chl Ba.Chl control Ba.Chl Ba.Chl
106cells 106cells %con 106cells 106cells %con 106cells 106cells %con
7.2 0.1 1.1 14.4 0.1 0.7 9.6 3.5 40.7
10.5 0.1 1.1 13.2 0.1 0.7 7.6 6.6 76.7
0.1 1.1 0.1 0.7 2.2 25.6
Ave 1.1 0.7 47.7
St Dev 0 26.3
t-test 0.006 8x10-5 0.09
CHLOROOUINE + 5-FLUOROURACIL:
COLO COLO COLO HT29 HT29 HT29 LOVO LOVO LOVO
control Ch5FU Ch5FU control Ch5FU Ch5FU control Ch5FU Ch5FU
106cells 106cells %con 106cells 106cells %con 106cells 106cells %con
7.2 1.5 16.7 14.4 0.1 0.7 9.6 5.4 62.8
10.5 0.6 6.7 13.2 0.1 0.7 7.6 5.6 65.1
1.1 12.3 0.1 0.7 3.9 45.3
Ave 11.9 0.7 57.7
St Dev 5.0 0 10.8
t-test 0.009 8x10-5 0.04
203
CHLOROOUINE +METHOTREXATE:
COLO COLO COLO HT29 HT29 HT29 LOVO LOVO LOVO
control Ch.Mtx Ch.Mtx control Ch.Mtx Ch.Mtx control Ch.Mtx Ch.Mtx
106cells 106cells %con 106eells 106cells %con 106cells 106cells %con
7.2 0.7 7.8 14.4 0.2 1.4 9.6 7.2 83.7
10.5 0.6 6.7 13.2 0.1 0.7 7.6 5.6 65.1
0.8 8.9 0.1 0.7 4.4 51.2
Ave 7.8 0.9 66.7
St Dev 1.1 0.4 16.3
t-test 0.007 8x10-5 0.11
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b. Immunocvtochemistrv Results:
Differentiating Agents: Butyric Acid., Theophylline., 5-Azacvtidine & Interferon
COLO
BA Theo 5-Aza IFN
Scores 0 0.5 1 0
0 0 3 0
0 0 0.5 0
AVE 0 0.17 1.5 0
St Dev 0 0.29 1.32 0
t-test NA 0.50 0.23 NA |
HT29 HT29 HT29 HT29 HT29
BA Theo 5-Aza IFN
Scores 6.5 3.5 3 4.5
7 2.5 2 2.5
7.5 3.5 2 3
AVE 7 3.17 2.33 3.33
St Dev 0.5 0.58 0.58 1.04
t-test 0.001 0.06 0.30 0.05
LOVO LOVO LOVO LOVO LOVO
BA Theo 5-Aza IFN
Scores 10 8 8 7.5
9.5 9 6.5 8.5
10 6 7 8.5
AVE 9.83 7.67 7.17 8.17
St Dev 0.29 1.53 0.76 0.58
t-test 0.03 0.79 0.08 0.72













6 0 0.5 10 0.5 0
6.5 0 2 10 1.5 0.5
7.5 0 0.5 10 1 0
AVE 6.67 0 1 10 1 0.17
StDev 0.76 0 0.87 0 0.5 0.29













6.5 1.5 3 6 1.5 0.5
6.5 1.5 3.5 9 1 1
6.5 0 3 1.5 2 1.5
AVE 6.5 1 3.17 5.5 1.5 1.0
St Dev 0 0.87 0.29 3.77 0.5 0.5













9.5 7 10 8 9 8.5
10 9 10 8 9 8
10 9 9 7.5 8.5 9
AVE 9.83 8.33 9.67 7.83 8.83 8.5
St Dev 0.29 1.15 0.58 0.29 0.29 0.5
t-test 0.22 0.50 0.72 0.24 0.36 0.59
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Cytotoxic Drugs: 5-Fluorouracil. Methotrexate, Taxol. Etoposide, Vincristine
COLO COLO COLO COLO COLO COLO
5FU Mtx Tax Etop Vine
0 0 0 0 0
0 0 1 0 0
0 0 0 0 0
AVE 0 0 0.33 0 0
St Dev 0 0 0.58 0 0
t-test NA NA 0.50 NA NA
HT29 HT29 HT29 HT29 HT29 HT29
5FU Mtx Tax Etop Vine
1.5 3.5 4 1 2
2.5 4 4 1 1
3 5.5 5.5 0.5 2
AVE 2.33 4.33 4.5 0.83 1.67
St Dev 0.76 1.04 0.87 0.29 0.58
t-test 0.10 0.12 0.05 0.79 0.50
LOVO LOVO LOVO LOVO LOVO LOVO
5FU Mtx Tax Etop Vine
8 8 9 7 9.5
9 8.5 8.5 7.5 9
10 10 9 7 8.5
AVE 9 8.83 8.83 7.17 9
St Dev 1 1.04 0.29 0.29 0.5
t-test 0.04 0.92 0.03 0..3 1
Combinations of factors:



















8 7.5 1 4 3.5 6.5 8.5 8.5 9
8 8 0 6 4.5 8.5 8 8 9.5
9 8 0 5 3 9 9.5 7 10
AVE 8.33 7.83 0.33 5 3.67 8 8.67 7.83 9.5
St Dev 0.58 0.29 0.58 1 0.76 1.32 0.76 0.76 0.5
t-test 0.0004 0.0007 0.78 0.06 0.13 0.008 0.10 0.40 0.007













0 2.5 3.5 4 9 9
1.5 2.5 2 2 9.5 9
0 0 2 1 9 9
AVE 0.5 1.67 2.5 2.33 9.17 9
St Dev 0.87 1.44 0.87 1.53 0.29 0
t-test 0.50 0.22 0.22 0.52 0.009 0.009
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7 10 9 7 4.5 2.5 10 9.5 9
1.5 10 6.5 7.5 3.5 1.5 10 10 9
10 6 5.5 7 7 2 10 9 9.5
AVE 6.17 8.67 7 7.17 5 2.0 10 9.35 9.17
St Dv 4.31 2.31 1.8 0.29 1.8 0.5 0 0.5 0.29
t-test 0.15 0.02 0.01 0.0001 0.08 0.27 0.12 0.16 0.19



















0 0 0 7.5 2 4.5 10 8.5 8.5
0 0.5 0.5 7 7.5 4 10 7.5 9.5
6.5 0 0 5 7.5 3 10 9 9
AVE 2.17 0.17 0.17 6.5 5.67 3.83 10 8.33 9
St Dev 3.75 0.29 0.29 1.33 3.17 0.76 0 0.76 0.5
t-test 0.60 0.50 0.50 0.03 0.27 0.10 0.0008 0.10 0.01













1.5 1.5 8 8.5 8.5 10
1.5 1 7 7.5 9.5 10
0 1 8 7 9.5 9
AVE 1.0 1.17 7.67 7.67 9.17 9.67
St Dev 0.87 0.29 0.58 0.76 0.58 0.58
t-test 0.55 0.05 0.001 0.002 0.03 0.006
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BUTYRIC ACID & HYPOXIA (l%OXYGEN), ALKALINE MEDIUM OR CHLOROQUINE:
COLO COLO COLO HT29 HT29 HT29 LOVO LOVO LOVO
Ba+Hyp Ba+Alk Ba+Chl Ba+Hyp Ba+Alk Ba+Chl Ba+Hyp Ba+Alk Ba+Chl
1 .5 8 1.5 2.5 9 9 8.5 10
0 0 7 1.5 1 7 9 9 10
1 0 7 1 1.5 5.5 5.5 9 10
AVE 0.67 0.17 7.33 1.33 1.67 7.17 7.83 8.83 10
StDev 0.58 0.29 0.58 0.29 0.76 1.76 2.02 0.29 0
t-test 0.22 0.50 0.0004 0.79 0.54 0.07 0.42 0.24 0.03
CHLOROQUINE + 5-FLUOROURACIL OR METHOTREXATE:
COLO COLO HT29 HT29 LOVO LOVO
Chl+5FU Chl+Mtx Chl+5FU Chl+Mtx Chl+5FU Chl+Mtx
2.5 1.5 8 7.5 9.5 9.5
5 5 6.5 5 10 10
5 4 6.5 6.5 10 10
AVE 4.17 3.5 7 6.33 9.83 9.83
St Dev 1.44 1.8 0.87 1.26 0.29 0.29

















Control 1 435.66 331.71 14.90 32.35 6.02 16.34
Control 2 390.27 326.15 18.39 30.68 7.76 17.12
But Acid 1 754.75 613.04 46.25 118.80 9.20 38.64
But Acid 2 963.97 1781.94 49.98 102.95 13.68 32.50
But Acid 3 594.91 2115.88 39.42 93.93 11.61 29.61
Neg Control 23.52 35.68 15.89 26.38 17.12 21.29
Theo 1 686.60 338.47 30.16 65.88 91.34 70.93
Theo 2 451.47 878.45 33.14 79.03 72.57 67.87
Theo 3 587.74 596.76 28.27 58.59 21.95 66.11
Neg Control 23.52 35.68 15.89 26.38 17.12 21.29
5 Aza 1 239.27 143.06 30.88 41.26 72.26 66.90
5 Aza 2 199.30 202.69 34.59 40.79 46.96 72.02
5 Aza 3 277.13 219.95 22.84 40.17 116.62 62.96
Neg Control 23.52 35.68 15.89 26.38 17.12 21.29
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Lovo Lovo HT29 HT29 Colo Colo
Surface Total Surface Total Surface Total
Control 1 717.25 863.06 21.21 35.28 19.23 39.17
Control 2 632.97 805.54 18.87 52.26 6.22 22.27
IFN 1 757.46 1085.24 30.79 71.22 11.95 36.09
IFN 2 819.36 1206.14 31.77 51.65 18.51 24.09
IFN 3 845.39 916.15 36.80 83.44 9.30 26.87
Neg Control 73.35 59.47 7.74 10.72 9.30 7.47
ENVIRONMENTAL FACTORS:
Lovo Lovo HT29 HT29 Colo Colo
Surface Total Surface Total Surface Total
Control 1 841.39 564.96 17.48 16.56 17.3 12.99
Control 2 718.95 390.44 15.64 16.17 18.74 25.25
Chlor 1 1754.34 1236.05 83.29 78.56 57.71 52.22
Chlor 2 1503.58 1517.69 53.23 89.67 62.26 91.58
Chlor 3 890.95 1005.39 53.58 75.42 60.29 75.59
Neg Control 57.07 22.32 15.83 12.42 12.49 35.1
Control 1 325.77 369.46 15.11 34.38 80.38 86.53
Control 2 248.41 337.19 16.77 35.76 11.81 34.19
Starved 1 223.05 364.12 16.14 53.82 11.98 20.85
Starved 2 308.31 298.64 15.71 29.53 8.42 26.54
Starved 3 230.19 275.27 18.58 27.55 21.45 35.79














Control 1 380.63 379.59 20.63 28.51 7.81 15.06
Control 2 423.93 160.36 21.61 22.65 11.57 12.80
Hypl% 1 118.98 221.08 81.29 74.17 81.77 104.44
Hypl% 2 228.16 362.16 73.55 128.43 67.11 96.74
Hypl% 3 141.13 229.83 86.00 130.59 76.36 106.58
Neg Control 36.02 16.10 31.26 14.68 12.63 15.97
Control 1 73.94 208.01 22.66 49.01 21.24 24.30
Control 2 173.44 204.61 27.56 21.82 34.73 23.86
Hyp5% 1 212.65 222.44 29.36 33.67 224.41 94.10
Hyp5% 2 213.29 235.59 21.73 44.55 151.65 51.32
Hyp5% 3 221.94 311.87 24.58 24.01 29.04 41.40
Hyp12% 1 212.65 368.95 26.37 27.74 139.13 117.72
Hyp12% 2 200.40 270.56 18.02 32.17 15.90 18.54
Hyp 12% 3 211.59 185.30 13.99 25.87 16.90 22.24
Neg Control 92.69 121.06 21.09 27.53 26.27 23.15
Control 1 188.33 308.79 26.89 19.32 34.96 53.92
Control 2 182.28 216.61 28.58 19.63 34.58 53.87
DXT 1 234.41 336.18 28.49 25.39 15.92 24.77
DXT 2 166.66 400.66 28.93 29.15 15.59 26.84
DXT 3 223.22 475.51 28.40 27.35 15.65 23.81















Control 1 291.76 158.34 18.30 18.90 14.78 35.27
Control 2 245.17 364.95 24.02 25.90 28.37 31.01
5FU 1 488.22 134.59 62.67 73.43 29.19 17.79
5FU2 602.51 911.09 58.62 66.43 14.44 20.66
5FU3 406.50 863.63 47.91 66.37 10.66 20.11
Neg Control 42.14 30.22 11.71 14.35 7.01 23.51
Control 1 258.22 142.47 34.35 61.99 10.53 17.75
Control 2 325.37 136.77 26.05 34.05 14.67 16.81
Mtx 1 925.87 297.04 44.84 44.94 34.45 34.03
Mtx 2 761.09 355.43 54.92 43.87 32.20 42.93
Mtx 3 662.78 349.59 37.46 32.16 28.75 41.02
Neg Control 38.74 36.63 43.23 44.06 17.35 25.70
Control 1 407.53 608.80 27.29 39.73 18.32 29.95
Control 2 424.58 582.57 25.44 39.85 21.04 25.81
Control 3 329.11 606.21
Control 4 439.81 734.44
Taxol 1 843.62 1552.97 72.61 94.34 21.55 29.51
Taxol 2 828.10 1244.46 80.26 81.88 22.30 30.34
Taxol 3 899.28 1325.72 69.53 88.51 21.72 31.02
Neg Control 38.36 42.56 21.07 34.26 25.51 25.65
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Lovo Lovo HT29 HT29 Colo Colo
Surface Total Surface Total Surface Total
Control 1 717.25 863.06 21.21 35.28 19.23 39.17
Control 2 632.97 805.54 18.87 52.26 6.22 22.27
Etop 1 692.45 756.79 12.39 36.97 13.91 29.26
Etop 2 594.62 704.88 15.83 37.58 7.51 32.90
Etop 3 681.61 796.98 15.94 71.22 9.58 26.80
Neg Control 73.35 59.47 7.74 10.72 9.30 7.47
Control 1 670.55 380.75 26.16 36.18 6.98 16.76
Control 2 701.38 340.24 17.59 26.33 6.42 31.93
Vine 1 1082.17 364.35 19.31 26.71 6.53 17.41
Vine 2 562.41 468.88 23.47 22.77 5.44 23.92
Vine 3 565.11 257.06 22.47 34.41 9.37 15.62
Neg Control 47.11 49.26 21.93 28.79 6.81 17.05
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COMBINATIONS OF FACTORS:
Lovo Lovo HT29 HT29 Colo Colo
Surface Total Surface Total Surface Total
Control 1 209.64 96.73 22.66 49.01 21.24 24.3
Control 2 193.02 60.15 27.56 21.82 34.73 23.86
Control 3 152.31 168.95
Control 4 224.34 169.75
Ba+Th 1 423.34 100.16 31.81 17.76 99.62 167.25
Ba+Th 2 285.22 62.16 28.69 46.91 257.59 204.42
Ba+Th 3 458.36 111.31 88.48 30.65 105.48 76.85
Ba+5aza 1 347.32 118.84 20.47 33.67 94.90 68.55
Ba+5aza2 316.48 89.63 25.18 44.55 55.50 80.51
Ba+5aza 3 656.45 235.00 22.11 24.01 83.47 32.49
Neg Control 28.07 28.56 21.09 27.53 26.27 23.15
Control 1 407.53 606.80 34.84 59.97 4.66 23.65
Control 2 424.58 582.57 34.74 59.87 9.92 27.95
Control 3 329.11 606.21
Control 4 439.81 734.44
Ba+IFN 1 1832.58 2701.88 111.07 183.27 39.88 29.45
Ba+IFN 2 1666.02 3051.52 137.61 269.11 82.93 108.07
Ba+IFN 3 1556.11 3075.25 82.67 262.02 13.31 30.88
Neg Control 38.36 42.56 44.76 32.64 17.86 23.83
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Lovo Lovo HT29 HT29 Colo Colo
Surface Total Surface Total Surface Total
Control 1 407.53 608.80 16.78 16.71 10.16 8.73
Control 2 424.58 582.57 22.87 32.57 8.56 13.26
Control 3 329.11 606.21
Control 4 439.81 734.44
Ifn+Th 1 422.56 736.99 13.90 16.35 49.52 58.66
Ifn+Th 2 676.89 1105.63 14.81 15.77 86.23 62.58
Ifn+Th 3 633.48 993.90 21.13 18.12 58.45 37.24
Ifn+5aza 1 1023.58 1636.56 19.84 15.75 70.27 76.76
Ifn+5aza 2 916.99 1537.32 13.36 14.24 89.64 52.12
Ifn+5aza 3 962.62 1533.93 13.13 17.50 55.98 55.53
Neg Control 38.36 42.56 21.09 16.43 8.82 11.95
Control 1 97.88 237.88 27.01 41.96 24.63 37.99
Control 2 95.28 299.7 24.72 37.14 20.55 39.64
5FU+Ba 1 339.7 968.24 60.06 97.29 52.98 43.35
5FU+Ba 2 316.53 911.99 57.88 89.86 70.41 92.00
5FU+Ba 3 387.87 1109.30 75.94 92.98 49.51 98.52
5FU+Th 1 538.21 847.37 22.44 43.96 92.31 101.81
5FU+Th 2 442.93 918.17 22.59 43.98 82.33 184.89
5FU+Th3 343.41 839.97 22.38 48.46 78.34 74.33
5FU+5aza 1 137.33 139.10 25.88 45.14 105.85 153.92
5FU+5aza 2 195.95 226.83 31.77 51.19 129.62 108.30
5FTJ+5aza 3 181.90 242.28 23.67 38.14 70.69 85.09
Neg Control 20.40 28.16 35.62 51.23 29.36 38.58
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Lovo Lovo HT29 HT29 Colo Colo
Surface Total Surface Total Surface Total
Control 1 209.64 96.73 24.00 28.20 11.43 16.19
Control 2 152.31 60.15 21.52 32.48 8.29 12.07
Control 3 193.02 168.95
Control 4 224.34 169.95
Mtx+Ba 1 935.93 1232.14 84.10 87.07 15.31 15.80
Mtx+Ba 2 819.03 1240.05 101.17 100.25 11.00 13.52
Mtx+Ba 3 838.94 1285.01 76.54 107.47 18.58 26.94
Mtx+Th 1 526.52 541.72 53.57 81.21 34.62 34.19
Mtx+Th 2 529.57 949.96 56.82 64.80 27.25 59.31
Mtx+Th 3 416.34 309.08 58.38 72.81 29.43 69.50
Mtx+5aza 1 555.12 324.89 38.14 42.84 33.72 37.94
Mtx+5aza 2 532.50 317.59 36.36 45.69 45.76 39.30
Mtx+5aza 3 501.21 322.15 60.69 70.94 20.23 26.94
Neg Control 28.07 28.56 21.34 30.12 9.11 23.18
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Lovo Lovo HT29 HT29 Colo Colo
Surface Total Surface Total Surface Total
Control 1 407.53 608.80 34.84 59.97 4.66 23.65
Control 2 424.58 582.57 34.74 59.87 9.92 27.95
Control 3 329.11 606.21
Control 4 439.81 734.44
Ifn+5FU 1 529.67 734.86 119.5 192.51 9.22 29.14
Ifn+5FU 2 672.51 1246.89 106.72 251.26 9.86 27.92
Ifn+5FU 3 774.64 1148.94 98.63 295.26 12.17 34.64
Ifn+Mtx 1 890.48 1290.93 150.72 222.46 11.11 25.63
Ifn+MLx 2 685.62 855.14 98.65 204.62 14.36 39.03
Ifh+Mtx 3 433.92 704.93 162.27 192.14 9.53 34.55
Neg Control 38.36 42.56 44.76 32.64 17.86 23.83
Control 1 243.68 473.84 23.45 37.55 12.32 16.28
Control 2 179.13 529.15 17.57 31.84 14.79 24.43
Ba+Hyp 1 698.92 474.08 89.56 118.71 19.53 31.92
Ba+Hyp 2 34.26 319.31 58.41 90.58 21.52 42.62
Ba+Hyp 3 150.37 345.44 42.06 80.20 27.63 98.52
Ba+Alk 1 305.59 546.96 18.97 30.23 10.93 23.11
Ba+Alk 2 313.53 361.96 16.80 26.26 8.41 14.86
Ba+Alk 3 325.37 699.04 15.19 35.69 8.69 18.36
Neg Control 33.25 49.92 18.56 32.12 8.86 16.16
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Lovo Lovo HT29 HT29 Colo Colo
Surface Total Surface Total Surface Total
Control 1 375.88 457.94 17.96 23.94 13.05 23.42
Control 2 560.07 672.20 22.58 30.33 15.73 21.38
Ba+Chlor 1 870.97 1624.31 88.44 68.25 102.89 76.64
Ba+Chlor 2 349.64 348.17 102.34 50.44 129.04 131.77
Ba+Chlor 3 783.22 625.38 57.50 62.94 54.68 68.33
Neg Control 26.36 35.02 16.44 19.20 9.18 24.76
Control 1 375.88 457.94 17.96 23.94 13.05 23.42
Control 2 560.07 672.20 22.58 30.33 15.73 21.38
Chlr+5FU1 425.03 217.22 61.46 36.37 19.29 38.20
Chlr+5FU2 351.03 245.42 57.88 63.19 21.46 30.90
Chlr+5FU3 356.28 316.74 54.65 59.48 20.49 29.90
Chlr+Mtxl 461.65 839.42 25.33 50.07 30.98 34.95
Chlr+Mtx2 299.19 568.39 69.97 57.02 149.26 212.25
Chlr+Mtx3 326.14 939.70 55.46 61.30 60.71 74.03




The process of defrosting cancer cells and growing them on is a delicate one, withmuch scope for
variability in the growth rates and health of the cells. Different passages of cells may be expected to
behave differently from others, since effectively they should be an increasingly selected population,
with only the more resistant cells surviving the rigours of repeated trvpsinisation and centrifuging.
Additionally, new batches ofWhole Medium were being made up every 10 days, each potentially
slightly different from the last.
In attempting to create as uniform a system of cell culture as possible, cells were not used beyond 10
passages; conditions in the incubator and hood were unchanging; and feeding of the cells was
performed according to their confluence state or when their supernatant medium began to lighten in
colour. Wherever possible, one batch of Whole Medium was used throughout each experiment.
When comparing proliferation between control and experiment cells, only the flasks grown
simultaneously from the same parent cells were counted.
Harvesting
Trvpsin-EDTA was used for all the cells, to separate them from the tissue culture flasks. It should be
explained that the live, growing cells attached themselves to the plastic base of the flasks - dead cells
were unable to adhere and were sloughed off into the medium, which was subsequently removed. The
cells harvested from the flasks by the Trypsin were therefore regarded as a viable growing population
of cells. Trypsin has been shown to damage cells and indeed to reduce the amount of CEA activity in
Lovo cells by up to 55% (80). A consistent method of trypsinisation was used for all the cells, and a
crude measure of cell damage which occurred was provided within the Trypan Blue cell counting
method, which showed dead cells clearly as bright blue on phase microscopy. The proportion of dead
cells in the harvested population was less than 10% in each experiment.
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Cell Counting
The accuracy of the Hemocytometer cell counting was reduced when the cell numbers fell to 0.1 x 106
cells per ml; this was the lowest number of cells which could be visualised. The results reported did
not quantify the degrees of growth inhibition observed in any experiment, but merely the presence of
significant growth inhibition. More sensitive methods to measure proliferation rates than cell counting
could be employed if quantifying growth inhibitory effects was deemed necessary; cell counting was
sufficient to demonstrate differences between control and experiment cell proliferation in this work.
Immunocvtochemistrv
Within the method for Immunocytochemistry are a number of measures to prevent or counteract
potential errors in the staining and grading processes:
1.The antibodies were applied in solutions containing animal or human serum to provide a sink for
endogenous cell peroxidase, which could otherwise cause background staining.
2. Antibodies were obtained from the same sources for each experiment.
3. Each run of immunostains for each cell line was checked against its own set of negative controls:
(a) No primary antibody
(b) No primary and no secondary antibody
(c) Isotype-specific mouse IgGl antibody
4. Grading of the slides was all performed blind and in duplicate, by the same observer.
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Fluorescein Activated Cell Sorting
As in the immunocytochemistry, mouse IgGl isotype-specific negative controls were scanned for each
cell line and each experiment.
Permeabolising the cells to measure the amount of total cell CEA is likely to cause some damage to the
cells. The comparison of membrane and total CEA values in four of the experiments on Lovo cells
showed significant falls in CEA levels in the permeabolised cells.
The experiment total CEA values were compared to a large number of permeabolised control cells of
each cell line to isolate the effects of the tested agents from those of the Permeafix. It is recognised
that the experiment cells may have been more sensitive to the Permeafix than the control cells because
of the toxic effects of the experiment agents.
The number of cells analysed through the FACS scanner varied from 1000 to 3000 within each cell
sample, because of the sparsity of cells in some of the experiment groups. The lowest numbers of cells
still provided a normal distribution on the single dot histograms, with the Ht29 and Colo cells noted to
show considerably tighter normal distributions than the Lovo cells.
Radioimmunoassay
The main potential for errors in the Radioimmunoassay occurred in the hand pipetting of the samples
into the ELSA-tubes. The 4 graphs of the CEA standards which were pipetted in the same way, at the




Measures to prevent errors have been described in the methodology in each chapter. It is recognised
however, that Type 1 (false positive) and Type 2 (false negative) results may occur when the number of
factors being tested is high. The statistical analysis used indicates positivity at p<0.05, implying that
the result is 95% likely to be positive, with a 5% error margin. It might be expected that ifmore than
twenty factors are studied, one result would fall into this 5% margin, but the logistical necessity of
testing the various factors metachronously should combat this possible source of error.
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APPENDIX FOUR: STATISTICS
COMPARISON OF TWO POPULATIONS
Replicated samples of cells which were exposed to various differentiating and cytotoxic agents and to
alterations in their environment were compared to replicated control samples grown in conventional
culture conditions. The parameters measured, or the response variable, from these two kinds of
populations of cells, control and experimental, i.e. their growth rates and degree of CEA expression or
release were then analysed to test for an observable differences in the populations. Significant
differences between the control and experiment population would be surmised to have arisen because
of the specific change in culture conditions applied.
The principle features of the response variables which were considered were:
1. Measure of Location : the means and medians.
2. Measure of Spread: the standard deviation
3. Shape ofDistribution: normal or skewed.
The mean is calculated by dividing the sum of all of the sample variables by the number of samples.
The median is the mid-point sample in a range of samples variables.




A distribution is taken to be "Normal" if 66% of the samples lie within one standard deviation of the
mean, 95% of the variables within two standard deviations and 99% within three standard deviations.
If populations of data are normally distributed, it may be analysed using parametric tests, such as the
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t-test. If the data distributions are not normal, a non-parametric test such as the Wilcoxon Rank Sum
test should be used for analysis.
T-test
The t-test is used to test whether there is a significant difference between the population means of two
populations, using the following algebraic formula:
T= x! - x2
sp2+ sp2
V ni n2
where xl and x2 are the two sample means, nl and n2 are the two sample sizes and Sp2 is the pooled
variance, calculated using the formula:
Sp2= (ni - l)si2 + (n2 - l)s?~
ni + n2 - 2
where Si2 and s22 are the squares of the two standard deviations.
Populations with equal variance (taken as ± 100%) are distinguished from those with unequal
variance.
Mann-Whitnev-U Test
The Mann Whitney -U test describes the probability that a new experimental observation will have a
rank lower than a new control observation. (The null hypothesis is that there is no difference in the
ranks of experimental and control observations.) The test is performed by assigning all control and
experimental observations a rank, grouping the samples from the two populations together and
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ranking them upwards in numerical order, the lowest rank being one. Equal values receive equal
proportions of n successive ranks.
The value U is calculated by the following equation, and then checked against tabulated values
according to the sample sizes, to ascertain the p-value, or the probability of the null hypothesis being
correct.
U = nin2 + l/2ni(ni+l) - T
Where ni is the number of observations in the experiment group, n2 is the number of observations in
the control group, and T is the sum of ranks in the smaller group.
The data from the immunocytochemstry and FACS analyses for CEA expression represent repeated
examples of the same experimental process, and would therefore be expected to follow a normal
distribution. The t-test is appropriate to use in looking for differences between two such populations
of data; however, the small size of the populations compromises the accuracy of the t-test. The
Mann Whitnev-U test was therefore performed in analysing the FACS results to improve accuracy.
In all tests, differences between control and experimental groups which showed significance at p<0.05
were taken as positive results.
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DIFFERING PATTERN OF IN VITRO CEA EXPRESSION AND SUPERNATANT RELEASE
BY AUGMENTED COLORECTAL CANCER CELLS
M.H.S. COLLIE; J. BHATIA; R. AUSTEN; M. C WINSLET, Dept of Surgery, Royal Free
Hospital, Pond St, London NW12.
Colorectal cancer cells are known to be heterogenous expressors of the tumour associated
antigen Carcinoembryonic Antigen (CEA), which may be targetted by antibodies. The
efficiency of this antibody guided detection and treatment is compromised by the heterogeneity
of expression of the CEA.
Certain chemical agents, cytotoxic drugs and environmental changes have been shown to
increase CEA expression in colorectal cancer cells.
In this study, three colorectal cancer cell lines, Lovo,HT29 and Colo, known to be high, low and
non-expressors of CEA were grown in monolayer cell culture for five days in the presence of a
differentiating agent (Butyric Acid, Theophylline, 5-Azactidine or Interferon), or with altered
environment (Acid medium, alkaline medium, starvation or hypoxia)or with 5Fluorouracil. The
cells were then immunostained and their CEA expression measured by Fluorescein Activated
Cell Sorting. Radioimmunoassay of the supernatants from the culture flasks was performed to
measure CEA released.
Significant changes in CEA expression and release as analysed by the Wilcoxon Rank Sum
test were as follows:
Starve Acid Alkali Hypox ButAc Theop 5-Azac IFN 5FU
Colo Exp T Exp T Exp t
HT29
RelT















The changes in CEA expression were not mirrored by similar or reciprocal changes in
supernatant release, although results were influenced by natural expression levels.
In vitro, it is concluded that chemical agents or environmental changes which lead to
augmented CEA expression by colorectal cancer cells do not cause matching increases in CEA
supernatant release. If the same mechanism applies in vivo, augmentation may not
necessarily increase serum CEA levels, with resultant high non-specific antibody binding and
background noise.
229
GROSS VARIATION IN CEA EXPRESSION AUGMENTATION BY
DIFFERENTIATING AGENTS
M.H.S.COLLIE, N.J.BRADLEY, M.C.WINSLET, Dept of Surgery, Royal Free
Hospital, Pond St., London NW12.
Colorectal cancer cells are heterogenous expressors of the tumour associated
antigen Carcinoembryonic Antigen (CEA). It is possible to target CEA on
tumour cells in vivo with anti-CEA antibodies, conjugated to radioisotopes or
cytotoxic drugs for the purposes of detection and treatment. The efficiency of
this antibody guided detection is compromised by the heterogeneity of
expression of the CEA.
This study compared the effects of 4 differentiating agents, (Butyric Acid, y-
Interferon, Theophylline and 5-Azacytidine) on 3 colorectal cancer cell lines,
Lovo, HT29 and Colo, known to be high, low and non- expressors of CEA
respectively. The cells were grown in standard tissue culture with one of the
agents for 5 days, before being harvested and immunostained for CEA. The
degree of CEA expression was analysed by Fluorescein Activated Cell
Sorting.
Average Fluorescence of Cells:











HT29 18.3 ±2.6 45.2 ± 5.4 33.1 ± 3.2 30.9 ± 2.4 29.4 ± 6.0
COLO 9.8 ± 7.2 11.5 ±2.2 13.2 ±4.7 61.9 ±35.9 78.6 ± 35.3
Different colorectal cancer cell lines may be induced by various differentiating
agents to increase their expression of CEA, but they do not appear to share
common pathways to CEA expression.
Using a combination of agents may be a more efficacious way of inducing the
increased CEA expression of a typical heterogenous colorectal cancer.
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DIFFERENTIATING EFFECT OF CHLOROQUINE IN COLORECTAL CANCER CELLS IN
VITRO
M.H.S. COLLIE; S. TOFFA; M. C WINSLET, Dept of Surgery, Royal Free Hospital, Pond St,
London NW12.
Colorectal cancer cells are known to be heterogenous expressors of the tumour associated
antigen Carcinoembryonic Antigen (CEA), which may be targetted by antibodies. The
efficiency of this antibody guided detection and treatment is compromised by the heterogeneity
of expression of the CEA, which is associated with the degree of differentiation of the cells.
Altering pH has been shown to induce differentiation in lymphoblastoid cells (1).
A pH study was devised, using Chloroquine. Chloroquine is known to cross biological
membranes and to enter lysosomes, where it becomes protonated, is no longer free to traverse
the membranes and so accumulates in the lysosome, mopping up Hydrogen ions (2). The
cytoplasmic pH being robbed of its hydrogen ions, thereby rises.
Ht29 colorectal cancer cells were grown in standard monolayer culture in medium containing
serial dilutions of Chloroquine, from 10 3 M to 109 M. After 5 days, the cells were counted,
immunostained for membrane CEA and scanned using Fluorescein Activated Cell Sorting.
Marked growth inhibition and increased membrane CEA expression was seen in all samples
exposed to Chloroquine at concentrations □ 10-5 Molar.
A further study was performed, with three human colorectal cancer cell lines Lovo, HT29 and
Colo (high,low and non-expressors of CEA respectively) grown in standard monolayer cell
culture medium containing 1(T5 M Chloroquine. Total cell CEA was measured in addition to
membrane CEA, by permeabolising duplicates of each cell sample.
Results:
The proliferation rate of each cell line was significantly reduced (T-test, p<0.01). Membrane
and total CEA expression measured by fluorescence on FACS, was increased in all three cells
according to the non-parametric Wilcoxon Rank Sum test. Using the T-test total cell CEA was
increased in all three cell lines, and membrane CEA in the Colo cells.
Lovo Lovo Ht29 HT29 Colo Colo
Surface Total Surface Total Surface Total
Control Ave 780.17 477.7 23.56 34.21 15.86 22.62
Chlor Ave 1382.96 1253.04 63.37 81.22 60.10 73.13
T-test 0.17 0.06 0.03 1x10-5 3x10-9 2x10-7
Conclusion: Chloroquine is effective as a CEA- inducer in Colorectal cancer cells in vitro at a
concentration of 10-5 M., whether they are naturally high, low or non-expressors or CEA.
Further studies on cell spheroids and transfected colorectal cancer are needed, before the
clinical potential of Chloroquine in tumour targeting can be realised.
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